Page last updated: 2024-08-21

arsenic trioxide and Acute Promyelocytic Leukemia

arsenic trioxide has been researched along with Acute Promyelocytic Leukemia in 963 studies

Research

Studies (963)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's48 (4.98)18.2507
2000's353 (36.66)29.6817
2010's421 (43.72)24.3611
2020's141 (14.64)2.80

Authors

AuthorsStudies
Micieli, JA; Paxton, AB1
Costa, LJ; Dhir, A; Jamy, OH; Xavier, AC1
Annibali, O; Autore, F; Beltrami, G; Bernardi, M; Borlenghi, E; Breccia, M; Carluccio, P; Cottone, F; D'Ardia, S; Di Bona, E; Efficace, F; Fazi, P; Fiedler, W; Finizio, O; Fracchiolla, NS; Fumagalli, M; Levato, L; Mancini, V; Mayer, K; Melillo, L; Platzbecker, U; Salutari, P; Schlenk, RF; Vignetti, M; Voso, MT1
Alex, AA; Balasubramanian, P; Balasundaram, N; Chendamarai, E; David, S; Ganesan, S; Janet, NB; Korula, A; Krishna, S; Kulkarni, U; Kumar, SP; Mathews, V; Palani, HK; Radhakrishnan, NR; Venkatraman, A; Yasar, M1
Allen, S; Budman, D; Calabro, A; Devoe, C; Dhingra, R; Ghiuzeli, CM; Saunders, J; Stýblo, M1
Ammatuna, E; Diepstra, A; Hazenberg, CLE; Huls, GA; Santing, M1
Abla, O; Alonzo, TA; Feusner, JH; Gamis, AS; Gerbing, RB; Gregory, J; Hardy, KK; Hardy, S; Hirsch, BA; Kahwash, S; Kolb, EA; Kutny, MA; Meshinchi, S; Raimondi, S; Rajpurkar, M; Wang, YC1
Li, Y; Xu, Q; Yu, J; Zhang, K1
Hayakawa, A; Horibe, K; Iijima-Yamashita, Y; Kato, M; Kiyotani, C; Matsumoto, K; Osumi, T; Shioda, Y; Terashima, K; Tomizawa, D; Yamada, Y1
Abraham, A; Arunachalam, AK; Balasubramanian, P; Balasundaram, N; Devasia, AJ; Fouzia, NA; George, B; Janet, NB; Korula, A; Kulkarni, UP; Lakshmanan, J; Lionel, S; Mani, T; Mathews, V; Nair, SC; Palani, HK; Prakash, MA; Selvarajan, S; Venkataraman, A1
Jin, J; Naranmandura, H; Wang, HF; Wang, QQ; Zhao, JZ; Zhu, HH1
Chen, X; Yu, D; Yu, Q1
Mao, Y; Tang, F; Xu, X; Zhu, X1
Fang, M; Liao, C; Shen, D; Shen, H; Song, H; Tang, Y; Wang, Y; Zhang, J; Zhu, H1
Campbell, LJ; Derkach, A; Epstein-Peterson, ZD; Geyer, S; Iland, H; Kohlschmidt, J; Larson, RA; Mrózek, K; Park, JH; Poiré, X; Powell, BL; Rajeeve, S; Stein, EM; Stock, W; Stone, RM; Tallman, MS; Zhang, Y1
Fang, S; Shi, J; Wang, C; Wang, Y; Yang, H; Zuo, N1
Chahardouli, B; Hoseinzadeh, G; Moghaddam, KA; Mohammadzadeh, Z; Mousavi, SA; Omidkhoda, A; Rostami, S1
Chen, YQ; Huang, DP; Huang, LB; Li, Y; Liang, C; Liao, LH; Luo, JS; Luo, XQ; Mai, HR; Tang, YL; Wang, LN; Yang, LH; Ye, ZL; Zhang, XL1
Ahn, MJ; Bae, SH; Bang, SM; Cho, EK; Choi, JH; Chong, SY; Hyun, MS; Jo, DY; Kim, B; Kim, BS; Kim, CS; Kim, DY; Kim, H; Kim, HJ; Kim, HS; Kim, I; Kim, SH; Kwon, H; Lee, JH; Lee, KH; Lee, MH; Lee, WS; Min, YJ; Moon, HN; Mun, YC; Nam, SH; Oh, D; Park, JH; Park, KT; Park, SY; Park, YH; Ryoo, HM; Seo, JJ; Seong, CM; Yoon, HJ; Yoon, SS; Zang, DY1
Kumar, S; Tchounwou, PB2
Fan, S; Li, WW; Mo, XD; Sui, XF; Wang, CL; Wang, FY; Xu, H1
Yanada, M1
Herold, T; Hiddemann, W; Rausch, C; Spiekermann, K; von Bergwelt-Baildon, M1
Korsos, V; Miller, WH1
Chen, K; Chen, W; Clode, P; Guagliardo, P; Huang, S; Jiang, H; Leung, JK; Song, W; Xu, J; Young, SG1
Bunce, CM; Drayson, MT; Khanim, FL1
Hussain, L; Kang, YY; Ma, YF; Maimaitiyiming, Y; Naranmandura, H; Wang, QQ; Wang, SC; Yang, C; Yang, T; Yu, PH; Yu, WJ; Zhu, CY1
Bai, LH; Jiang, YF; Li, J; Li, RJ; Peng, HL; Shen, JK; Yan, WZ1
Chen, SN; Huang, J; Jin, J; Li, L; Li, ZY; Lou, LJ; Lou, YJ; Lu, Y; Ma, YF; Mao, LP; Meng, HT; Qian, JJ; Sun, CH; Wang, HY; Wei, JY; Wu, Q; Xu, GX; Xu, JY; Yan, XY; Yang, M; Yu, WJ; Zhu, HH; Zhu, XL1
Wiernik, PH1
Dubey, S; Goswami, N; Mishra, N; Siddiqui, MQ; Varma, AK1
Chen, LM; Gong, S; He, PC; Li, GH; Liu, HB; Liu, L; Lu, XH; Qin, WW; Wald, DN; Wang, HY; Wang, MC; Wei, SH; Xi, JY; Yao, YZ; Zhang, CS; Zhang, HY; Zhang, M; Zhang, XX; Zheng, YS; Zhu, HH1
Cui, X; He, C; Huang, J; Jia, Y; Li, H; Li, J; Liu, Z; Ma, H; Niu, T; Tang, Y; Wu, Y; Xiang, B; Xie, L1
Das, C; Das, R; Jain, A; Jandial, A; Jindal, N; Karunakaran, P; Khadwal, A; Kumar, SR; Lad, D; Malhotra, P; Naseem, S; Prakash, G; Saini, N; Singh, C; Varma, N; Varma, S; Yanamandra, U1
He, J; Li, W; Lu, D; Lu, P; Shi, Y; Su, Y; Wu, S; Yang, J; Zhang, G; Zhang, M; Zhang, X1
Chen, W; Ge, Z; Han, J; Yu, S1
Duan, X; Liu, B; Yang, M1
Ball, ED; Borthakur, G; Cai, Z; Chen, SN; Chu, XX; Du, X; Gao, SJ; Hao, JP; Hu, J; Huang, JY; Huang, RB; Jin, J; Kantarjian, HM; Li, J; Li, JH; Liu, HX; Liu, LP; Liu, YJ; Lu, Y; Luo, H; MacMahon, S; Mi, YC; Qin, YZ; Sanz, MA; Shen, SH; Su, Z; Such, E; Taussig, DC; Wang, HY; Wang, W; Wang, Y; Welch, JS; Wen, LJ; Xu, R; Yan, XJ; Yin, CC; You, MJ; Yu, L; Yu, YF; Yuan, HJ; Zhang, C; Zhang, JY; Zhang, LP; Zhang, XY; Zhang, ZL; Zhou, HS; Zhu, HH1
Dai, B; Gao, W; Hu, J; Li, J; Li, K; Li, Y; Wang, F; Wang, L; Wang, Y; Zhang, T; Zhao, L; Zhu, H; Zhu, J1
Borges, GSM; de Mello Gomides Loures, C; de Paula Sabino, A; Evangelista, FGC; Fernandes, C; Ferreira, LAM; Richard, S; Sales, CC; Sicard, P1
Benoit, TM; Gundermann, S1
Balajthy, Z; Botó, P; Czimmerer, Z; Fésüs, L; Jambrovics, K; Kolostyák, Z; Pap, A; Sarang, Z; Szatmari, I; Uray, IP1
Gao, C; Hai, X; Li, J; Lin, L; Lv, J; Tian, S; Wu, M1
Chen, C; Hu, J; Liu, YM; Wang, J1
Cao, P; Chen, J; Chen, X; Fang, J; Li, H; Li, L; Liu, H; Liu, M; Ma, X; Wang, F; Wu, H; Yuan, L; Zhang, Y; Zhao, Z; Zhou, X1
Hai, X; Hostetter, TH; Lu, S; Pang, C; Wu, M1
Duan, R; Hai, X; Lv, J; Pang, C; Tian, S; Wu, M; Yang, H; Zhang, H1
Bajel, A; Blombery, PA; Chan, KL; Dun, K; Nedumannil, R; Ng Liet Hing, M; Nguyen, T; Ninkovic, S; Ryland, GL; Tiong, IS; Westerman, DA1
Chen, J; Chen, S; Luo, H; Wang, S; Wu, W1
Abraham, A; Balasubramanian, P; Fouzia, NA; George, B; Kulkarni, UP; Lionel, S; Mani, T; Mathews, V; Nair, SC; Selvarajan, S1
Acconcia, F; Albanesi, J; Bianchi, F; di Masi, A; Franza, M; Leone, S; Mancini, B; Pennisi, R1
Balajthy, Z; Jambrovics, K; Póliska, S; Scholtz, B; Uray, IP1
Amirzargar, MR; Faranoush, M; Kooshari, A; Nekouian, R; Shahidi, M; Shahriyary, F; Vafajoo, M1
Bachiashvili, K; Bathini, S; Bhatia, R; Choi, JK; Dunn-Valadez, S; Godby, K; Goyal, G; Jamy, O; Mehta, A; Mikhail, FM; Morlote, D; Oliver, JD; Purdy, KE; Rangaraju, S; Reddy, VB; Vachhani, P; Worth, S1
Fan, S; Fu, Y; Guo, D; Hou, J; Lei, R; Li, H; Liu, J; Tang, L; Wu, Y; Zhao, Y1
Ahluwalia, J; Jain, A; Jandial, A; Jindal, N; Karunakaran, P; Khadwal, A; Kumar, N; Kumar, SR; Lad, D; Malhotra, P; Naseem, S; Prakash, G; Saini, N; Singh, C; Varma, N; Varma, S; Yanamandra, U1
Chen, GH; Chen, HQ; Chen, YQ; Fan, Z; Feng, XQ; Guo, BY; Huang, DP; Huang, LB; Lan, HK; Li, B; Li, WL; Li, Y; Liang, C; Liu, RY; Luo, JS; Luo, XQ; Mai, HR; Tang, YL; Wan, WQ; Wang, LN; Yang, LC; Yang, LH; Zhang, XL; Zhen, ZJ; Zhou, DH1
Stahl, M; Tallman, MS2
Bai, L; Fu, J; Li, M; Lu, J; Sun, Z; Wu, M; Wu, Y; Zhang, Y; Zhou, C1
Fang, Q; Lu, T; Ma, D; Wang, J; Wang, W; Wei, D; Yu, K; Zhang, T; Zhang, Z1
Chen, Y; Lai, BB; Mu, QT; Ouyang, GF; Zhang, YL1
Albano, F; Amadori, S; Annibali, O; Avvisati, G; Borlenghi, E; Brandts, CH; Breccia, M; Brossart, P; Cairoli, R; Cicconi, L; Cortelezzi, A; Di Bona, E; Di Renzo, N; Divona, M; Dohner, H; Dohner, K; Efficace, F; Ehninger, G; Fabbiano, F; Fazi, P; Ferrara, F; Fiedler, W; Fozza, C; Frairia, C; Ganser, A; Hanel, M; Hertenstein, B; La Nasa, G; Link, H; Lo-Coco, F; Lubbert, M; Mandelli, F; Maria D'Arco, A; Melillo, L; Paoloni, F; Platzbecker, U; Rambaldi, A; Rollig, C; Salih, HR; Sborgia, M; Schlenk, RF; Schmitz, N; Thiede, C; Vignetti, M; Voso, MT; Wattad, M1
Bachiasvili, K; Erba, HP; Mikhail, FM; Papadantonakis, N; Shah, G; Vachhani, P1
Bu, N; Chen, WZ; Hao, R; Hussain, L; Lu, XY; Ma, LY; Naranmandura, H; Shao, YM; Su, L; Wang, C; Wang, QQ1
Bu, N; Chen, WZ; Jiang, Y; Lu, XY; Ma, LY; Maimaitiyiming, Y; Naranmandura, H; Shao, YM; Wang, QQ1
Cao, F; Fu, J; Hou, J; Hou, W; Jin, B; Li, H; Lu, M; Tian, X; Wang, Y; Yang, H; Zhang, Y; Zhou, J1
Gunji, T; Hattori, D; Hosoba, R; Momoki, M; Nagao, R; Uryu, H; Yahagi, Y; Yamazaki, H1
Chen, X; Feng, J; Hong, Y; Huang, Z; Wang, Y; You, X; Zheng, P1
Eskazan, AE; Yilmaz, U1
Li, D; Que, Y; Sun, Y; Wang, L; Yang, X; Zhu, H1
Hua, HU; Moshfeghi, AA; Rayess, N1
Boissel, N; Brethon, B; Carausu, L; Ducassou, S; Gandemer, V; Garcia Spezza, E; Leverger, G; Mazingue, F; Petit, A; Reguerre, Y1
Abraham, A; Balasubramanian, P; Bankar, A; Devasia, AJ; George, B; Janet, NB; Jeyaseelan, V; Korula, A; Kulkarni, UP; Lionel, S; Mathews, V; N, J; Na, F; Nair, SC; Prasad, J; S, S1
Gong, BF; Gong, XY; Li, Y; Lin, D; Liu, BC; Liu, KQ; Liu, YT; Mi, YC; Wang, JX; Wang, Y; Wei, H; Wei, SN; Zhang, GJ; Zhou, CL1
Abraham, A; Alex, AA; Balasubramanian, P; Balasundaram, N; David, S; Devasia, A; Ganesan, S; George, B; Janet, NB; Jeyaseelan, L; Korula, A; Kulkarni, U; Mathews, V; Palani, H; Thenmozhi, M; Venkatraman, A1
Jiang, Y; Naranmandura, H; Wang, QQ1
Bashash, D; Esmaeili, S; Gharehbaghian, A; Hamidpour, M; Pourbagheri-Sigaroodi, A; Safaroghli-Azar, A; Salari, S1
Bo, P; Fu, X; Guo, S; Kuang, T; Li, L; Liu, S; Xiang, X; Xie, X; Zhang, Y1
Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, GJ; Park, S; Park, SS; Shin, SH; Yahng, SA; Yoon, JH1
Breccia, M; Cordoba, R; Hamaker, ME; Klepin, HD; Larson, RA; Montesinos, P; Neuendorff, NR1
Chan, SY; Dang, CC; Guan, YK; Lau, NS1
Appelbaum, FR; Coutre, SE; DeAngelo, DJ; Erba, HP; Komrokji, RS; Lancet, JE; Litzow, MR; Moseley, AB; Othus, M; Tallman, MS1
Bellot, A; Chauvelot, J; Clerc, S; Delaitre, B; Derache, A; Kichenbrand, C; Phulpin, B1
Chen, X; Guo, J; Jiang, L; Lei, P; Liu, Z; Ma, R; Shi, J; Yang, J; Yang, S; Yuan, X; Zang, Y; Zhang, L; Zhang, Y; Zhu, X; Zhu, Z1
Fujita, H; Ishikawa, Y; Yokoyama, Y1
Farmer, I; Gupta, S; Kulasekararaj, AG; Littlewood, S; Moonim, M; Okikiolu, J; Oram, SH; Steel, M; Thanigaikumar, M; Wanniarachchi, C; Yeghen, T1
Hirano, S1
Akhtar, S; Avagyan, A; Bird, ST; Blumenthal, G; Chuk, M; de Claro, RA; Deisseroth, AB; Farrell, AT; Graham, DJ; Kelman, JA; Li, Y; Liao, J; MaCurdy, TE; Norsworthy, KJ; Pazdur, R; Swain, R; Wernecke, M1
Hashmi, H; Nishihori, T1
Abolghasemi, H; Anoushirvani, AA; Bashash, D; Pourbagheri-Sigaroodi, A; Safaroghli-Azar, A; Sayyadi, M1
Annibali, O; Borlenghi, E; Breccia, M; Cottone, F; Efficace, F; Luppi, M; Rodeghiero, F; Vignetti, M1
Maimaitiyiming, Y; Naranmandura, H; Yang, C; Zhu, HH1
Chaudhry, S; Gupta, DK; Jain, A; Khosla, H; Nagpal, K; Prasad, P; Saluja, S; Sharma, M; Tatawadiya, S1
Fortier, H; Gies, V; Variola, F; Wang, C; Zou, S1
Ahn, JY; Huh, J; Lee, KE; Mun, YC; Nam, EM; Rhee, SG; Seong, CM; Woo, HA; Yoo, ES1
Fang, Y; Zhang, Z1
Ji, L; Jiang, Y1
Ge, Z; Gu, S; Ma, J; Zi, J1
Cassinat, B; Dagher, T; de Thé, H; Edmond, V; Giraudier, S; Kiladjian, JJ; Lallemand-Breitenbach, V; Maslah, N; Niwa-Kawakita, M; Pasquier, F; Plo, I; Vainchenker, W; Verger, E; Villeval, JL1
Hua, HY; Naranmandura, H; Wang, QQ; Zhu, HH1
Baron, J; Freyer, CW; Luger, SM; Man, Y; Peterson, CE; Przespolewski, A1
He, J; Wang, L; Yan, X1
Yokoyama, Y1
Feng, H; He, P; Li, M; Wang, H; Wang, W; Wang, X; Zhao, J; Zheng, X; Zhu, H1
Fakhimahmadi, A; Ghavamzadeh, A; Haghi, A; Mohammadi Kian, M; Mohammadi, S; Moosavi, MA; Nikbakht, M; Rahmati, M; Salemi, M; Yousefi, H1
Breccia, M1
Abraham, A; Balasubramanian, P; Balasundaram, N; David, S; Devasia, AJ; Fouzia, NA; Ganesan, S; George, B; Janet, NB; Korula, A; Kulkarni, UP; Lakshmanan, J; Mani, T; Mathews, V; Nair, SC; Palani, HK; Sharma, V1
Fukuda, K; Iimura, Y; Isshiki, T; Nagasawa, T; Sato, Y; Suzuki, S; Yoshizawa, Y1
Chen, S; Chen, SJ; Li, YT; Liang, Y; Lu, M; Lu, X; Song, HX; Tang, YG; Wang, ZY; Wu, JL; Wu, LL; Xiao, SJ; Xing, YF; Yan, N1
Bashash, D; Esmaeili, S; Mousavi, FS; Safaroghli-Azar, A; Yousefi, AM; Zamani-Moghaddam, N1
Shen, X; Sui, M; Wei, H; Xiu, R; Zhang, Q; Zhang, Z; Zhou, J1
Gang, EJ; Le, J; Li, SY; Liu, HC; Lu, Y; Pei, RZ; Qian, SY; Si, T; Tang, SH1
Yousefnia, S1
Buhtoiarov, IN1
Chen, S; Han, Y; Hu, X; Ke, P; Li, C; Ma, X; Qiu, H; Sun, A; Tang, X; Wu, D; Wu, Y; Zhou, H1
Abele, M; Döring, M; Ebinger, M; Handgretinger, R; Hartmann, U; Lang, P; Müller, SL; Queudeville, M; Schleicher, S1
Chen, H; Fan, S; Gao, Y; Guo, M; Hai, X; Lin, L; Wu, Z; Zhao, Q1
Chen, H; Fan, S; Guo, M; Hai, X; Li, L; Lin, L; Liu, W; Wang, X; Wu, Z; Zhao, Q; Zhou, J1
DiNardo, CD; Kadia, TM; Kantarjian, HM; Ravandi, F; Welch, MA1
Bai, Y; Dou, L; Li, D; Niu, J; Niu, X; Qin, L; Sun, K; Wei, S; Xiao, M; Zhang, L; Zhang, W; Zhou, P1
Ahr, K; Derkach, A; Douer, D; Glass, JL; Hilden, P; King, A; Kishtagari, A; Levine, RL; Seo, SK; Tallman, MS1
Chen, H; Gao, C; Gao, Y; Guo, M; Guo, S; Hai, X; Lin, L; Wang, X; Wu, Z1
Binu, P; Nair, RH; Narayanan, SP; Soman, R; Zakhariah Hisham, O1
Pemmaraju, N1
Costa, LJ; Dhir, A; Godby, R; Jamy, OH; Xavier, AC1
Cao, F; Hou, W; Jin, B; Li, H; Sun, J; Yan, L; Zhang, Y; Zhao, H; Zhou, J1
Haghighat, S; Mokhtari, M; Rezvani, A1
Chen, X; Fan, S; Zhao, Y; Zhou, J1
Bhattacharyya, P; Gehani, A; Ghara, N; Ghosh, P; Sarkar, S1
Fujii, K; Fujii, N; Maeda, Y; Matsuoka, H; Matsuoka, KI; Nakamura, K; Nishimori, H; Sugiura, H1
Annibali, O; Arcese, W; Castelli, R; Cicconi, L; Cristiano, A; Della Porta, M; Divona, M; Esteve, J; Fabiani, E; Falconi, G; Lazarevic, V; Lo-Coco, F; Montesinos, P; Nardozza, AM; Ottone, T; Rego, E; Rossi, M; Testi, AM; Venditti, A; Voso, MT1
Abraham, J; Adès, L; Aljijakli, A; Arar, A; Aulitzky, WE; Baldus, CD; Berceanu, A; Berthon, C; Bonmati, C; Bornhäuser, M; Braun, T; Carassou, P; Carre, M; Chermat, F; De Wit, M; Fenaux, P; Gnadler, M; Görner, M; Götze, KS; Haiat, S; Hicheri, Y; Hiddemann, W; Jost, E; Kayser, S; Keller, U; Krämer, A; Krause, SW; Kunzmann, V; Lebon, D; Lengfelder, E; Müller-Tidow, C; Niemann, D; Noppeney, R; Orvain, C; Peterlin, P; Platzbecker, U; Raffoux, E; Rahme, R; Reichle, A; Rigaudeau, S; Röllig, C; Saillard, C; Schäfer-Eckart, K; Schlenk, RF; Schwänen, C; Serve, H; Spiekermann, K; Stölzel, F; Thiede, C; Wemeau, M; Willekens, C1
Levis, M1
Alves, VM; Brassesco, MS; Fugio, LB; Garcia, CB; Goto, RN; Greene, LJ; Leopoldino, AM; Padovani, KS; Rego, EM1
Chen, Y; Dai, Y; Fang, Y; Feng, X; Gao, H; Han, Y; Hao, G; He, Z; Hu, Q; Hu, S; Jiang, H; Jin, R; Ju, X; Li, F; Li, J; Li, L; Liang, H; Liao, N; Lin, L; Ling, Y; Liu, A; Liu, W; Luo, J; Luo, X; Pan, K; Peng, X; Peng, Y; Qu, L; Shen, D; Sun, L; Tao, Y; Tian, X; Wang, L; Wang, N; Wang, T; Xiao, P; Yan, M; Yin, Q; Zhai, X; Zhang, J; Zhang, R; Zhang, Y; Zheng, H; Zhou, M; Zhu, J1
Chen, Y; Li, S; Liu, S; Rao, Q; Tang, K; Tian, Z; Wang, J; Wang, M; Xing, H; Xu, Y; Yang, X1
Breccia, M; Cannella, L; Efficace, F; Olivieri, J; Platzbecker, U; Vignetti, M1
Baer, MR; DeZern, A; Duong, VH; Emadi, A; Gehrie, E; Ghiaur, G; Gojo, I; Hambley, B; Hickey, E; Kashanian, S; Levis, MJ; Li, A; Newman, MJ; Smith, BD; Varadhan, R; Zacholski, K1
Arena, V; Diverio, D; Foà, R; Ladogana, S; Lo Nigro, L; Locatelli, F; Masetti, R; Menna, G; Micalizzi, C; Micheletti, MV; Mohamed, S; Onofrillo, D; Piciocchi, A; Pierani, P; Putti, C; Rizzari, C; Santoro, N; Testi, AM; Timeus, F; Zecca, M; Ziino, O1
Su, YZ; Tao, HF; Xu, LW1
Kantarjian, H; Ravandi, F; Yilmaz, M1
de Thé, H; Rérolle, D; Wu, HC1
Kalalinia, F; Khaleghian, A; Mirjalili, S1
Au, WY; Cheuk, D; Chu, HT; Gill, H; Ha, SY; Kumana, CR; Kwong, YL; Lee, E; Lee, P; Leung, RYY; Ma, ESK; Yim, R; Yip, PK; Yung, Y1
Chang, YJ; Gong, LZ; Huang, XJ; Jia, JS; Jiang, H; Jiang, Q; Liu, XH; Lu, SY; Qin, YZ; Shi, HX; Tang, FF; Wang, J; Zhao, T; Zhao, XS1
Baer, MR; Benner, A; Burnett, AK; Ehninger, G; Elliott, MA; Estey, EH; Gonzales, P; Görner, M; Grimwade, D; Hills, RK; Ho, AD; Kayser, S; Krämer, A; Krzykalla, J; Levis, MJ; Mayer, J; Norsworthy, K; Novak, J; Platzbecker, U; Ráčil, Z; Röllig, C; Russell, NH; Schlenk, RF; Smith, BD; Szotkowski, T; Tallman, MS; Thiede, C; Walter, RB; Westermann, J; Žák, P1
Chavda, SJ; Koh, M; Lindsay, S; Willis, F1
Dunoyer-Geindre, S; Kruithof, EKO; Lecompte, T; Rivier-Cordey, AS; Tsopra, O1
An, R; Fu, W; He, H; Hou, J1
Angelini, DF; Battistini, L; Berardi, A; Castelli, G; Catalano, G; Cicconi, L; D'Angiò, A; Fioritoni, G; Graziani, G; Guerrera, G; Lo-Coco, F; Massai, L; Mastrangelo, D; Noguera, NI; Pasquini, L; Pelosi, E; Piras, E; Piredda, ML; Testa, U; Voso, MT1
Chen, J; Dai, J; Guo, H; Liu, X; Yan, L; Yu, S; Zhang, W; Zhu, J1
Feng, L; Li, B; Li, F; Liu, Y; Shi, Y; Wang, J; Yan, M1
Soloway, AH; Warner, VD1
Guo, J; Li, X; Mu, G; Quan, L; Wang, Y; Xu, W; Yao, J1
Alonzo, TA; Feusner, JH; Fu, CH; Gamis, AS; Gerbing, RB; Gregory, JJ; Hirsch, BA; Kutny, MA; Meshinchi, S; Raimondi, SC; Wang, YC1
Banella, C; Blandino, G; Capuano, E; De Panfilis, S; Divona, M; Fazi, F; Fontemaggi, G; Lo-Coco, F; Masciarelli, S; Noguera, NI; Ottone, T; Picardi, A1
Das, M1
Boddu, P; Ferrajoli, A; Jain, N; Kadia, T; Pemmaraju, N; Ravandi, F; Schlette, E; Tang, G; Thakral, B; Wierda, W1
Fan, D; Fu, J; Ge, F; Hou, J; Hou, W; Li, H; Li, X; Sun, J; Wang, P; Wang, S; Yang, K; Yang, Y; Zhang, Y; Zhao, H; Zhou, J1
Federzoni, EA; Humbert, M; Tschan, MP1
Brossart, P; Gembruch, U; Giovannini, G; Janzen, V; Mayer, K; Merz, WM; Nellessen, CM1
Chen, S; Dai, H; Drexler, HG; Geffers, R; Kaufmann, M; Li, J; MacLeod, RAF; Meyer, C; Nagel, S; Pommerenke, C; Quentmeier, H; Schneider, B; Thress, KS1
Ahmadian, S; Alimoghaddam, K; Alizadeh, S; Ghaffari, SH; Ghavamzadeh, A; Hassani, S; Khaleghian, A1
de Thé, H2
Carcelero San Martín, E; Creus Baró, N; Riu Viladoms, G1
Guo, ZP; Huang, XJ; Jia, JS; Jiang, H; Jiang, Q; Zhu, HH1
Chen, C; Huang, JB; Liu, ZL; Wang, J; Xu, HG; Xue, HM; Zhang, BH1
Chen, L; Chen, SJ; Chen, Z; Cui, W; Gao, MQ; Hu, J; Li, JM; Mi, JQ; Nie, RM; Shen, ZX; Wang, J; Wang, KK; Wang, ZY; Xi, XD; Zhao, LL; Zhu, HM1
Asik, A; Balcı Okcanoglu, T; Biray Avci, C; Dogan Sigva, ZO; Gunduz, C; Kayabasi, C; Ozmen Yelken, B; Saydam, G; Yılmaz Susluer, S1
Kjeldsen, E; Nørgaard, JM; Stentoft, J; Tøstesen, M; Østgård, LSG1
Kjeldsen, E; Nørgaard, JM; Stentoft, J; Tøstesen, M; Østergård, LSG1
Bi, Y; Chen, H; Fang, S; Hu, S; Kou, J; Li, T; Ma, R; Mo, H; Novakovic, VA; Shi, J; Wang, J; Wang, L; Yang, X; Yu, B; Zhang, Y; Zhou, J1
Akasaka, T; Honjo, G; Minoda, S; Nakagawa, M; Ohno, H; Okanoue, Y1
Aliabadi, LS; Alimoghaddam, K; Fumani, HK; Ghavamzadeh, A; Jahani, M; Jalili, M; Mousavi, SA; Rostami, S; Vaezi, M; Yaghmaie, M1
Hofmann, WK; Lengfelder, E; Nolte, F2
Balme, B; Carlioz, V; Collinge, E; Gerland, LM; Paubelle, E; Salles, G; Sujobert, P; Thomas, X; Tigaud, I1
Chen, X; Luo, Z; Pei, Y; Sun, W; Tong, Q; Wang, K; You, H; Yuan, M; Zhang, Y; Zhao, X; Zhu, H1
Au, WY; Chan, TSY; Gill, H; Hwang, YY; Ip, HW; Kho, B; Kumana, CR; Kwong, YL; Lau, JSM; Lee, HKK; Li, W; Lin, SY; Mak, V; Tse, E; Yim, R; Yip, SF1
Bøe, SO; Eriksson, J; Lång, A; Lång, E; Rowe, AD; Øye, A1
Karunakaran, P; Khadwal, A; Lad, D; Malhotra, P; Nampoothiri, RV; Naseem, S; Prakash, G; Sinha, A; Varma, N; Varma, S; Yanamandra, U1
An, W; Chang, L; Chen, X; Chen, Y; Guo, Y; Liu, F; Liu, T; Liu, X; Qi, B; Ren, Y; Ruan, M; Wang, S; Yang, W; Zhang, J; Zhang, L; Zhu, X; Zou, Y1
Imagawa, J1
Cao, F; Chen, B; Le, XC; Lu, X; Shen, S; Zhou, J1
Hou, J; Hou, W; Jin, B; Li, H; Wang, P; Yang, H; Zhang, Y; Zhao, H; Zhou, J1
Balasubramanian, P; Goni, D; Malhotra, P; Nampoothiri, RV1
Kayser, S; Platzbecker, U; Schlenk, RF1
Chen, YJ; Islam, K; Maimaitiyiming, Y; Naranmandura, H; Wang, C; Wang, QQ; Xu, S; Yang, C1
Ades, L; Bordessoule, D; Castaigne, S; Chevret, S; Damaj, G; Fenaux, P; Guerci-Bresler, A; Lejeune, J; Marolleau, JP; Pigneux, A; Raffoux, E; Rahmé, R; Spertini, O; Thomas, X; Vey, N; Wittnebel, S1
Ades, L; Bally, C; Berthier, C; Cassinat, B; de Thé, H; Fenaux, P; Hirsch, P; Jollivet, F; Kogan, S; Lehmann-Che, J; Letouzé, E; Mozziconacci, MJ; Pigneux, A; Yuan, H1
Chen, LM; Gong, S; Liu, X; Liu, Y; Wang, HY; Wang, MC; Xi, JY; Zhang, HY; Zhang, XX1
Alfonso, V; Breccia, M; Cicconi, L; Diverio, D; Divona, M; Foa, R; Franceschini, L; Iaccarino, L; Latagliata, R; Lo-Coco, F; Molica, M; Ottone, T; Rizzo, M; Voso, MT1
Chen, M; Gan, LG; Li, LW; Liu, BZ; Liu, L; Shan, ZL; Xiao, CL; Xu, T; Yao, SF; Zhao, Y; Zhong, L1
Cuccurullo, R; Diverio, D; Girardi, K; Gurnari, C; Lo-Coco, F; Locatelli, F; Micalizzi, C; Putti, MC; Santoro, N; Strocchio, L; Testi, AM; Zecca, M1
Farah, IO; Kumar, S; Tchounwou, PB1
Chen, CH; Chen, Y; Dhe-Paganon, S; Doctor, ZM; Gao, ZJ; Herbert, MK; Jackson, BP; Kozono, S; Lian, X; Lin, YM; Lu, KP; Massefski, W; Pinch, B; Qiu, C; Seo, HS; Tan, L; Zhou, XZ1
Betteridge, S; Burnett, A; Dennis, M; Dillon, R; Grimwade, D; Hills, R; Jovanovic, J; Russell, N1
Bashash, D; Bayati, S; Ghaffari, SH; Gharehbaghian, A; Momeny, M; Pourbagheri-Sigaroodi, A; Razani, E; Rezaie-Tavirani, M; Safaroghli-Azar, A; Sanjadi, M1
Chen, GH; Chen, HQ; Feng, X; Huang, K; Huang, LB; Ke, ZY; Li, B; Li, J; Liu, RY; Luo, JS; Luo, XQ; Mai, HR; Sun, XF; Tang, YL; Wan, WQ; Yang, LH; Yang, MH; Zheng, MC1
Chen, L; Gong, S; Gulati, ES; Li, D; Liu, X; Wang, H; Wang, M; Xi, J; Xie, M; Zhang, H; Zhang, X1
Ding, C; Liu, J; Ma, YY; Wang, P1
Huang, J; Shen, K; Yang, CL1
Cai, X; Hu, G; Ni, X1
Bashash, D; Delshad, M; Momeny, M; Pourbagheri-Sigaroodi, A; Riyahi, N; Safaroghli-Azar, A1
Liu, DM; Yang, L; Zhang, XD1
Dong, Z; Hai, X; Hu, S; Li, J; Lu, J; Wang, W; Zhou, J1
Creutzig, U; Dworzak, M; Rasche, M; Reinhardt, D; von Neuhoff, N1
Chen, Y; Deng, Y; Ding, B; He, Z; Ling, L; Shi, Y; Song, L; Tao, S; Wang, C; Yu, L1
Anderson, J; Christ, TN; Churpek, JE; Curran, E; Godley, LA; Larson, RA; Liu, H; Odenike, T; Osman, AEG; Stock, W; Thirman, MJ1
Armstrong, N; Deshpande, S; Duffy, S; Fayter, D; Grimm, S; Joore, MA; Kleijnen, J; Pouwels, X; Ramaekers, BLT; Riemsma, R; Witlox, W; Worthy, G1
Jiang, W; Lee, SH1
Buque Pardinho, R; da Rosa, FC; de Moraes Flores, ÉM; de Souza, LGT; Dressler, VL; Mortari, SR; Schultz Moreira, ME1
Bergua, J; Boluda, B; Brunet, S; Calasanz, MJ; Cervera, J; Chillón, MC; de laSerna, J; Esteve, J; Fernández, I; Gil, C; González-Campos, J; González-Sanmiguel, JD; Holowiecka, A; Krsnik, I; Labrador, J; Lowenberg, B; Luño, E; Manso, F; Montesinos, P; Moreno, MJ; Pérez-Encinas, M; Ribera, JM; Salamero, O; Sanz, MA; Sobas, M; Tormo, M; Vellenga, E1
Autore, F; Bacigalupo, A; Chiusolo, P; Giammarco, S; Innocenti, I; Laurenti, L; Leone, G; Metafuni, E; Pagano, L; Piccirillo, N; Sica, S; Sorà, F1
Batalini, F; Furtado, VF; Prilutskiy, A; Sloan, JM; Staziaki, PV1
Breccia, M; Foà, R1
Alfonso, V; Arcese, W; Cairoli, R; Ciardi, C; Cicconi, L; Cristiano, A; Divona, M; Falconi, G; Hasan, SK; Iaccarino, L; Lavorgna, S; Lo-Coco, F; Ottone, T; Travaglini, S; Venditti, A; Voso, MT1
Guffey, DJ; Teran, VA; Wilson, BB1
Du, Y; Sun, G; Sun, X; Wang, M; Wang, R; Wang, S; Xie, X; Ye, J; Ye, T; Zhang, J1
Cao, F; Cao, W; Chang, N; Fang, H; Li, X; Ma, Q; Qu, H; Wang, W; Yang, Y; Zhou, J1
Fan, S; Gao, C; Guo, M; Hai, X; Hu, S; Liu, S; Wang, B; Wang, W; Zhou, J1
Ahmad, Z; Aziz, SA; Baba, SM; Jan, A; Mir, KA; Pandith, AA; Shah, ZA1
Adès, L; Avvisati, G; Burnett, AK; Chen, SJ; Döhner, H; Estey, EH; Fenaux, P; Iland, H; Kantarjian, H; Lengfelder, E; Lo-Coco, F; Löwenberg, B; Mathews, V; Montesinos, P; Naoe, T; Platzbecker, U; Ravandi, F; Rego, E; Russell, NH; Sanz, MA; Tallman, MS1
Kato, M; Kiyotani, C; Matsumoto, K; Osumi, T; Shioda, Y; Terashima, K; Tomizawa, D; Tsumura, Y; Yamada, Y1
Huang, Y; Shao, S; Shi, P; Sun, Y; Wu, C; Zhao, S; Zhong, Q; Zhu, HH1
Iland, HJ1
Gao, J; Li, D; Lin, H; Luo, X; Mao, J; Shan, H; Su, Z; Wei, R; Zhang, K; Zhou, B1
Cao, P; Chen, X; Liu, H; Liu, M; Ma, X; Nie, D; Teng, W; Tian, Y; Wang, F; Wang, T; Wang, W; Zhang, J; Zhang, Y1
Aster, JC; Avigan, D; Bhasin, MK; Cheloni, G; Chen, M; Clohessy, JG; Galinsky, I; Guarnerio, J; Lane, AA; Lee, JD; Lo-Coco, F; Longo, L; Mendez, L; Menon, AV; Monteleone, E; Mugoni, V; Pandolfi, PP; Panella, R; Pozdnyakova, O; Stone, RM; Stroopinsky, D; Zamora, JC1
Fang, W; Hu, J; Sun, Q; Wang, Q1
Hu, J; Jin, J; Lo-Coco, F; Zhu, HH1
Cho, YY; Han, HT; Hwangbo, C; Jeong, JW; Kim, DH; Kim, KD; Kim, M; Lee, KW; Lim, JS; Oh, SS; Park, S; Yoo, J1
Aung, F; Borthakur, G; Chamoun, K; Cortes, J; Daver, N; DiNardo, CD; Garcia-Manero, G; Jabbour, E; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, M; Naqvi, K; Ravandi, F; Wang, X; Yilmaz, M1
Jin, J; Lou, Y; Mao, L; Tong, H; Wei, J; Xu, W; Yu, W1
Chan, AM; Mascarenhas, J; Rhee, JY; Tallman, MS; Tremblay, D1
Cruickshank, BM; Dean, CA; Holloway, RW; Hoskin, DW; Huynh, TT; Lee, K; Loung, CY; Marcato, P; Sultan, M; Vidovic, D; Waisman, DM; Weaver, ICG1
Alfonso, V; Arcese, W; Baer, C; Cicconi, L; Del Principe, MI; Divona, M; Falconi, G; Ferrantini, A; Forghieri, F; Haferlach, T; Iaccarino, L; Lavorgna, S; Lo-Coco, F; Ottone, T; Travaglini, S; Usai, M; Venditti, A; Voso, MT1
Benitez, L; Clemons, B; Cox, J; Griffin, S; Hickey, E; Ramlal, R; Sutphin, S1
Batista, DA; Borowitz, MJ; Burns, KH; Duffield, AS; Gocke, CD; Miller, KP; Pratz, K; Venkataraman, G1
Djavaheri-Mergny, M; Moosavi, MA1
De Simone, E; Di Micco, L; Mirenghi, F; Morelli, E1
Atsuta, Y; Emi, N; Fujimaki, K; Fujisawa, S; Fujita, H; Kobayashi, Y; Maeda, A; Miyazaki, Y; Naoe, T; Ohtake, S; Ohwada, A; Sunami, K; Takeshita, A; Taniwaki, M; Tsuboi, K; Tsuzuki, M; Yanada, M1
Hao, L; Wang, H; Wang, X; Xu, G; Zhao, J1
del Rincon, SV; Diaz, Z; Garnier, N; Gupta, A; Kourelis, M; Kwan, S; Mann, KK; Miller, WH; Molina, MF; Petruccelli, LA; Schipper, HM1
Abhilash, M; Abhilash, S; Manju, A; Mathews, VV; Nair, RH; Paul, MV1
Bradley, TP; Budman, DR; Kritharis, A1
Firkin, F; Iland, H1
Aizawa, S; Hatta, Y; Horikoshi, A; Iriyama, N; Takeuchi, J; Toyoda, H; Yoshino, Y; Yuan, B2
Liu, Z; Sun, G; Wang, F; Wang, H; Wang, Y; Xi, S; Xu, Y; Yang, Y; Zheng, Q; Zheng, Y1
Cao, JJ; Chen, D; Chen, LG; Du, XH; Fan, Z; Li, SY; Lin, L; Liu, XH; Ma, JX; Pei, RZ; Sha, KY; Shi, XW; Tang, SH; Wu, JY; Ye, PP; Zhang, BB; Zhang, PS; Zhuang, XX1
Belin, E; Chesnut, G; Taylor, S1
Cavenee, WK; Cloughesy, TF; Iwanami, A; Mischel, PS1
Dworzak, M; Lackner, H; Müller, E; Seidel, MG; Urban, C1
Li, R; Rao, Y; Zhang, D1
Alimoghaddam, K; Bashash, D; Ghaffari, SH; Ghavamzadeh, A; Hassani, S; Mardani, H; Mirzaee, R; Yousefi, M; Zaghal, A; Zaker, F; Zekri, A1
Kiyoi, H; Naoe, T; Tomita, A1
Fan, H; Li, S; Lin, J; Lu, X; Zhu, H1
Nakamura, Y; Taguchi, A; Tanaka, M; Tanaka, Y; Tanizawa, Y; Yujiri, T1
Arnold, LL; Cohen, SM; Dodmane, PR; Hoyt, R; Lele, SM; Maness-Harris, L; Muirhead, DE; Wedel, WR1
Jia, XH; Liu, JQ; Wang, KK; Wang, P; Xi, WD; Yang, XW; Zhang, H1
He, Y; Huang, S; Mao, C; Qin, X; Sun, X; Zhu, L1
Chen, M; Liu, T; Niu, T; Wang, L; Xie, LP; Zeng, K; Zou, XL1
Au, WY; Han, L; Ho, JC; Ip, MS; Kwong, YL1
Asou, N; Fujita, H; Hyo, R; Inaguma, Y; Ishigatsubo, Y; Iwanaga, M; Izumi, T; Kiyoi, H; Matsuda, M; Miyawaki, S; Miyazaki, Y; Nakaseko, C; Naoe, T; Nomura, S; Ohnishi, K; Ohtake, S; Okada, M; Shinagawa, K; Takeshita, A; Yamauchi, T1
Amadori, S; Avvisati, G; Brandts, CH; Breccia, M; Carella, AM; Cazzola, M; Cerqui, E; Cicconi, L; Ciceri, F; Di Bona, E; Divona, M; Döhner, H; Döhner, K; Ehninger, G; Fabbiano, F; Fazi, P; Ferrara, F; Fiedler, W; Finizio, O; Fioritoni, G; Ganser, A; Hänel, M; Hertenstein, B; Iacobelli, S; Kropp, MG; La Nasa, G; Levis, A; Link, H; Lo-Coco, F; Lübbert, M; Luppi, M; Mandelli, F; Melillo, L; Morra, E; Orlando, SM; Platzbecker, U; Rambaldi, A; Salih, HR; Sauer, M; Schlenk, RF; Schmitz, N; Sica, S; Specchia, G; Thiede, C; Venditti, A; Vignetti, M; von Lilienfeld-Toal, M; Wattad, M1
Chen, SJ; Chen, Z2
Cao, F; Li, Y; Liu, X; Shi, C; Wang, H; Yang, D; Ye, X; Zhao, H; Zhou, J1
Chen, X; Shao, J; Yan, J1
Kuo, TC; Tian, TF; Tseng, YJ1
de Thé, H; Lallemand-Breitenbach, V1
Fung, TK; So, CW1
Chen, Z; Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Suo, S; Tong, H; Tong, Y; Wang, Y; Ye, X1
Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Tong, H; Tong, Y2
Au, WY; Fong, BM; Lang, BH; Mao, KJ; Tam, S1
Iacoboni, G; Montesinos, P; Sanz, MA2
Delaune, A; Dubus, I; Falluel-Morel, A; Goullé, JP; Petit, A; Vannier, JP; Vasse, M1
Hoffman, E; Mielicki, WP1
Cheng, Y; Liu, G; Lu, A; Wang, B; Wu, J; Zhang, L1
Hofmann, WK; Lengfelder, E; Nowak, D2
Mayor, S1
Chen, L; Hu, X; Wang, J; Xu, X1
Hasan, SK; Lo-Coco, F; Montesinos, P; Sanz, MA1
Matsue, K; Nisihida, Y; Sugihara, H; Takeuchi, M; Tsuda, K; Ugai, T; Yamakura, M1
Chen, SJ; Huang, XJ; Jiang, H; Jin, J; Li, JY; Ma, J; Wang, JX; Wu, DP; Zhu, HH1
Firkin, F2
Chen, H; Hankins, PL; Miodragović, DU; O'Halloran, TV; Swindell, EP1
Appelbaum, FR; Bloomfield, CD; Gallagher, RE; Gulati, K; Holowka, N; Koval, G; Larson, RA; Laumann, K; Moser, BK; Paietta, E; Poiré, X; Powell, BL; Sher, D; Stock, W; Tallman, MS; Willman, C1
Dillon, R; Grimwade, D1
Douer, D; Ganzel, C; Tallman, MS1
Dos Santos, GA; Kats, L; Pandolfi, PP1
Cui, H; Gu, Y; Guo, R; Hu, M; Li, T; Li, X; Liang, H; Liu, X; Lu, Y; Pan, Z; Shan, H; Wang, L; Xu, C; Xu, Z; Yang, B; Yu, S; Zhang, Y1
Macheta, A; Podhorecka, M1
Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Suo, S; Tong, H; Tong, Y; Yu, W1
Ablain, J; de Reynies, A; de Thé, H; Minucci, S; Rice, K; Soilihi, H1
Mische, SE; Seigneres, B; Zhu, G1
Breccia, M; Cicconi, L; Lo-Coco, F2
Ito, K; Nakahara, F; Weiss, CN1
Ansari, M; Bourquin, JP; Gumy-Pause, F; Huezo-Diaz, P; Judas, C; Mattiello, V; Rock, N1
Altman, JK; Appelbaum, FR; Attar, EC; Coutre, SE; Gore, SD; Kopecky, KJ; Larson, RA; Levitan, D; Maher, T; Othus, M; Paietta, E; Powell, B; Stock, W; Tallman, MS; Wetzler, M; Willman, CL1
Chen, L; Gao, L; Hu, X; Lü, S; Song, X; Wang, J; Yang, J; Zhang, W1
Montesinos, P; Sanz, MA1
de Thé, H; Rice, KL1
Altman, JK; Cull, EH1
Cicconi, L; Lo-Coco, F2
Bochtler, T; Egerer, G; Hohmann, N; Mikus, G; Siller, N1
Guan, X; Li, C; Li, M; Shu, X; Sun, Y1
Huang, XJ; Qin, YZ; Zhu, HH1
Mousavizadeh, K; Noori, S; Pourfathollah, A; Safa, M; Zand, H1
Ahmadian, S; Alimoghaddam, K; Ghaffari, SH; Ghavamzadeh, A; Khaleghian, A1
Kumar, S; Tchounwou, PB; Yedjou, CG1
Hasan, SK; Lo-Coco, F2
Cull, EH; Kwaan, HC1
Garnier, N; Miller, WH; Nichol, JN1
Iland, HJ; Seymour, JF; Wei, A1
Grimwade, D; Hills, RK; Jovanovic, JV1
Douer, D; Ganzel, C1
Feusner, JH; Gregory, J; Kutny, MA1
Komatsu, N1
Chen, S; Chen, Z; Hu, J; Li, J; Mi, J; Wang, Z; Zhu, H1
Cheong, HJ; Jung, YS; Kim, KH; Kim, SJ; Lee, N; Park, HS; Won, JH1
Breccia, M; Efficace, F; Foà, R; Latagliata, R; Lo Coco, F; Minotti, C; Molica, M1
Cao, F; Lan, W; Li, D; Li, J; Li, L; Li, Y; Liu, X; Meng, R; Shi, C; Wang, H; Yang, B; Zhang, Y; Zhang, Z; Zhao, H; Zhou, J1
Buc Calderon, P; Felipe, KB; Glorieux, C; Kviecinski, MR; Sandoval, JM; Sid, B; Stockis, J; Valenzuela, M; Verrax, J1
Gill, H; Hai, JJ; Kumana, CR; Kwong, YL; Siu, CW; Tse, HF1
Lei, H; Ma, CM; Song, LL; Tu, YY; Wang, WW; Wei, W; Wen, DH; Wu, YL; Xia, L; Xu, HZ1
Cortes, J; Daver, N; Eghtedar, A; Ferrajoli, A; Garcia-Manero, G; Kadia, T; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F; Rodriguez, I1
Fang, ZG; He, Y; Hu, Y; Huang, RW; Li, XD; Lin, DJ; Liu, JJ; Liu, Q; Long, ZJ; Wang, DN; Xiao, RZ; Yan, JS1
Chen, M; Fan, Y; Fang, K; Meng, J; Tu, Y; Wan, L; Yu, L; Zhu, W1
Chen, RL; Huang, BT; Li, BS; Zeng, QC; Zhao, WH1
He, Y; Hu, Y; Huang, R; Li, X; Wang, D; Wang, W; Xiao, R; Zhang, E1
Bally, C; de Thé, H; Lehmann-Che, J1
Ai, WZ; Andreadis, C; Caballero, L; Damon, LE; Emi, N; Gaensler, KM; Greene, CC; Gupta, NK; Hwang, J; Kaplan, LD; Leavitt, AD; Logan, AC; Mahindra, A; Mannis, GN; Martin, TG; Miyazaki, Y; Naoe, T; Ohtake, S; Olin, RL; Sayre, PH; Smith, CC; Venstrom, JM; Wolf, JL; Yanada, M1
Amadori, S; Avvisati, G; Breccia, M; Cerqui, E; Cottone, F; Di Bona, E; Efficace, F; Ferrara, F; Finizio, O; Fioritoni, G; Kropp, MG; Levis, A; Lo-Coco, F; Mandelli, F; Platzbecker, U; Schlenk, RF; Sica, S; Specchia, G; Vignetti, M1
Arteaga, MF; Fung, TK; Mikesch, JH; So, CW1
Ablain, J; de Reynies, A; de Thé, H; Halftermeyer, J; Le Bras, M; Metzger, D; Peres, L; Vitaliano-Prunier, A1
Sui, M; Zhang, Z; Zhou, J1
Gore, SD; Zeidan, AM1
Fujita, H1
Anderlini, P; Borthakur, G; Brandt, M; Cortes, J; Daver, N; Dinardo, C; Ferrajoli, A; Garcia-Manero, G; Hosing, C; Kadia, T; Kantarjian, H; Marcucci, G; O'Brien, S; Pemmaraju, N; Pierce, S; Popat, U; Ravandi, F; Verstovsek, S1
Nitto, T; Sawaki, K1
Barakat, S; Couban, S; Lachaine, J; Mathurin, K1
Barakat, S; Lachaine, J; Mathurin, K; Schuh, AC1
Hatakeyama, N; Hori, T; Igarashi, K; Inazawa, N; Noguchi, H; Sasaki, M; Somekawa, Y; Suzuki, N; Tsutsumi, H; Yamamoto, M1
Bashey, A; Carraway, HE; Gore, SD; Holland, K; Leech, M; Morris, L; Pratz, K; Smith, BD; Solomon, S; Stewart, M; Zeidan, AM; Zhang, X1
Firkin, F; Ho, WK; Roncolato, F1
Ades, L; Breccia, M; Cassinat, B; Di Bona, E; Fenaux, P; González-Sanmiguel, JD; Görlich, D; Grimwade, D; Hofmann, WK; Huerta, AJ; Kishore, B; Lambert, JF; Lehmann, S; Lengfelder, E; Lo-Coco, F; Montesinos, P; Nloga, AM; Pagoni, M; Ramadan, SM; Sanz, M; Sauerland, MC; Schmidt, A1
Dai, L; Li, P; Liu, Y; Song, T; Wang, L; Wang, Z; Zhang, H1
Abraham, A; Aiyaz, M; Alex, AA; Balasubramanian, P; Chandy, M; Chendamarai, E; Chomienne, C; Ganesan, S; George, B; Janet, NB; Kamath, V; Lakshmi, KM; Mathews, V; Mugasimangalam, R; Mullapudi, N; Nair, SC; Nellickal, AJ; Padua, RA; Srivastava, A; Srivastava, V; Viswabandya, A1
Coombs, CC; Tallman, MS; Tavakkoli, M1
Ma, H; Yang, J1
Bernardi, R; Coltella, N; Ponente, M; Ponzoni, M; Valsecchi, R1
Eyler, R; Moeller, J; Patel, K; Perreault, S; Pham, T; Podoltsev, N; Russell, K1
Jin, J; Li, F; Lu, Y; Mai, W; Meng, H; Mu, Q; Pei, R; Qian, W; Tong, H; Yu, M; Zhao, X1
Chen, X; Guo, S; Qin, N; Zhang, X1
Chen, SJ; Chen, Z; Mi, JQ; Yan, XJ; Zhou, GB1
Geng, Z; Ouyang, J; Wang, S; Wang, Z; Zhou, M1
Huang, J; Jin, J; Lou, Y; Ma, Y; Mai, W; Mao, L; Meng, H; Ni, W; Pan, H; Qian, W; Suo, S; Tong, H; Wang, Y; Wei, J; Yu, W1
Allen, SL; Altman, JK; Cortes, JE; Coutre, S; Di Bona, E; Kantarjian, H; Lo-Coco, F; Ravandi, F; Sanford, D; Sanz, MA; Wetzler, M1
Bu, N; Cao, FL; Naranmandura, H; Wang, QQ; Zhang, YF; Zhou, J; Zhou, XY1
Barnes, G; Kruse, M; Lo-Coco, F; Martin, M; Mueller, U; Pathak, A; Wildner, R1
Chen, B; Chen, C; Chen, L; Chen, SJ; Chen, Z; Fu, YK; Gu, ZH; Hu, J; Jin, J; Li, JM; Lou, YJ; Mi, JQ; Shen, Y; Shen, ZX; Shi, JY; Wang, ZY; Zhao, WL; Zhu, HH; Zhu, HM; Zhu, YM1
Clarke, KM; Mills, KI; Young, CS1
He, J; Jin, J; Lou, Y; Ma, Y; Mai, W; Meng, H; Pan, H; Qian, W; Sun, J; Tong, H; Wang, Y; Ye, X1
Aznab, M; Rezaei, M1
Ravandi, F4
Barnes, G; Kruse, M; Lo-Coco, F; Martin, M; Mueller, U; Tallman, M; Tang, B; Wildner, R1
Bowen, D; Burnett, AK; Clark, RE; Friis, L; Grech, A; Grimwade, D; Hills, RK; Hunter, A; Jones, G; Kell, J; Khwaja, A; Knapper, S; Lok, J; McMullin, MF; Morgan, YG; Russell, NH1
Han, S; Huang, XJ; Jiang, H; Jiang, Q; Liang, GW; Shi, LW; Zhu, HH1
Cottone, F; Efficace, F; Lo Coco, F; Mandelli, F; Platzbecker, U1
Aviram, A; Klein, A; Muchtar, E; Oniashvili, N; Parnes, D; Raanani, P; Rabizadeh, E; Shepshelovich, D; Yeshaya, J1
Cantú-Rodríguez, OG; Gómez-Almaguer, D; Gómez-De León, A; González-Leal, XJ; Gutiérrez-Aguirre, H; Jaime-Pérez, JC; Pinzón-Uresti, MA1
Ren, YQ; Wang, LL1
Matsushita, H1
Huang, XJ; Jiang, H; Jiang, Q; Liu, J; Zhu, HH1
Chen, Z; Hu, R; Li, W; Lu, H; Zhang, T1
Ablain, J; de Thé, H; Esnault, C; Lehmann-Che, J; Poirot, B1
Kolb, EA; Meshinchi, S1
Adès, L; Alex, AA; Chomienne, C; Fenaux, P; Ganesan, S; Gorombei, P; Guerenne, L; Krief, P; Mathews, V; Omidvar, N; Padua, RA; Patel, S; Pla, M; Schlageter, MH; West, R1
Černelč, P; Falnoga, I; Podgornik, H; Šlejkovec, Z1
Bashford, J; Bradstock, K; Browett, P; Campbell, LJ; Catalano, A; Collins, M; Di Iulio, J; Filshie, R; Firkin, F; Grigg, A; Hertzberg, M; Hugman, A; Iland, HJ; Moore, J; Reynolds, J; Seldon, M; Seymour, JF; Supple, SG; Szer, J; Taper, J; Taylor, K; Tiley, C1
Al Ustwani, O; Griffiths, EA; Torka, P; Wang, ES; Wetzler, M1
Falchi, L; Kantarjian, HM; Ravandi-Kashani, F; Verstovsek, S1
Cairoli, R; Cicconi, L; Divona, M; Iaccarino, L; Lo-Coco, F; Ottone, T; Voso, MT1
Degos, L1
Khadwal, A; Malhotra, P; Saikia, UN; Yanamandra, U1
Adachi, K; Honma, Y; Kawakami, K; Miyake, T; Suzumiya, J; Takahashi, T1
Gerber, JM; Grunwald, MR; Lipford, EH; McDonnell, MH; Smith, ET1
Li, D; Luo, D; Wu, S; Zhang, Y; Zhou, J1
Hu, L; Huang, L; Li, C; Meng, F; Tang, Y; Wan, K; Wang, Y; Xu, D; Zhou, J1
Altman, JK; Norsworthy, KJ1
Chi, X; Gao, J; Liu, H; Shan, H; Zhang, Z; Zhao, Z; Zhou, H; Zhu, X1
Cao, F; Ge, F; Hou, J; Li, H; Li, J; Li, L; Li, X; Liu, S; Lv, C; Su, Y; Wang, P; Wang, S; Xu, M; Zhang, Y; Zhou, J1
Lo-Coco, F; Testa, U1
Hao, L; Lu-Qun, W; Ran, W; Xiang-Xin, L; Xiao-Ning, Y1
Di Donato, L; Lo-Coco, F; Schlenk, RF1
Li, L; Liu, Y; Pan, C; Wang, D; Zen, K; Zhang, CY; Zhu, D; Zhuo, J1
Blondeau, S; Bouyer, S; Colin, O; Houeto, JL; Julian, A; Meurin, E; Neau, JP; Puyade, M1
Chung, H; Jo, S; Kim, S; Lee, H; Lee, YL1
Alimoghaddam, K; Devlin, S; Douer, D; Esteve, J; Ganzel, C; Ghavamzadeh, A; Kuk, D; Mathews, V; Mohty, M; Nagler, A; Polge, E; Rowe, JM; Tallman, MS; Wang, H; Weisdorf, D; Zhang, MJ1
Albano, F; Alfonso, V; Amadori, S; Avvisati, G; Breccia, M; Cerqui, E; Ciardi, C; Cicconi, L; Di Bona, E; Divona, M; Ferrantini, A; Ferrara, F; Kropp, MG; Lavorgna, S; Levis, A; Lo-Coco, F; Mandelli, F; Ottone, T; Paoloni, F; Piciocchi, A; Santoro, A; Sborgia, M; Sica, S; Voso, MT1
Afroze, D; Azad, NA; Aziz, SA; Baba, SM; Dar, FA; Jan, A; Pandith, AA; Shah, ZA1
Koike, S; Nishimoto, S; Ogasawara, Y; Suzuki, T; Takagi, N; Yuan, B1
Atashrazm, F; Dickinson, JL; Holloway, AF; Lowenthal, RM; Woods, GM1
Jin, J; Liu, L; Lou, Y; Ma, Y1
Albano, F; Amadori, S; Avvisati, G; Borlenghi, E; Brandts, CH; Breccia, M; Brossart, P; Cairoli, R; Cicconi, L; Cortelezzi, A; D'Arco, AM; Di Bona, E; Di Renzo, N; Divona, M; Döhner, H; Döhner, K; Efficace, F; Ehninger, G; Fabbiano, F; Fazi, P; Ferrara, F; Fiedler, W; Fozza, C; Frairia, C; Ganser, A; Hänel, M; Hertenstein, B; La Nasa, G; Link, H; Lo-Coco, F; Lübbert, M; Mandelli, F; Melillo, L; Paoloni, F; Platzbecker, U; Pogliani, EM; Rambaldi, A; Röllig, C; Salih, HR; Sborgia, M; Schlenk, RF; Schmitz, N; Thiede, C; Vignetti, M; Wattad, M1
Chen, L; Chen, Q; Chen, S; Chen, Y; Chen, Z; Hu, J; Li, J; Li, X; Mi, J; Shen, Z; Sun, H; Wang, A; Wang, L; Wang, Z; Zhang, Y; Zhao, H; Zhao, W; Zhao, X; Zhou, W; Zhu, H1
Chen, XY; Fan, XY; Jiang, FL; Liu, Y; Liu, YJ; Zhong, HM1
Béné, MC; Bonnet, A; Chevallier, P; Garandeau, C; Garnier, A; Guillaume, T; Houreau-Langlard, D; Hourmant, M; Le Gouill, S; Moreau, P; Peterlin, P; Tissot, A; Vantyghem, S1
Bonora, M; Gafà, R; Giorgi, C; Kroemer, G; Lanza, G; Magri, E; Missiroli, S; Pandolfi, PP; Patergnani, S; Perrone, M; Pinton, P; Poletti, F; Raimondi, A; Tacchetti, C1
Abraham, A; Aiyaz, M; Alex, AA; Balasubramanian, P; Balasundaram, N; Chendamarai, E; Chomienne, C; David, S; Ganesan, S; George, B; Korula, A; Kulkarni, U; Mathews, V; Mugasimangalam, R; Padua, RA; Palani, HK; Srivastava, A1
Atsuta, Y; Emi, N; Gotoh, M; Hashimoto, H; Henzan, H; Ichinohe, T; Kanamori, H; Kanda, Y; Kohno, A; Kurokawa, M; Mori, T; Murata, M; Nishikawa, A; Sawa, M; Takami, A; Tomita, N; Watakabe, K; Yanada, M; Yano, S1
Cai, Y; Chen, W; Du, X; Huang, J; Lou, J; Sun, M; Wang, Z; Zhang, Q1
Alimoghaddam, K; Alizadeh, N; Ghaffari, SH; Ghavamzadeh, A; Hosseini, E; Momeny, M; Rostami, S; Zaki Dizaji, M1
Abedin, S; Altman, JK1
Angelopoulou, MK; Asimakopoulos, JV; Kelepesis, G; Konstantopoulos, K; Koutsi, C; Meletis, J; Papageorgiou, L; Petevi, K; Plata, E; Tsaftaridis, P; Vassilakopoulos, TP1
Bochennek, K; Creutzig, U; Dworzak, MN; Faber, J; Flotho, C; Graf, N; Kontny, U; Mueller, JE; Reinhardt, D; Rossig, C; Schmid, I; von Neuhoff, C; von Neuhoff, N; von Stackelberg, A1
Gnadler, M; Hecht, A; Lengfelder, E; Mezger, J1
Huang, F; Ling, X; Ren, G; Su, Y; Xie, P; Xu, L; Zeng, Z; Zhang, W; Zhang, XK; Zhou, H1
Pan, J; Zhang, X1
Gao, N; Li, XZ; Sun, JR; Wang, XX; Yu, WZ1
Huang, LB; Ke, ZY; Li, Y; Liu, XJ; Luo, XQ; Tan, HZ; Tang, YL; Wang, LN; Zhang, YC; Zhang, ZH1
Chen, D; Chi, J; Ding, X; Hao, J; Ji, W; Liu, C; Liu, X; Niu, Y; Wang, X; Wu, X; Yang, X; Zhu, C1
Akiyama, H; Hiruma, K; Jinta, M; Ohashi, K; Okuyama, Y; Sakamaki, H; Ueki, T1
Alimoghaddam, K; Ghaffari, SH; Ghavamzadeh, A; Jamialahmadi, AH; Shayan-Asl, N1
Litzow, MR1
Nelson, R; Self, WT; Talbot, S1
Jin, H; Li, L; Shi, G; Tang, X; Wang, J; Ye, RD; Yi, J1
Ammatuna, E; Lo-Coco, F; Montesinos, P; Sanz, MA1
Au, WY; Fong, BM; Kwong, YL; Tam, S4
Dohmen, RJ; Göttsche, K; Horst, C; Keusekotten, K; Krause, A; Praefcke, GJ; Springer, HM; Weisshaar, SR1
Tallman, MS8
Creus, A; Marcos, R; Soriano, C1
Allen-Bard, S; Carlin, R; Christos, PJ; Curcio, T; Feldman, EJ; Mathew, S; Mazumdar, M; Provenzano, J; Ritchie, EK; Roboz, GJ; Samuel, M; Wittenberg, B1
Carney, DA1
Coe, E; Schimmer, AD1
Dalley, CD; Ezaydi, Y; Goepel, JR; Kirkbride, P; Krishna, R; Smith, DJ; Snowden, JA; Sorour, Y1
Horikoshi, A; Iriyama, N; Kaise, T; Miyashita, SI; Shikino, O; Toyoda, H; Yoshino, Y; Yuan, B1
Abreu e Lima, RS; Falcão, RP; Freitas, RA; Garcia, AB; Gimenes Teixeira, HL; Jordão, AA; Lima, AS; Lucena-Araujo, AR; Rego, EM; Scheucher, PS; Silva dos Santos, GA; Vannucchi, H1
Cheng, YF; Liu, CF; Liu, GL; Lu, AD; Wang, B; Zhang, LP1
Arai, S; Hangaishi, A; Koike, Y; Kurokawa, M; Masamoto, Y; Nannya, Y; Yatomi, Y1
Bobé, P; Chelbi-Alix, MK1
Altman, JK; Tallman, MS2
Blamble, D; Cortes, J; Estey, E; Estrov, Z; Faderl, S; Ferrajoli, A; Fiorentino, J; Garcia-Manero, G; Jones, D; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F; Verstovsek, S; Wierda, W1
Fang, H; Wang, K; Zhang, J1
Dou, AX; Jia, PM; Lou, YJ; Pan, XR; Tong, JH; Zhang, CL1
Kogan, SC2
Cherian, OL; Raghu, KG1
Chen, B; Chen, QS; Chen, SJ; Chen, Z; Hu, J; Li, JM; Liu, YF; Shen, ZX; Sun, HP; Tang, W; Wang, ZY; Waxman, S; Wu, CF; Wu, W; Xu, F; Zelent, A; Zhao, WL; Zhou, GB; Zhu, YM1
Cao, YX; Dai, CW; Li, RJ; Pei, MF; Peng, HL; Shen, JK; Xu, YX; Yang, JJ; Yi, Y; Zhang, GS; Zheng, WL; Zhong, HY1
Antoine, F; Binet, F; Girard, D1
Li, Y; Lu, XL; Wang, BX; Wang, L; Wang, PP1
Aubry, M; Chelbi-Alix, MK; Dianoux, L; Estephan, P; Galisson, F; Germain-Desprez, D; Mascle, XH; Percherancier, Y1
Tang, DZ; Tao, S; Zhou, K1
Chen, X; Lopez-Berestein, G; Ozpolat, B; Vivas-Mejía, PE1
Hou, K; Hu, X; Li, Y; Liu, J; Liu, Y; Qu, J; Qu, X; Teng, Y; Zhang, Y1
Di, C; Gu, S; Tan, X; Wu, Q; Xian, L; Yang, L1
Ammatuna, E; Ardiri, D; Centonze, D; Divona, M; Lo-Coco, F; Montefusco, E; Pacilli, M1
Angell, R; Aslett, H; Batson, E; Burnett, AK; Clark, RE; Diverio, D; Flora, R; Grimwade, D; Hills, RK; Jones, K; Jovanovic, JV; Lo-Coco, F; Nugent, EA; Patel, Y; Rennie, K; Solomon, E; Wheatley, K1
Duggan, J; Siderov, J1
Amadori, S; Ammatuna, E; Cavaliere, A; Divona, M; Lo-Coco, F; Scambia, G1
Chen, Y; He, PC; Lu, R; Lü, XH; Ni, ZF; Wang, HY; Zhang, M1
Dai, L; Liu, YH; Ruan, CG; Shen, WH; Wang, ZY; Zhang, W1
Kurokawa, M; Nagai, S; Takahashi, T2
Au, WY; Fong, BM; Hon, C; Kwong, YL; Lai, WW; Tam, S; Yau, K1
Akahane, D; Gotoh, M; Kaise, T; Kiguchi, T; Kitahara, T; Ohyashiki, K; Toyoda, H; Yoshino, Y; Yoshizawa, S; Yuan, B1
Chen, JP; Liu, JP; Xia, Y; Xu, SN2
Hangaishi, A; Ichikawa, M; Kaise, T; Kumano, K; Kurokawa, M; Miyashita, SI; Nagai, S; Nannya, Y; Ueda, K1
Bao, L; Guo, T; Hong, M; Hu, Y; Jiang, Q; Lu, XJ; Shen, GX; Song, SJ; Xia, LH; Yang, LH; Zhang, XH; Zhao, T; Zhu, HH1
Bajorin, DF; Halabi, S; Small, E1
Bornhäuser, M; Platzbecker, U; Röllig, C; Stölzel, F; Thiede, C; Wermke, M1
Oshimi, K; Sasaki, M; Sugimoto, K; Yamamoto, Y1
Balasubramanian, P; Chandy, M; Chendamarai, E; George, B; Lakshmi, KM; Mathews, V; Srivastava, A; Thirugnanam, R; Viswabandya, A1
de Witte, TJ; Jansen, JH; Linssen, PC; Luesink, M; Muus, P; Pennings, JL; Pfundt, R; van der Reijden, BA; Wissink, WM1
Feusner, J; Gregory, J1
Leu, L; Mohassel, L1
Bhadauria, S; Prathapan, A; Raghu, KG; Sharma, S; Singh, R; Yadav, GK1
Li, L; Zhang, ZH; Zhao, WD1
Duan, MH; Han, B; Jiao, L; Shen, T; Wang, SJ; Xu, Y; Zhang, W; Zhao, YQ; Zhou, DB; Zhu, TN; Zhuang, JL; Zou, N1
Chhabra, S; Kaufman, KR; Levitt, M; Sood, R1
Chen, XJ; Chen, YM; Wang, JX; Wang, SC; Yang, WY; Zhang, L; Zhu, XF; Zou, Y1
Fan, S; Han, X; Hou, J; Hu, L; Li, J; Li, L; Li, X; Liu, X; Lv, C; Wang, S; Zhang, Y; Zhao, Y; Zhou, J; Zhu, L1
Hatta, Y; Hirabayashi, Y; Ishizuka, H; Kobayashi, Y; Takei, K; Takeuchi, J; Tanaka, T1
Fukushima, N; Hisatomi, T; Ide, M; Itamura, H; Kimura, S; Sueoka, E; Tanaka, M; Tomimasu, R; Urata, C; Yokoo, M1
Asghari, F; Mozdarani, H1
Arceci, R; Dauses, T; Devetten, M; Gallagher, RE; Gojo, I; Gore, SD; Jamieson, K; Morris, L; Owoeye, I; Redner, RL; Schachter-Tokarz, E; Sekeres, MA1
Cao, F; Gilbert, GE; Heegaard, CW; Hou, J; Rasmussen, JT; Shi, J; Zhang, Y; Zhou, J1
Chai, L; Cheng, M; Ren, Y; Wang, S; Xie, Y1
Chang, YF; Chou, DS; Fan, CY; Hsiao, G; Jayakumar, T; Lee, JJ; Lin, KH; Sheu, JR1
Berthou, C; Charles, F; Eveillard, JR; Ianotto, JC; Tempescul, A1
Ferrara, F1
Alimoghaddam, K; Ghaffari, SH; Ghahremani, MH; Ghavamzadeh, A; Hosseini, R; Mandegary, A; Rostami, S1
Brûlé, AO; Coser, PL; Coser, VM; Lafayette, TC; Pereira, WV1
Kumagai, Y; Shinkai, Y; Sumi, D1
Baek, JH; Cha, SJ; Kim, H; Min, YJ; Noh, EK; Park, JH; Park, MJ; Won, JH1
Grimwade, D; Guidez, F; Mistry, AR; Solomon, E1
Arora, N; Das, R; Malhotra, P; Nath, A; Patel, FD; Varma, N; Varma, S1
Meng, WT; Yang, YM; Zhang, G; Zhou, J1
Chen, SJ; Chen, Z; de Thé, H; Hu, HY; Huang, QH; Jeanne, M; Lallemand-Breitenbach, V; Liang, WX; Song, AX; Sun, HB; Tong, JH; Wu, JH; Wu, ZY; Yan, XJ; Yang, FF; Yang, HY; Zhang, QY; Zhang, XW; Zhang, Y; Zhou, GB; Zhou, ZR1
Chen, Y; Gao, J; Gu, L; Jia, C; Li, Q; Ma, Z; Wu, X; Zhou, C; Zhu, Y1
Sekeres, MA3
de Thé, H; Nasr, R1
Bian, S; Hao, L; Li, J; Wang, H; Wang, X; Wu, Q1
Liu, D1
Blinder, R; Chang, P; Galinsky, I; Ho, VT; Housman, E; Kesari, S; Lane, SW; Mullally, A; Stone, RM1
Bjørås, M; Bøe, SO; Isakson, P; Simonsen, A1
Feng, G; Li, Z; Meng, R; Sui, M; Yang, B; Zhou, J1
García Salido, A; Lassaletta Atienza, A; Madero López, L; Moreno Tejero, ML; Sevilla Navarro, J1
Berthier, C; de Thé, H; Duffort, S; Ferhi, O; Jeanne, M; Koken, M; Lallemand-Breitenbach, V; Le Bras, M; Peres, L; Raught, B; Soilihi, H1
Bloom, SE; Bunaciu, RP; Nayak, S; Shen, M; Varner, JD; Yen, A1
Abraham, A; Balasubramanian, P; Chandy, M; Chendamarai, E; Desire, S; George, B; Lakshmi, KM; Mathews, V; Shaji, RV; Srivastava, A; Thirugnanam, R; Viswabandya, A1
Appelbaum, FR; Couban, S; Coutre, S; Feusner, JH; Gallagher, RE; Gregory, J; Larson, RA; Moser, B; Powell, BL; Rowe, JM; Stock, W; Stone, RM; Tallman, MS; Willman, CL1
Fry, RC; Jaspers, I; Kesic, M; Liu, Q; Pi, J; Smeester, L; Zhang, H; Zou, F1
Ambaglio, I; Bernasconi, P; Castagnola, C; Corso, A; Lazzarino, M; Rossi, M; Zappasodi, P1
Bøe, SO; Simonsen, A1
Cortes, J; Dayyani, F; Faderl, S; Garcia-Manero, G; Jones, D; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F1
Baĭdil'dina, DD; Dubrovina, ME; Maschan, AA; Maschan, MA; Rumiantsev, AG; Rumiantseva, IuV; Samochatova, EV; Skorobogatova, EV1
Chen, C; Gao, SM; Jiang, L; Tan, Y; Wu, J; Xing, CY; Ye, A; Yin, L; Yu, K1
Fu, CC; Jin, ZM; Liang, JY; Liu, YJ; Ma, X; Qiu, HY; Tang, XW; Wu, DP1
Douer, D; Gore, S; Powell, BL; Ranganathan, A; Ravandi, F; Rowe, J; Sanz, MA; Tallman, M1
Dai, L; Jiang, M; Liu, Y; Ruan, C; Wang, Z; Wu, D; Zhang, W1
Lo-Coco, F; Sanz, MA1
Manji, GA; Tallman, MS1
Gong, YP; Luo, S; Yang, L; Yang, YM1
Chen, X; Chen, Y; Zhang, L; Zhu, X; Zou, Y1
Ebinger, M; Feuchtinger, T; Gessler, P; Handgretinger, R; Hildenbrand, S; Lang, P; Scheel-Walter, HG; Schwarze, CP1
Rogers, JE; Yang, D1
Gore, SD; Prebet, T1
Chen, Z; Jin, J; Li, K; Mei, C; Tong, H; Wang, H1
Anderson, LD; Collins, RH; Kirk, A; Levitt, D; Naina, HV; Scaglioni, PP; Vusirikala, M1
Alimoghaddam, K; Ghaffari, H; Ghavamzadeh, A; Hosseini, R; Iravani, M; Jahani, M; Jalili, M; Mousavi, A; Rostami, S1
Alimoghaddam, K; Ghaffari, SH; Ghavamzadeh, A; Hajhashemi, M; Mozdarani, H; Yaghmaie, M1
Chen, XW; Xia, HL; Xia, RX1
Atsumi, A; Goto, E; Hayakawa, F; Kiyoi, H; Naoe, T; Tomita, A1
Estey, EH; Hutchinson, F1
Alimoghaddam, K; Bahar, B; Ghaffari, SH; Ghavamzadeh, A; Iravani, M; Jahani, M; Jalili, M; Mousavi, SA; Rostami, S1
Jeong, KH; Park, TS; Yoon, HS1
Breccia, M; Cicconi, L; Giannì, L; Latagliata, R; Lo-Coco, F; Minotti, C1
Ducas, J; Ducas, RA; Seftel, MD; Seifer, C1
Chen, JP; Qin, DB; Wang, SQ1
Chen, HZ; Chen, XY; Qi, H; Rong, ZX; Wang, BS; Wang, H1
Akashi, K; Harada, M; Kamimura, T; Miyamoto, T1
Shinagawa, K1
Abreu e Lima, RS; Curti, C; de Thé, H; dos Santos, GA; Falcão, RP; Gimenes-Teixeira, HL; Lima, AS; Lucena-Araujo, AR; Nasr, R; Pandolfi, PP; Pestana, CR; Rego, EM; Rodrigues, FP; Santana-Lemos, BA; Scheucher, PS; Thomé, CH; Uyemura, SA1
Park, JH; Tallman, MS1
Sanz, MA2
Au, WY; Chan, GC; Ha, SY; Kwong, YL; Lee, V; Li, CK; Yau, J; Yuen, HL1
Powell, BL2
Block, GJ; Chadwick, RW; Flemington, EK; Lasky, JA; Shan, B; Sides, MD1
Au, WY; Kumana, CR; Kwong, YL; Lau, JS; Lee, HK; Lin, SY; Liu, H; Yeung, DY1
Gurung, A; Huang, BT; Li, BS; Xiao, Z; Zeng, QC; Zhao, WH1
Chen, Z; de Thé, H; Lallemand-Breitenbach, V; Zhu, J2
Alimoghaddam, K; Bashash, D; Dizaji, MZ; Ghaffari, SH; Ghavamzadeh, A1
Mi, J1
Brenneman, MA; Chen, JD; Denissova, NG; Hakhverdyan, Z; Nasello, C; Yeung, PL1
Hatta, Y; Hirabayashi, Y; Horikoshi, A; Iriyama, N; Takeuchi, J; Toyoda, H; Yoshino, Y; Yuan, B1
Inoue, A; Kawakami, C; Takitani, K; Tamai, H1
Kwong, YL1
Abraham, A; Ahmed, R; Alex, AA; Balasubramanian, P; Chandy, M; Chendamarai, E; Ganesan, S; George, B; Janet, NB; Lakshmi, KM; Mathews, V; Nair, SC; Sitaram, U; Srivastava, A; Srivastava, VM; Viswabandya, A1
Chen, Y; Li, Z; Lu, Q1
Chen, P; Chen, YZ; Huang, HF; Lin, ZX; Lu, R; Wu, Y1
Beauchamp, EM; Uren, A1
Cao, Z; Li, Q; Ruan, M; Wang, J; Zhang, L; Zhu, X; Zou, Y1
Chen, SJ; Chen, Z; Li, JM; Mi, JQ; Shen, ZX1
Benoilid, A; Broly, F; Echaniz-Laguna, A; Fornecker, LM; Goullé, JP; Lannes, B; Mousson de Camaret, B; Vinzio, S1
Bagel, B; Gujral, S; Gupta, S; Khattry, N; Menon, H; Nair, R; Subramanian, PG1
Breccia, M; Lo-Coco, F1
Stein, EM; Tallman, MS2
Huang, H; Liu, H; Qin, Y; Teng, R; Xu, M; Xu, R; Yang, L; You, X1
Choudhry, A; DeLoughery, TG1
Angaran, P; Gula, LJ; Kathirgamanathan, K; Lazo-Langner, A1
Arcese, W; Aversa, F; Bacigalupo, A; Breccia, M; Camboni, A; Cupelli, L; Di Veroli, A; Iori, AP; Lo-Coco, F; Papayannidis, C; Ramadan, SM1
Bjerkvig, R; Bjørås, M; Bruserud, O; Bøe, SO; Grudic, A; Lång, E; Pankiv, S; Simonsen, A1
Chen, Y; Cortes, J; Kantarjian, H; Ravandi, F; Wang, H1
Chen, SJ; Zhou, GB1
Bashford, J; Bradstock, K; Browett, P; Catalano, A; Collins, M; Di Iulio, J; Filshie, R; Firkin, F; Grigg, A; Hertzberg, M; Hugman, A; Iland, HJ; Moore, J; Reynolds, J; Seldon, M; Seymour, JF; Supple, SG; Szer, J; Taper, J; Taylor, K; Tiley, C1
Andreeff, M; Cheng, X; Freireich, EJ; Gao, MZ; Golemovic, M; Kantarjian, HM; Quintás-Cardama, A; Verstovsek, S; Zingaro, R1
Cao, FL; Gao, CY; Hou, JX; Li, JM; Li, JN; Liu, SC; Liu, Y; Ma, RS; Shi, JL; Tan, XY; Wang, J; Yang, X; Zhou, J1
Chun, HJ; Chung, BH; Kim, JI; Kim, SJ; Min, WS; Moon, IS; Sun, IO; Yang, CW1
Chang, MC; Chang, YF; Chen, CG; Chiang, YH; Hsieh, RK; Lim, KH; Lin, HC; Lin, J1
Park, JH1
Fan, S; Han, L; Han, X; Hu, L; Li, J; Li, L; Li, X; Li, Y; Lv, C; Su, Y; Wang, S; Zhang, X; Zhang, Y; Zhang, Z; Zhao, H; Zhao, Y; Zhou, J1
Alimoghaddam, K; Bashash, D; Ghaffari, SH; Ghavamzadeh, A; Mirzaei, R; Momeny, M1
Chen, YZ; Li, XF; Liao, XY; Wu, Y; Yang, JH1
Zhou, J1
Aul, C; Berdel, WE; Braess, J; Büchner, T; Erben, P; Haferlach, C; Haferlach, T; Hanfstein, B; Hehlmann, R; Heinecke, A; Hiddemann, W; Hofmann, WK; Horst, HA; Kreuzer, KA; Krug, U; Lengfelder, E; Müller-Tidow, C; Sauerland, C; Schneider, S; Schnittger, S; Schultheis, B; Serve, H; Spiekermann, K; Wörmann, B1
Chen, P; Chen, YZ; Huang, HF; Lu, R; Wu, Y1
Emi, N2
Cao, J; Chen, D; Chen, L; Du, X; Fan, Z; Li, S; Lin, L; Liu, X; Ma, J; Pei, R; Sha, K; Tang, S; Wu, J; Ye, P; Zhang, B; Zhang, P1
Shih, HM; Yang, WC1
Chen, MH; Liu, M; Liu, TB; Xle, JM; Yang, AQ; Yang, P1
Attarbaschi, A; Boztug, H; Chen, HY; Cooper, BW; Dworzak, MN; König, M; Strehl, S; Suzukawa, K; Zhang, SJ1
Alimoghaddam, K; Bashash, D; Ghaffari, SH; Ghavamzadeh, A; Hassani, S; Hezave, K; Kazerani, M; Rostami, M; Zaker, F1
Gagat, M; Grzanka, A; Grzanka, D; Izdebska, M1
Cao, F; Chen, B; Le, XC; Lu, X; Shen, S; Yuan, C; Zhou, J1
Iland, HJ; Seymour, JF1
Chen, Y; Han, L; Meng, H; Shi, C; Sui, M; Wang, H; Zhang, Z; Zhou, J; Zhou, Q1
Lee, JS; Miller, WH; Schipper, HM; Singer, J; Waxman, S1
Jing, Y; Waxman, S; Xia, L1
Cai, X; Chen, G; Huang, Y; Jia, P; Yu, Y1
Lopez-Berestein, G; Ozpolat, B1
Nabhan, C; Tallman, MS1
Guo, P; Hu, Y; Qiao, Z; Shen, G; Song, S; Wang, J; Yang, L; Zhang, X; Zhou, H1
Chim, CS; Kam, S; Kwong, YL; Lam, CC; Man, C; Wong, KF1
Balasubramanian, P; Chandy, M; George, B; Mathews, V; Shaji, RV; Srivastava, A2
Au, WY; Chim, CS; Kwong, YL; Pang, A; Wai Lie, AK1
Barnes, J; Chen, P; Chrest, FJ; Gorospe, M; Li, J; Liu, Y; Sinogeeva, N; Wersto, RP1
Bachleitner-Hofmann, T; Gisslinger, H; Kees, M1
Daniel, MT; De Thé, H; Degos, L; Dombret, H; Gourmel, B; Guillemin, MC; Janin, A; Kogan, S; Lallemand-Breitenbach, V; Lanotte, M; Raffoux, E; Soilihi, H; Vitoux, D; Zhu, J1
Chen, GQ; Chen, SJ; Chen, Z; Jia, PM; Tong, JH; Wang, ZY; Yu, Y; Zhu, Q1
Au, WY; Chim, CS; Chung, LP; Kwong, YL; Ma, SK1
Cairoli, R; Di Bona, E; Marenco, P; Montillo, M; Morra, E; Nosari, A; Tedeschi, A; Tresoldi, E1
Li, J; Shen, T; Zhang, ZN; Zuo, L1
Chen, SY; Li, XM; Liu, SX1
Feng, CQ; Ma, WL; Zheng, WL1
Horii, T; Kitamura, K; Maekawa, M; Matsui, H; Naito, K; Nakamura, S; Naoe, T; Ohnishi, K; Ohno, R; Shigeno, K; Shinjo, K; Takeshita, A1
Hirayama, Y; Matsunaga, T; Niitsu, Y; Sagawa, T; Sakamaki, S; Takayanagi, N; Tsuji, Y1
Cai, X; Chen, SJ; Chen, Z; Jia, PM; Tong, JH; Wang, ZY; Yu, Y; Zhu, Q1
Cao, Q; Chen, SJ; Chen, X; Chen, Z; Liu, YF; Shen, ZX; Wang, AH; Wang, ZY; Zhu, YM1
Li, DP; Li, HQ; Li, R; Qi, JY; Qian, LS; Wan, CC; Wang, ZQ; Zhao, YZ; Zhou, CL1
Baccarani, M; Malagola, M; Martinelli, G; Piccaluga, PP; Rossi, M; Visani, G1
DiPersio, J; Douer, D; Giralt, S; Hu, W; Lill, M1
Au, WY; Chan, CH; Chan, JC; Chen, YT; Chim, CS; Kwong, YL; Liang, R; Lie, AK; Liu, SY; Ma, SK; Mak, YK; So, CC; Wong, LG; Yeung, YM; Yip, SF1
Chen, GQ; Chen, Z; Jing, Y; Styblo, M; Walton, F; Waxman, S; Weinberg, R; Zhou, L1
Cortes, J; Estey, E; Kantarjian, H; Lazo, G; O'Brien, S; Thomas, D1
Côté, S; Davison, K; Mader, S; Miller, WH1
Buzyn, A; Cassinat, B; Chomienne, C; Cimerman, P; Daniel, MT; de Thé, H; Degos, L; Delarue, R; Dombret, H; Fermand, JP; Hermine, O; Lebbé, G; Poupon, J; Raffoux, E; Réa, D; Rousselot, P; Taksin, AL; Tibi, A1
Au, WY; Chan, GC; Kou, M; Kumana, CR; Kwong, YL; Lam, CW; Mak, R1
Cai, X; Chen, GQ; Chen, Z; Dai, W; Huang, Y; Jia, PM; Tong, JH; Yu, Y; Zhang, L; Zhao, Q1
Liu, SX; Wang, HY; Zhang, M1
Han, ZC; Liu, P1
Grigg, A; Kimber, R; Szer, J1
Song, J; Zhang, DS1
Barbey, JT; Pezzullo, JC; Soignet, SL1
Udvardy, M1
Aguilar, TM; Bahlis, NJ; Boise, LH; Krett, N; Lee, KP; McCafferty-Grad, J; Reis, I1
Peng, L; Xu, X1
Lü, CF; Meng, R; Wang, W; Yang, BF; Zhou, J1
Huang, X1
Bi, K; Guo, G; Jiang, F; Jiang, G; Liu, C; Liu, X; Peng, J; Ren, H; Ren, Q; Tang, T; Tian, Z; Zhang, Y; Zhen, G1
Fan, S; Li, X; Lu, C; Meng, R; Yang, B; Zhou, J1
Benoit, G; Bobé, P; Canova, A; Chelbi-alix, MK; Pine, R1
Hayashi, H; Kamikawa, T; Katoh, H; Maekawa, M; Naito, K; Ohnishi, K; Ohno, R; Sahara, N; Shinjo, K; Takeshita, A; Uehara, A; Yamazaki, K1
Davison, K; Mann, KK; Miller, WH; Waxman, S1
Gong, Z; Le, XC; Lu, X; Wang, Z; Zhou, J1
Li, BX; Liu, Y; Meng, R; Wang, W; Yang, BF; Zhou, J1
Aisa, Y; Iguchi, T; Ikeda, Y; Miyamoto, K; Mori, T; Okamoto, S; Shimizu, T; Yokoyama, K1
Lanska, DJ1
Chen, SJ; Chen, Y; Chen, Z; De Thé, H; Fang, J; Gu, BW; Li, JM; Liu, YF; Shen, Y; Shen, ZX; Shi, JY; Shi, ZZ; Tang, W; Wang, ZY; Waxman, S; Wu, W; Yan, H; Zheng, PZ; Zhu, YM1
Meng, R; Wang, Y; Yang, BF; Zhou, J1
Nand, S; Tanvetyanon, T1
Bradley, D1
Hong, WD; Li, J; Li, QH; Luo, SK; Peng, AH; Tan, EX; Tong, XZ; Zhang, GC; Zheng, D1
Hara, S; Ishitsuka, K; Iwao, Y; Shirahashi, A; Shishime, M; Suzumiya, J; Takamatsu, Y; Takatsuka, Y; Tamura, K; Utsunomiya, A1
Mann, KK; Miller, WH1
Hayakawa, F; Privalsky, ML1
Cannizzaro, L; Ding, W; Gallagher, RE; Guidez, F; Kim, SH; Paietta, E; Ramesh, KH; Sun, Y; Warrell, RP; Zelent, A; Zhou, DC1
Avvisati, G; Breccia, M; Carmosino, I; Finolezzi, E; Latagliata, R; Lo Coco, F; Petti, MC1
Jing, Y1
Dryden, MJ; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, HM; Pierce, S; Ratnam, S; Tsimberidou, AM; Whitman, GJ1
Khan, MA; Oubrahim, H; Stadtman, ER1
Hayash, H; Horii, T; Kitamura, K; Kobayashi, M; Maekawa, M; Naito, K; Nakamura, S; Naoe, T; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shinjo, K; Takeshita, A1
Pan, B; Xu, L; Yang, X1
Feusner, J; Gregory, J; Ravindranath, Y1
Chandy, M; George, B; Mathews, V; Poonkuzhali, B; Shaji, RV; Srivastava, A1
Meng, R; Yang, BF; Zhou, J2
Cai, L; Cui, J; Gao, S; Jiang, Z; Li, W; Liu, Z; Song, Y; Wang, G; Yang, Y; Yao, C; Yuan, CJ1
Balasubramanian, P; Chandy, M; George, B; Mathews, L; Shaji, RV; Srivastava, A1
Li, J; Shen, T; Wang, X; Xu, CM; Yang, Y; Zhang, ZN; Zuo, L1
Bonati, A; Lo-Coco, F; Lunghi, P; Pelicci, P; Pelicci, PG; Tabilio, A1
Chandy, M; George, B; Poonkuzhali, B; Srivastava, A; Srivastava, VM1
Chou, WC; Dang, CV1
Körper, S; Rojewski, MT; Schrezenmeier, H1
Chen, G; Chen, L; Chen, S; Fang, Z; Huang, Y; Li, X; Liu, H; Ni, J; Shen, Z; Wang, Z1
Chen, G; Chen, L; Chen, S; Jia, P; Ni, J; Shen, Z; Shi, G; Shi, X; Tang, W; Wang, Z1
Du, J; Liu, BR; Qian, XP; Wang, LF; Yin, HT; Zou, ZY1
Lu, M; Meng, R; Sui, XH; Wang, DS; Yang, BF; Zhou, J1
Benecke, A; Cayre, YE; Denis, FM; Di Gioia, Y; Lutz, PG; Touw, IP1
Meng, R; Sui, XH; Yang, BF; Zhou, J1
Daniel, PT; Dörken, B; Essmann, F; Scholz, C; Schulze-Osthoff, K; Stärck, L; Wieder, T1
Jena, RK; Sahu, GR1
Emi, N; Kajiguchi, T; Naoe, T; Sawa, M; Yamamoto, K1
Fung, Y; Lin, B; Liu, D; Ma, X; Qin, J; Wang, W; Ye, N; Yu, L1
Ikeda, T; Kimura, F; Kufe, D; Motoyoshi, K; Nakata, Y; Ogura, K; Sato, K; Sporn, M1
Beal, N; Diehl, LF; Huff, CA; Jones, RJ; Matsui, W; Smith, BD; Vala, M1
Chen, SJ; Zhao, WW1
Au, WY; Cheung, GT; Kumana, CR; Kwong, YL; Yuen, TW1
Auffray, C; Chen, SJ; Chen, YL; Chen, Z; Du, YZ; Eveno, E; Fan, HY; Huang, QH; Imbeaud, S; Jin, G; Shen, SH; Wang, KK; Waxman, S; Xiao, DK; Zhang, J; Zhang, QH; Zhang, QY; Zhao, CJ; Zheng, PZ1
Horii, T; Maekawa, M; Matsui, H; Naito, K; Naoe, T; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shinjo, K; Shirai, N; Takeshita, A1
Arai, A; Kitano, A; Kurosu, T; Miki, T; Miura, O; Murakami, N; Yamamoto, K1
Akay, C; Gazitt, Y1
Cui, JW; Gao, SJ; Jiang, ZY; Li, W; Liu, ZL; Song, YQ; Wang, GJ; Yang, Y; Yao, C; Yuan, CJ1
Bai, SZ; Chen, GQ; Fu, GH; Guo, ZW; Liu, XB; Wang, Y; Xi, YH; Yang, BF1
Tajima, M1
Hao, LC; Wang, H; Zhang, LZ1
Aradi, J; Dudognon, C; Hillion, J; Lanotte, M; Pendino, F; Ségal-Bendirdjian, E; Tarkanyi, I1
Baccarani, M; Billi, AM; Bortul, R; Evangelisti, C; Grafone, T; Martelli, AM; Martinelli, G; Tabellini, G; Tazzari, PL1
Fenaux, P; Lo Coco, F; Sanz, MA1
Jia, J; Meng, L; Meng, R; Sui, X; Yang, B; Zhou, J1
Asou, N1
Kobayashi, M; Maekawa, M; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shinjo, K; Takeshita, A1
Estey, E; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Kantarjian, H; Patel, SP; Verstovek, S1
Colosimo, AL; Guo, Q; Kurie, JM; Lee, HY; Mann, KK; Miller, WH; Padovani, AM1
Chen, SJ; Chen, Z; Zhou, GB1
Hu, Y; Qiao, Z; Song, S; Yang, L; Zhang, X; Zhou, H1
Fujisawa, S; Kobayashi, M; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shinjo, K; Takeshita, A1
Aghdami, N; Alimoghaddam, K; Bahar, B; Baybordi, E; Ghaffari, SH; Ghavamzadeh, A; Hosseini, R; Iravani, M; Jahani, M; Khodabadeh, A; Mortazavi, Y; Mossavi, A; Rostami, S; Totonchi, M1
Büchner, T; Hehlmann, R; Lengfelder, E; Saussele, S; Weisser, A1
Alimoghaddam, K; Ghavamzadeh, A; Jahani, M; Rostami, S; Sanaat, Z; Shariftabrizi, A; Tavangar, M; Tavangar, SM1
Tamm, I1
Chen, GQ; Huang, Y; Jiang, Y; Peng, ZG; Wu, YL; Yan, H; Yu, Y; Zhao, Q; Zhu, YS1
Au, WY; Chan, CH; Chim, CS; Fung, AT; Kwong, YL; Liang, RH; Ma, ES; Wong, KF1
Bajel, A; Balasubramanian, P; Chandy, M; George, B; Lakshmi, KM; Mathews, V; Shaji, RV; Srivastava, A; Srivastava, VM; Viswabandya, A1
Estey, E; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Jones, D; Kantarjian, H; Verstovsek, S1
Frankfurt, O; Tallman, MS1
Fukuda, M1
Akioka, T; Hanafusa, T; Hara, S; Oka, T; Tsuji, M; Yamano, T; Yokote, T1
Chen, GQ; Huang, Y; Jiang, Y; Liu, W; Peng, ZG; Song, LP; Zhao, Q1
Au, WY; Kumana, CR; Kwong, YL; Lau, CP; Siu, CW; Tse, HF; Yung, C1
Bajel, A; Chandy, M; Desire, S; George, B; Lakshmi, KM; Mathews, V; Rao, JG; Srivastava, A; Srivastava, VM; Viswabandya, A1
Ades, L; Bordessoule, D; Castaigne, S; Chevret, S; de Botton, S; Degos, L; Dombret, H; Fegueux, N; Fenaux, P; Guerci, A; Kelaidi, C; Link, H; Meyer-Monard, S; Raffoux, E; Rayon, C; Rigal-Huguet, F; Sanz, M; Stoppa, A; Thomas, X; Vekhoff, A1
Ammatuna, E; Lo Coco, F; Noguera, N1
Fukai, Y; Hirata, M; Ichikawa, N; Kaise, T; Kinoshita, K; Kobayashi, H; Ohta, S; Saitoh, H; Sakurai, T; Ueno, M1
Au, WY; Chan, EY; Cheng, VC; Kumana, CR; Kwong, YL; Lam, CW; Liu, R; Shek, TW1
Bellincampi, L; Bernardini, S; Bonati, A; Federici, G; Lo Coco, F; Lunghi, P; Mann, K; Miller, WH; Noguera, NI; Nuccetelli, M1
Caillot, D; Fenaux, P; Huguet, F; Pigneux, A; Raffoux, E; Thomas, X1
Kobayashi, M; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shinjo, K; Takeshita, A; Tobita, T1
Kai, T; Kimura, H; Maruyama, Y; Ogawa, K; Sato, H; Shiga, Y1
Fan, SJ; Han, XY; Hu, LH; Wang, Y; Wu, N; Zhou, J1
Beran, M; Freireich, E; Giles, F; Kantarjian, H; Perez, N; Quintás-Cardama, A; Ravandi-Kashani, F; Verstovsek, S1
Deng, SH; Han, MZ; Li, QC; Li, X; Li, Y; Li, YT; Li, ZJ; Qiu, LG; Wan, CC; Yang, RC; Zhao, YZ1
Alimoghaddam, K; Ghavamzadeh, A; Jahani, M1
Davis, RJ; Giafis, N; Higgins, LS; Katsoulidis, E; Nebreda, AR; Platanias, LC; Sassano, A; Tallman, MS1
Alimoghaddam, K; Bashash, D; Ghaffari, SH; Ghavamzadeh, A; Rostami, S1
Meng, L; Meng, R; Sui, XH; Yang, BF; Zhou, J1
Ehninger, G; Helwig, A; Illmer, T; Klemm, M; Röllig, C; Schüttig, R; Wassilew, N1
Duan, LN; Guo, ZK; Ji, SQ; Wang, HX1
Fujisawa, S; Hashimoto, H; Kaise, T; Kinoshita, K; Kobayashi, M; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shimoya, M; Shinjo, K; Suzuki, Y; Takeshita, A1
Kwong, YL; Leung, J; Pang, A; Tse, EW; Yuen, WH1
Aller, P; Amrán, D; de Blas, E; Esteban, D; Fernandez, C; Palacios, MA; Ramos, AM1
Ohnishi, K2
Chang-chun, W; Jian-xiang, W; Lu-gui, Q; Ming-zhe, H; Qiao-chuan, L; Ren-chi, Y; Wan-jun, S; Xin, L; Yan, L; Yao-zhong, Z; Yun-tao, L; Zeng-jun, L1
Buscemi, S; Cai, L; Chen, GQ; Fu, GH; Pan, XY1
Hayashi, H; Katoh, H; Naito, K; Ohnishi, K; Satoh, H; Takeshita, A; Terada, H; Uehara, A; Yamazaki, K1
Agrawal, N; Kumar, A; Kumar, R; Mahapatra, M; Naithani, R1
Emi, N; Kajiguchi, T; Kinoshita, T; Naoe, T; Ninomiya, M; Yamamoto, K1
Hou, KZ; Jin, B; Liu, YP; Yu, P1
Estey, E; Kantarjian, H; Keating, MJ; Tsimberidou, AM1
Avvisati, G; Breccia, M; Buffolino, S; Cimino, G; De Angelis, G; Lo-Coco, F; Mariella, M; Martini, V; Minotti, C1
Baysan, A; Gollapudi, S; Gupta, S; Su, H; Yel, L1
Chen, SJ; Chen, Z; de Thé, H; Guillemin, MC; Lallemand-Breittenbach, V; Li, JM; Shen, ZX; Vitoux, D; Zhao, WL; Zhou, J; Zhu, J1
Jing, Y; Waxman, S1
Bi, KH; Jiang, GS1
Büchner, T; Hehlmann, R; Lengfelder, E; Schultheis, B1
Chen, SJ; Chen, Z; Wang, ZY; Zhang, J; Zhou, GB1
Aribi, A; Cortes, JE; Estey, EH; Faderl, SH; Garcia-Manero, G; Kantarjian, HM; Koller, CA; Kornblau, SM; Laddie, NM; Thomas, DA1
Akay, C; Gazitt, Y; Kircelli, F1
Ammatuna, E; Lo Coco, F; Sanz, MA1
Beissert, T; Bug, G; Henschler, R; Hoelzer, D; Puccetti, E; Rüster, B; Ruthardt, M; Seshire, A; Zheng, X1
Besançon, F; Mathieu, J1
Gattermann, N; Germing, U; Käferstein, H; Knipp, S; Schapira, M1
de The, H; Nasr, R; Vitoux, D1
Hede, K1
Guo, T; Hong, M; Hu, Y; Shen, GX; Song, SJ; Wei, WN; Xia, LH; Zhang, XH1
Karlsson, J; Påhlman, S; Pettersson, HM; Pietras, A; Øra, I1
Abdallah, M; Bazarbachi, A; Darwiche, N; Dbaibo, GS; de Thé, H; El-Sabban, M; Hermine, O; Kfoury, Y; Kozhaya, L; Nasr, R; Panjarian, S1
Emi, N; Kajiguchi, T; Naoe, T; Ono, Y; Yamamori, S; Yamamoto, K1
Au, WY; Fong, BM; Hui, CK; Kwong, YL; Liu, CL; Shek, TW; Tam, S1
Berridge, MV; Herst, PM; Hesketh, EL; Ritchie, DS1
Chandy, M; George, B; Mathews, V; Srivastava, A; Srivastava, VM; Thomas, M1
Ma, J1
Ahn, HS; Kang, HJ; Park, JA; Shin, HY; Yun, JH1
Au, WY; Kwong, YL; Tam, S1
Campbell, LJ; Catalano, A; Dawson, MA; Iland, H; Opat, S; Schwarer, A; Somana, K1
Chen, GQ; Wang, LS; Wu, YL; Yu, Y1
Jin, Z; Man, Z; Ran, M1
Cang, H; Li, L; Shi, G; Wang, J; Yi, J1
Au, WY; Fong, BM; Ho, KL; Kwong, YL; Tam, PC; Tam, S1
Adamson, PC; Balis, FM; Blaney, SM; Fox, E; Goodspeed, W; Murgo, AJ; O'Brien, M; Razzouk, BI; Reaman, GH; Widemann, BC; Xiao, S1
Warrell, RP2
Cunha De Santis, G; Cunha, FQ; Faccioli, LH; Falcão, RP; Garcia, AB; Lima, AS; Moreno, SE; Rego, EM; Secco, D; Sousa, RB; Tamarozzi, MB1
Antonioli, E; Cas, LD; D'Aloia, A; Raddino, R; Vizzardi, E; Zanini, G1
Hu, Y; Shen, GX; Song, SJ; Wei, WN; Zhang, XH1
Cernelc, P; Falnoga, I; Goessler, W; Podgornik, H; Raml, R; Slejkovec, Z; van Elteren, JT1
Dawes, IW; Dilda, PJ; Hogg, PJ; Lock, RB; Perrone, GG; Philp, A1
Jardin, F; Massy, J; Massy, N; Stamatoullas, A; Thery, JC; Tilly, H1
Abe, Y; Muta, K; Nakashima, Y; Ohtsuka, R; Sada, E; Tachikawa, Y; Takayanagi, R1
Aoki, S; Asai, T; Chiba, S; Hangaishi, A; Kanda, Y; Kurokawa, M; Motokura, T; Nagai, S; Ohtomo, K; Oshima, K; Watanabe, T1
Li, D; Wei, F; Zhang, W; Zhang, X1
Estey, E; Kopp, L; Quezada, G; Wells, RJ1
Altman, JK; Carayol, N; Dolniak, B; Fukunaga, R; Katsoulidis, E; Platanias, LC; Redig, AJ; Tallman, MS; Ueda, T; Watanabe-Fukunaga, R1
Chen, Z; Wang, ZY1
Levy, M; McLean, TW; Powell, BL; Wofford, MM1
Bazarbachi, A; de Thé, H; Habib, A; Hamade, E; Mahfouz, R; Nasrallah, MS1
Isobe, Y; Oshimi, K; Sasaki, M; Sugimoto, K1
Chen, X; Chen, Y; Zhang, L; Zhao, H; Zhu, X; Zou, Y1
Burry, L; Cashin, R; Peckham, K; Reynolds, S; Seki, JT1
Hazaka, Y; Kondo, T; Minami, Y; Onishi, N; Tanaka, Y; Toyoshima, K; Tsukada, J; Tsukuda, Y; Watanabe, Y; Yoda, A1
Acevedo-Alvarez, M; Akar, U; Lopez-Berestein, G; Ozpolat, B; Vivas-Mejia, P; Zorrilla-Calancha, I1
Mervis, J1
Chen, GQ; Chen, SJ; Chen, Z; Gazin, C; Jin, XL; Li, XS; Ma, J; Naoe, T; Ni, JH; Shen, ZX; Shi, XG; Si, GY; Sun, GL; Tang, W; Wang, ZY; Xong, SM; Zhang, P; Zhang, TD; Zhong, HJ; Zhu, J1
Andre, C; Chelbi-Alix, MK; Chen, Z; de The, H; Degos, L; Dhumeaux, D; Guillemin, MC; Herve, L; Koken, MH; Quignon, F; Wang, ZY; Zhu, J1
Cai, X; Chen, GQ; Chen, SJ; Chen, Z; de The, H; Han, ZG; He, KL; Jia, PM; Kitamura, K; Liu, MM; Ma, J; Miller, W; Naoe, T; Ni, JH; Niu, C; Paul, P; Shi, GY; Shi, XG; Tang, W; Wang, ZY; Waxman, S; Xiong, SM; Zhang, P; Zhang, TD; Zhu, J1
Chen, GQ; Chen, SJ; Chen, Y; Chen, Z; Fang, ZW; Li, XS; Ma, J; Ni, JH; Qiu, QY; Shen, ZX; Sun, GL; Tang, W; Wang, YT; Wang, ZY; Xiong, SM; Yang, KQ; Zhang, P; Zhang, TD; Zhou, L; Zhu, J1
Kitamura, K; Kiyoi, H; Naoe, T; Ohno, R; Takeshita, A; Tobita, T; Yoshida, H1
Look, AT1
Avvisati, G; Davison, K; Fanelli, M; Ferrara, FF; Gambacorti-Passerini, C; Lamph, WW; Lo Coco, F; Miller, WH; Nervi, C; Pelicci, PG; Peschle, C; Riccioni, R; Rosenauer, A; Shao, W; Testa, U; Waxman, S1
Benoit, G; Chelbi-Alix, MK; Chen, Z; de Thé, H; Giannì, M; Koken, MH; Lanotte, M1
Delva, L; Gabrilove, JL; Gambacorti-Passerini, C; König, A; Pandolfi, PP; Rivi, R; Scheinberg, DA; Wang, ZG; Warrell, RP1
Chen, G; Shi, G; Tang, W1
Zhang, Z1
Calleja, E; Corso, D; Dardashti, LJ; DeBlasio, A; Gabrilove, J; Jhanwar, S; Maslak, P; Pandolfi, PP; Scheinberg, DA; Soignet, SL; Wang, ZG; Warrell, RP1
Gallagher, RE2
Avvisati, G; Lo Coco, F; Mandelli, F; Nervi, C1
Miller, M1
Ikeda, Y; Kinjo, K; Kizaki, M; Muto, A; Ueno, H1
Chang, CS; Chen, YC; Chou, WC; Chung, CY; Huang, SF; Huang, SY; Kuo, TL; Shen, MC; Tang, JL; Tien, HF; Wang, CH; Yao, YT1
Buzyn, A; Daniel, MT; de Thé, H; Degos, L; Gianni, M; Koken, MH; Licht, J; Minard, P; Varet, B; Zelent, A1
Paternostro, G; Tamm, I; Zapata, JM1
Conrad, ME1
Hoelzer, D; Jensen, K; Ottmann, OG; Puccetti, E; Ruthardt, M; Sternsdorf, T; Will, H1
de Thé, H; Giannì, M1
Chen, WJ; Chen, YC; Huang, CH; Lee, YT; Wu, CC1
Vincent, PC1
Caen, J; Cai, X; Chen, GQ; Chen, SJ; Chen, Z; Guo, WM; Ju, B; Pan, L; Sun, GL; Wang, HL; Wang, ZY; Yao, YY; Zhao, WL; Zhu, J1
Carmignani, A; Fazzi, R; Galimberti, S; Papineschi, F; Petrini, M; Testi, R1
Agis, H; Edelhäuser, M; Fonatsch, C; Geissler, K; Lechner, K; Mitterbauer, G; Seewann, HL; Thalhammer, R; Valent, P; Weltermann, A1
Chalmers-Redman, RM; Dai, J; Jing, Y; Tatton, WG; Waxman, S1
Haanen, C; Vermes, I1
Chan, P; Huff, J; Nyska, A; Waalkes, M1
Cao, Q; Chen, GQ; Chen, SJ; Chen, Y; Chen, Z; Gu, BW; Gu, FY; Hu, J; Li, JM; Li, XS; Liu, JX; Niu, C; Ren, MY; Shen, ZX; Su, XY; Sun, HP; Wang, ZY; Waxman, S; Wu, W; Xiong, SM; Yan, H; Yang, RR; Yu, T; Yuan, MM; Zeng, XY; Zhang, FQ; Zhang, TD; Zhou, L1
Donelli, A; Galimberti, S; Leonardi, G; Luppi, M; Marasca, R; Petrini, M; Torelli, G; Vaccari, P; Zucchini, P1
Chen, SJ; Chen, Z; Hu, J; Shen, ZX; Sun, GL; Wang, ZY1
Cai, X; Chen, GQ; Chen, SJ; Chen, Z; Huang, Y; Jia, PM; Shen, YL; Wang, ZY; Xiong, SM; Yu, Y; Zhang, JW; Zhou, L; Zhu, Q1
Fabry, U; Galm, O; Osieka, R1
Annunziata, M; Boccuni, P; Cimino, R; Copia, C; Costantini, S; Del Vecchio, L; Dello Russo, A; Di Noto, R; Ferrara, F; Lo Pardo, C1
Fukuchi, Y; Hata, J; Ikeda, Y; Ito, M; Kinjo, K; Kizaki, M; Muto, A; Nishihara, T; Ueyama, Y; Umezawa, A; Yamato, K1
Akao, Y; Nakagawa, Y; Yamada, H1
Kizaki, M1
Hoshi, S; Kitamura, K; Kiyoi, H; Koike, M; Naoe, T; Saito, H1
Hirosawa, S; Kamei, S; Koyama, T; Ohsawa, M; Shibakura, M1
Chang, IY; Huang, MJ; Lin, CP; Lin, WY1
Chang, IY; Huang, MJ; Lin, WY; Sheu, YT1
Chen, YC; Huan, SY; Yang, CH1
Hayashi, T; Imanaka, T; Ishii, K; Komatsu, H; Nakamura, F; Ono, Y; Sawada, H; Tanaka, Y1
Firkin, F; Spencer, A1
Camacho, LH; Chanel, S; Ellison, R; Heller, G; Ho, R; Scheinberg, DA; Soignet, SL; Warrell, RP1
He, LZ; Pandolfi, PP; Rego, EM; Wang, ZG; Warrell, RP1
Hess, JL; Westervelt, P; Zhang, T1
Au, WY; Kwong, YL; Liang, R; Ma, SK; Ooi, C1
Akao, Y; Kitamura, K; Kiyoi, H; Minami, Y; Naoe, T; Saito, H; Yamamoto, K1
Novick, SC; Warrell, RP1
Henney, JE1
Miller, JL1
Fujisawa, S; Fujita, Y; Matsui, H; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Satoh, H; Shigeno, K; Shinjo, K; Sugiyama, S; Takeshita, A; Terada, H; Yoshida, H1
Scheinberg, DA1
Calleja, EM; Warrell, RP1
Chen, GQ; Chen, Z; Jing, Y; Miller, WH; Wang, L; Waxman, S; Xia, L1
Cohen, MH; Flamm Honig, S; Hirschfeld, S; Ibrahim, A; Johnson, JR; O'Leary, JJ; Pazdur, R; White, RM; Williams, GA1
Cobcroft, R; Gill, D; Kennedy, GA; Marlton, P1
Chen, GQ; Chen, SJ; Chen, Z; Shen, ZX; Wang, ZY1
Miller, KB; Relias, V; Roberts, TF; Schenkein, D; Sprague, K1
Bai, Y; Huang, S1
Guo, W; Wang, H; Zhao, W2
Cai, X; Jia, P; Shi, X1
Api, M; Chiaramida, S; Dutcher, JP; Garl, S; Lucariello, R; Unnikrishnan, D; Varshneya, N; Wiernik, PH1
Dejean, A; Lehembre, F; Müller, S; Pandolfi, PP1
Chen, G; Chen, S; Chen, Z; Fang, Z; Huang, Y; Li, X; Liu, H; Ni, J; Shen, Z; Wang, Z1
Au, WY; Chim, CS; Kwong, YL; Liang, R; Pang, A; Suen, C1
Soignet, SL1
Rust, DM; Soignet, SL1
Chen, J; Chen, SJ; Chen, Z; Li, JM; Li, XS; Liu, YF; Niu, C; Shen, Y; Shen, ZX; Tang, W; Wang, ZY; Wu, F; Wu, W; Xiong, SM; Yan, H; Zeng, XY; Zhao, WL1
Guo, W; Qu, B; Shen, Z; Wang, H; Wang, X; Wang, Z; Wu, F; Zhao, W1
Zelent, A1
Altucci, L; Chomienne, C; Gronemeyer, H; Raffelsberger, W; Reitmair, A; Rossin, A1
Adkins, DR; Brown, RA; Curtin, P; DiPersio, JF; Hurd, D; Khoury, H; Ley, TJ; Luger, SM; Ma, MK; Westervelt, P1
Fukuchi, Y; Hata, J; Hozumi, N; Ikeda, Y; Ito, M; Kawamura, C; Kizaki, M; Matsushita, H; Muto, A; Ueyama, Y; Umezawa, A; Yamada, T; Yamato, K1
Acar, V; Bénazeth, S; Chaumeil, JC; Corriol, O; Curis, E; Deschamps, P; Guyon, F; Nicolis, I; Zerrouk, N1
Baek, SH; Choi, YJ; Jang, MA; Kwon, TK; Lim, JH; Park, JW; Passaniti, T1
Calleja, E; Coutré, S; Dahlberg, S; Douer, D; Ellison, R; Frankel, SR; Kalaycio, M; Kantarjian, H; Scheinberg, DA; Sievers, EL; Soignet, SL; Steinherz, P; Stone, RM; Tallman, MS; Warrell, RP1
Au, WY; Chan, GC; Chim, CS; Ho, WK; Kwong, YL; Ooi, GC; Shek, TW1
Hong, SH; Privalsky, ML; Yang, Z1
Pandolfi, PP1
Barbey, JT; Soignet, S1
Chelbi-Alix, MK; de Thé, H1
Chen, GQ; Chen, SJ; Chen, Z; Wang, ZG; Wang, ZY; Zhang, TD1
de Thé, H; Lallemand-Breitenbach, V; Zhu, J1
Lanotte, M; Roussel, MJ1
Cai, X; Chen, G; Jia, P1
Guo, W; Wang, H; Zhu, J1
De Santis, S; Diverio, D; Lo Coco, F; Mandelli, F; Meloni, G; Petrucci, MT; Petti, MC; Pinazzi, MB; Romano, A; Tafuri, A1
Hirayama, Y; Ishikawa, K; Ishitani, K; Kondo, A; Koyama, R; Matsunaga, T; Nagai, T; Niitsu, Y; Ohta, H; Sakamaki, S1
Chen, Z; Guo, W; Qu, B; Shen, Z; Wang, H; Wang, X; Wang, Z; Zhao, W1
Hu, J; Li, X; Shen, Z; Sun, G; Sun, H; Wang, Z; Wu, W1
Bi, K; Jiang, G; Tang, T1
Guo, W; Ju, B; Wang, H; Wang, X; Zhao, W; Zhu, J1
Hu, N; Hu, X; Ma, L1
Zhang, T1
Shen, Z; Wang, H; Wang, X; Wu, F; Zhao, W1
Qiao, Z; Yang, L; Zhang, X1
Chen, G; Pan, L; Zhou, L1
Feusner, JH; Nabhan, C; Rowe, JM; Tallman, MS1
Cai, X; Chen, SJ; Chen, Z; Flexor, M; Jia, PM; Lanotte, M; Shen, YL; Tong, JH; Waxman, S; Yu, Y; Zhang, JW; Zhu, HQ; Zhu, Q1
Kuriyama, K1
Douer, D1
Akiyama, H; Fukuhara, O; Hiruma, K; Maeda, Y; Mikoshiba, M; Ohashi, K; Okuyama, Y; Sakamaki, H; Takei, N; Takeshita, A1
Han, X; Hu, L; Li, X; Liu, P; Qiu, F; Wang, S; Xiao, Y; Yang, H; Zhang, P; Zhou, J1
Chu, H; Guo, W; Pan, L; Qu, B; Wang, H; Wang, X; Zhao, W; Zhu, J1
Au, WY; Chim, CS; Kwong, YL; Liang, R; Lie, AK1
Fujisawa, S; Fujita, Y; Matsui, H; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Sahara, N; Satoh, H; Shigeno, K; Shinjo, K; Takeshita, A; Terada, H; Yoshida, H1
Bloomfield, CD; Slack, JL; Tallman, MS; Tricot, G; Waxman, S1
Miller, WH1
Lo Coco, F1
Annunziata, M; Ciolli, S; Fanci, R; Ferrara, F; Gianfaldoni, G; Leoni, F; Nozzoli, C1
Davison, K; Mann, KK; Miller, WH1
Dombret, H; Fenaux, P; Soignet, SL; Tallman, MS1
Chen, GQ; Chen, SJ; Chen, Z; Shen, ZX; Sun, GL; Tong, JH; Wang, ZY1
Garnier-Suillerot, A; Petroutsa, M; Salerno, M1
Miller, WH; Waxman, S1
DiPersio, JF; Ley, TJ; Ma, MK; Oldfather, KM; Pollock, JL; Walter, MJ; Westervelt, P; Williams, A1

Reviews

193 review(s) available for arsenic trioxide and Acute Promyelocytic Leukemia

ArticleYear
Transformation from polycythemia vera to acute promyelocytic leukemia: Case report and literature review.
    Medicine, 2022, Aug-12, Volume: 101, Issue:32

    Topics: Arsenic Trioxide; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Myeloproliferative Disorders; Polycythemia Vera; Primary Myelofibrosis

2022
Treatment for relapsed acute promyelocytic leukemia.
    Annals of hematology, 2022, Volume: 101, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Treatment Outcome; Tretinoin

2022
How retinoic acid and arsenic transformed acute promyelocytic leukemia therapy.
    Journal of molecular endocrinology, 2022, 11-01, Volume: 69, Issue:4

    Topics: Arsenic; Arsenic Trioxide; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transcription Factors; Translocation, Genetic; Tretinoin; Tumor Suppressor Proteins

2022
Does the pursuit of scientific excellence serve or hamper translational medical research: an historical perspective from hematological malignancies.
    Blood cancer journal, 2022, 10-07, Volume: 12, Issue:10

    Topics: Arsenic Trioxide; Arsenicals; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Thalidomide; Translational Research, Biomedical; Tretinoin

2022
Refractory acute promyelocytic leukemia with PLZF/RARa rearrangement: a case report and literature review.
    Anti-cancer drugs, 2023, 06-01, Volume: 34, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin

2023
Potential of natural products in combination with arsenic trioxide: Investigating cardioprotective effects and mechanisms.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 162

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biological Products; Cardiotonic Agents; Heart; Humans; Leukemia, Promyelocytic, Acute; Oxides

2023
The application of arsenic trioxide in cancer: An umbrella review of meta-analyses based on randomized controlled trials.
    Journal of ethnopharmacology, 2023, Nov-15, Volume: 316

    Topics: Arsenic Trioxide; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Leukemia, Promyelocytic, Acute; Liver Neoplasms; Randomized Controlled Trials as Topic; Tretinoin

2023
Differentiation syndrome in acute promyelocytic leukaemia.
    British journal of haematology, 2019, Volume: 187, Issue:2

    Topics: Acute Kidney Injury; Arsenic Trioxide; Cell Differentiation; Humans; Hypotension; Leukemia, Promyelocytic, Acute; Pulmonary Edema; Steroids; Syndrome; Tretinoin

2019
Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Disease-Free Survival; Hemorrhage; Humans; Incidence; Leukemia, Promyelocytic, Acute; Mortality; Neoplasm Recurrence, Local; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Remission Induction; Standard of Care; Time Factors; Tretinoin

2019
Therapeutic strategy of arsenic trioxide in the fight against cancers and other diseases.
    Metallomics : integrated biometal science, 2020, 03-01, Volume: 12, Issue:3

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Arsenic Trioxide; Humans; Leukemia, Promyelocytic, Acute; Neoplasms; Virus Diseases

2020
Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force.
    Journal of geriatric oncology, 2020, Volume: 11, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Humans; Leukemia, Promyelocytic, Acute; Remission Induction; Treatment Outcome; Tretinoin

2020
Osteonecrosis of the jaw induced by arsenic trioxide therapy in a leukemia patient: A rare case report and literature review.
    Oral oncology, 2020, Volume: 109

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Biomarkers; Combined Modality Therapy; Humans; Jaw Diseases; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Osteonecrosis; Tomography, X-Ray Computed; Treatment Outcome

2020
Biotransformation of arsenic and toxicological implication of arsenic metabolites.
    Archives of toxicology, 2020, Volume: 94, Issue:8

    Topics: Animals; Antineoplastic Agents; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Biotransformation; Humans; Leukemia, Promyelocytic, Acute; Risk Assessment; Toxicity Tests

2020
Role of hematopoietic cell transplantation in relapsed acute promyelocytic leukemia.
    Clinical transplantation, 2020, Volume: 34, Issue:9

    Topics: Arsenic Trioxide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Transplantation, Autologous; Treatment Outcome; Tretinoin

2020
Biotransformation of arsenic trioxide by AS3MT favors eradication of acute promyelocytic leukemia: revealing the hidden facts.
    Drug metabolism reviews, 2020, Volume: 52, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Biotransformation; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Methyltransferases; Pharmaceutical Preparations

2020
Arsenic trioxide as a novel anti-glioma drug: a review.
    Cellular & molecular biology letters, 2020, Volume: 25

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Autophagy; Glioma; Humans; Leukemia, Promyelocytic, Acute

2020
Cryptic t(15;17) acute promyelocytic leukemia with a karyotype of add(11)(p15) and t(13,20)- A case report with a literature review.
    Bosnian journal of basic medical sciences, 2021, Apr-01, Volume: 21, Issue:2

    Topics: Antineoplastic Agents; Arsenic Trioxide; Humans; Karyotype; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Tretinoin

2021
Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia.
    Toxicology and applied pharmacology, 2020, 12-15, Volume: 409

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute

2020
Does acute promyelocytic leukemia patient with the STAT5B/RARa fusion gene respond well to decitabine?: A case report and literature review.
    Medicine, 2020, Oct-23, Volume: 99, Issue:43

    Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Asian People; Consolidation Chemotherapy; Cytarabine; Decitabine; Drug Therapy, Combination; Female; Hospitalization; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Recurrence; Retinoic Acid Receptor alpha; STAT5 Transcription Factor; Treatment Outcome; Tretinoin

2020
Mechanistic effects of arsenic trioxide on acute promyelocytic leukemia and other types of leukemias.
    Cell biology international, 2021, Volume: 45, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Promyelocytic Leukemia Protein; Retinoic Acid Receptor alpha; Signal Transduction

2021
Arsenic trioxide in pediatric cancer - a case series and review of literature.
    Pediatric hematology and oncology, 2021, Volume: 38, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Child; Child, Preschool; Female; Hematologic Neoplasms; Humans; Infant; Leukemia, Promyelocytic, Acute; Male; Young Adult

2021
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
    Cancer, 2021, 04-15, Volume: 127, Issue:8

    Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Core Binding Factors; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm, Residual; Sulfonamides; Survival Rate; Translational Research, Biomedical; Tretinoin; Vidarabine

2021
Acute promyelocytic leukemia with myelofibrosis: A case report and literature review.
    Medicine, 2021, Apr-02, Volume: 100, Issue:13

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Primary Myelofibrosis; Treatment Outcome; Tretinoin

2021
Successful treatment of acute promyelocytic leukemia in a patient with prosthetic heart valves: a case report and review of the literature.
    Journal of medical case reports, 2021, May-04, Volume: 15, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Heart Valves; Heparin; Humans; Leukemia, Promyelocytic, Acute; Male; Tretinoin

2021
Health-related quality of life in patients with acute promyelocytic leukemia: a systematic literature review.
    Expert review of hematology, 2021, Volume: 14, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Humans; Leukemia, Promyelocytic, Acute; Quality of Life; Treatment Outcome; Tretinoin

2021
Acute promyelocytic leukemia current treatment algorithms.
    Blood cancer journal, 2021, 06-30, Volume: 11, Issue:6

    Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Tretinoin

2021
Successful treatment of acute promyelocytic leukemia in pregnancy with single-agent all-trans retinoic acid.
    Archives of gynecology and obstetrics, 2018, Volume: 297, Issue:2

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Gestational Age; Humans; Leukemia, Promyelocytic, Acute; Neoadjuvant Therapy; Pregnancy; Pregnancy Complications, Neoplastic; Treatment Outcome; Tretinoin

2018
Differentiation therapy revisited.
    Nature reviews. Cancer, 2018, Volume: 18, Issue:2

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Tretinoin

2018
[Acute promyelocytic leukaemia].
    Ugeskrift for laeger, 2018, 01-15, Volume: 180, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Disseminated Intravascular Coagulation; History, 20th Century; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Tretinoin

2018
Management of patients with acute promyelocytic leukemia.
    Leukemia, 2018, Volume: 32, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Electrocardiography; Female; Fetus; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Leukocytosis; Neoplasms, Second Primary; Pregnancy; Recurrence; Renal Dialysis; Renal Insufficiency; Tretinoin

2018
The success and the challenge of all-trans retinoic acid in the treatment of cancer.
    Critical reviews in food science and nutrition, 2019, Volume: 59, Issue:sup1

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Cell Differentiation; Cell Proliferation; Drug Therapy; Humans; Leukemia, Promyelocytic, Acute; Neoplasms; Receptors, Retinoic Acid; Signal Transduction; Tretinoin

2019
[Acute Promyelocytic Leukemia: New treatment strategies with ATRA and ATO - AML-BFM-Recommendations].
    Klinische Padiatrie, 2018, Volume: 230, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Child; Humans; Leukemia, Promyelocytic, Acute; Treatment Outcome; Tretinoin

2018
Treatment of Acute Promyelocytic Leukemia in Adults.
    Journal of oncology practice, 2018, Volume: 14, Issue:11

    Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Central Nervous System Neoplasms; Clinical Trials as Topic; Consolidation Chemotherapy; Disease Management; Drug Administration Schedule; Expert Testimony; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Neoplasm Grading; Neoplasm Staging; Tretinoin

2018
Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    PharmacoEconomics, 2019, Volume: 37, Issue:7

    Topics: Antineoplastic Agents; Arsenic Trioxide; Cost-Benefit Analysis; Disease-Free Survival; Humans; Leukemia, Promyelocytic, Acute; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Rate; Technology Assessment, Biomedical

2019
Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.
    Expert review of hematology, 2019, Volume: 12, Issue:2

    Topics: Administration, Intravenous; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Humans; Leukemia, Promyelocytic, Acute; Treatment Outcome; Tretinoin

2019
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.
    Blood, 2019, 04-11, Volume: 133, Issue:15

    Topics: Aged; Arsenic Trioxide; Disease Management; Female; Hemorrhagic Disorders; Humans; Leukemia, Promyelocytic, Acute; Practice Guidelines as Topic; Pregnancy; Recurrence; Tretinoin

2019
Curative strategies in APL.
    Seminars in hematology, 2019, Volume: 56, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Humans; Leukemia, Promyelocytic, Acute; Treatment Outcome

2019
The simpler, the better: oral arsenic for acute promyelocytic leukemia.
    Blood, 2019, 08-15, Volume: 134, Issue:7

    Topics: Administration, Oral; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Chemical and Drug Induced Liver Injury; China; Diarrhea; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis

2019
Myoclonic jerks complicating treatment of acute promyelocytic leukemia: case report and literature review.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Aged; Antineoplastic Agents; Arsenic Poisoning; Arsenic Trioxide; Drug Therapy, Combination; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Myoclonus; Remission Induction; Steroids; Topoisomerase II Inhibitors; Treatment Outcome; Tretinoin; Withholding Treatment

2019
Autophagy: New Insights into Mechanisms of Action and Resistance of Treatment in Acute Promyelocytic leukemia.
    International journal of molecular sciences, 2019, Jul-20, Volume: 20, Issue:14

    Topics: Arsenic Trioxide; Autophagy; Cell Differentiation; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute

2019
The evolving use of arsenic in pharmacotherapy of malignant disease.
    Annals of hematology, 2013, Volume: 92, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Biotransformation; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Gastrointestinal Diseases; Gene Expression Regulation; Heart Diseases; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Metabolic Networks and Pathways; Methyltransferases; Neoplasms; Oxides; Reactive Oxygen Species; Signal Transduction; Treatment Outcome

2013
A drug from poison: how the therapeutic effect of arsenic trioxide on acute promyelocytic leukemia was discovered.
    Science China. Life sciences, 2013, Volume: 56, Issue:6

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Asian People; China; Drug Discovery; Humans; Leukemia, Promyelocytic, Acute; Medicine, Chinese Traditional; Oxides; Remission Induction; Treatment Outcome

2013
Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia.
    International journal of hematology, 2013, Volume: 97, Issue:6

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Tretinoin

2013
Management of elderly patients with acute promyelocytic leukemia: progress and problems.
    Annals of hematology, 2013, Volume: 92, Issue:9

    Topics: Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Disease Management; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin

2013
Acute promyelocytic leukemia: do we have a new front-line standard of treatment?
    Current oncology reports, 2013, Volume: 15, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Remission Induction; Tretinoin

2013
[Arsenic trioxide: impact on the growth and differentiation of cancer cells and possible use in cancer therapy].
    Postepy higieny i medycyny doswiadczalnej (Online), 2013, Aug-06, Volume: 67

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Caspases; Cell Differentiation; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; MAP Kinase Kinase 4; Mitochondria; Neoplasms; NF-kappa B; Oxides

2013
Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical results and open questions.
    Expert review of anticancer therapy, 2013, Volume: 13, Issue:9

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides; Remission Induction

2013
Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
    Hematology (Amsterdam, Netherlands), 2014, Volume: 19, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Treatment Outcome; Tretinoin

2014
Biology and management of therapy-related acute promyelocytic leukemia.
    Current opinion in oncology, 2013, Volume: 25, Issue:6

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Early Diagnosis; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Oxides; Retrospective Studies; Risk Factors; Tretinoin

2013
Anticancer activity of small-molecule and nanoparticulate arsenic(III) complexes.
    Inorganic chemistry, 2013, Nov-04, Volume: 52, Issue:21

    Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Drug Carriers; Humans; Inactivation, Metabolic; Leukemia, Promyelocytic, Acute; Nanoparticles; Oxides; Sulfhydryl Compounds; Thermodynamics

2013
Postconsolidation maintenance and monitoring in patients with acute promyelocytic leukemia.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2013, Dec-01, Volume: 11, Issue:12

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Consolidation Chemotherapy; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Monitoring, Physiologic; Oncogene Proteins, Fusion; Oxides; Polymerase Chain Reaction; Tretinoin

2013
Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia.
    The Journal of experimental medicine, 2013, Dec-16, Volume: 210, Issue:13

    Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Transformation, Neoplastic; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Mice; Oncogene Proteins, Fusion; Oxides; Remission Induction; Signal Transduction; Transcriptional Activation; Tretinoin

2013
[Acute promyelocytic leukemia--modern approach to disease pathogenesis and differentiation treatment].
    Postepy higieny i medycyny doswiadczalnej (Online), 2013, Nov-25, Volume: 67

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Secondary Prevention; Survival Rate; Tretinoin

2013
Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology.
    Current pharmaceutical biotechnology, 2013, Volume: 14, Issue:9

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Retinoids; Transcription Factors; Tumor Suppressor Proteins

2013
ATRA + ATO: has a new standard of care been established in low-risk acute promyelocytic leukaemia?
    Current opinion in hematology, 2014, Volume: 21, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Randomized Controlled Trials as Topic; Standard of Care; Treatment Outcome; Tretinoin

2014
The role of PML in hematopoietic and leukemic stem cell maintenance.
    International journal of hematology, 2014, Volume: 100, Issue:1

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Fatty Acids; Hematopoietic Stem Cells; Humans; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Signal Transduction; Transcription Factors; Tumor Suppressor Proteins

2014
How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia.
    Blood, 2014, May-01, Volume: 123, Issue:18

    Topics: Adult; Arsenic Trioxide; Arsenicals; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Premedication; Syndrome; Tretinoin

2014
Contemporary treatment of APL.
    Current hematologic malignancy reports, 2014, Volume: 9, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin

2014
What is the standard regimen for patients with acute promyelocytic leukemia?
    Current hematologic malignancy reports, 2014, Volume: 9, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Oxides; Practice Guidelines as Topic; Tretinoin

2014
Advanced progress on the relationship between RA and its receptors and malignant tumors.
    Critical reviews in oncology/hematology, 2014, Volume: 91, Issue:3

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Proliferation; Drug Resistance, Neoplasm; Drug Therapy, Combination; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Neoplastic Cells, Circulating; Oxides; Receptors, Retinoic Acid; Signal Transduction; Tretinoin

2014
Understanding the molecular pathogenesis of acute promyelocytic leukemia.
    Best practice & research. Clinical haematology, 2014, Volume: 27, Issue:1

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Clinical Trials as Topic; Disease Models, Animal; DNA End-Joining Repair; Drug Synergism; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Mice; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms, Second Primary; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Oxides; Signal Transduction; Topoisomerase II Inhibitors; Translocation, Genetic; Tretinoin

2014
The coagulopathy in acute promyelocytic leukaemia--what have we learned in the past twenty years.
    Best practice & research. Clinical haematology, 2014, Volume: 27, Issue:1

    Topics: Annexin A2; Anticoagulants; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation Disorders; Blood Coagulation Tests; Carboxypeptidase B2; Disseminated Intravascular Coagulation; Fibrinolysis; Forecasting; Granulocyte Precursor Cells; Hemorrhagic Disorders; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recombinant Proteins; Risk Factors; S100 Proteins; Thrombomodulin; Thrombophilia; Thromboplastin; Tretinoin; Urokinase-Type Plasminogen Activator

2014
Triple A therapy: the molecular underpinnings of the unique sensitivity of leukemic promyelocytes to anthracyclines, all-trans-retinoic acid and arsenic trioxide.
    Best practice & research. Clinical haematology, 2014, Volume: 27, Issue:1

    Topics: Anthracyclines; Antibiotics, Antineoplastic; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Topoisomerase II Inhibitors; Transcription, Genetic; Tretinoin

2014
Conventional induction and post-remission therapy in APL: have we arrived?
    Best practice & research. Clinical haematology, 2014, Volume: 27, Issue:1

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Consolidation Chemotherapy; Daunorubicin; Harringtonines; Homoharringtonine; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mercaptopurine; Methotrexate; Mitoxantrone; Multicenter Studies as Topic; Oxides; Remission Induction; Tretinoin

2014
Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.
    Best practice & research. Clinical haematology, 2014, Volume: 27, Issue:1

    Topics: Adult; Age Factors; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation Factors; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Hydroxyurea; Idarubicin; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Oxides; Platelet Transfusion; Practice Guidelines as Topic; Remission Induction; Risk Assessment; Thioguanine; Treatment Outcome; Tretinoin

2014
Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?
    Best practice & research. Clinical haematology, 2014, Volume: 27, Issue:1

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Cell Differentiation; Clinical Trials as Topic; Disease Management; Drug Monitoring; Drug Resistance, Neoplasm; Historically Controlled Study; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Leukocytosis; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Real-Time Polymerase Chain Reaction; Remission Induction; Salvage Therapy; Tretinoin

2014
Extramedullary disease in APL: a real phenomenon to contend with or not?
    Best practice & research. Clinical haematology, 2014, Volume: 27, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Cerebral Hemorrhage; Humans; Incidence; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Models, Biological; Multicenter Studies as Topic; Organ Specificity; Oxides; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Risk Factors; Tetrahydronaphthalenes; Tretinoin

2014
Treatment of paediatric APL: how does the therapeutic approach differ from adults?
    Best practice & research. Clinical haematology, 2014, Volume: 27, Issue:1

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Age of Onset; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Blood Coagulation Disorders; Bone Marrow Examination; Cell Differentiation; Child; Child, Preschool; Heart Diseases; Humans; Infant; Leukemia, Promyelocytic, Acute; Multicenter Studies as Topic; Neoplasm, Residual; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Oxides; Prognosis; Pseudotumor Cerebri; Randomized Controlled Trials as Topic; Remission Induction; Risk Factors; Salvage Therapy; Tretinoin

2014
Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction.
    International journal of hematology, 2014, Volume: 100, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides; Salvage Therapy; Tretinoin

2014
Epigenetics in acute promyelocytic leukaemia pathogenesis and treatment response: a TRAnsition to targeted therapies.
    British journal of cancer, 2015, Feb-03, Volume: 112, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; DNA Methylation; Epigenesis, Genetic; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Treatment Outcome; Tretinoin

2015
Inhibition factors of arsenic trioxide therapeutic effects in patients with acute promyelocytic leukemia.
    Chinese medical journal, 2014, Volume: 127, Issue:19

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Mutation; Oxides

2014
New strategies in acute promyelocytic leukemia: moving to an entirely oral, chemotherapy-free upfront management approach.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Oct-01, Volume: 20, Issue:19

    Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease Management; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Oxides; Tretinoin

2014
[Treatment for acute promyelocytic leukemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Clinical Trials, Phase III as Topic; Consolidation Chemotherapy; Disseminated Intravascular Coagulation; Gene Fusion; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Molecular Targeted Therapy; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Recurrence; Remission Induction; Retinoic Acid Receptor alpha; Tetrahydronaphthalenes; Transcription Factors; Tretinoin; Tumor Suppressor Proteins

2014
Molecular mechanisms of the antileukemia activities of retinoid and arsenic.
    Journal of pharmacological sciences, 2014, Volume: 126, Issue:3

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Drug Synergism; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Treatment Outcome; Tretinoin

2014
Acute promyelocytic leukemia: where did we start, where are we now, and the future.
    Blood cancer journal, 2015, Apr-17, Volume: 5

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Failure; Tretinoin

2015
Insights into the All-trans-Retinoic Acid and Arsenic Trioxide Combination Treatment for Acute Promyelocytic Leukemia: A Meta-Analysis.
    Acta haematologica, 2015, Volume: 134, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Chemical and Drug Induced Liver Injury; Controlled Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Randomized Controlled Trials as Topic; Remission Induction; Risk; Tretinoin

2015
Synergistic targeted therapy for acute promyelocytic leukaemia: a model of translational research in human cancer.
    Journal of internal medicine, 2015, Volume: 278, Issue:6

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Oxides; Translational Research, Biomedical; Tretinoin

2015
[Pathogenesis of Acute Promyelocytic Leukemia].
    Rinsho byori. The Japanese journal of clinical pathology, 2015, Volume: 63, Issue:5

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease Models, Animal; Epigenomics; Humans; Leukemia, Promyelocytic, Acute; Medicine, Chinese Traditional; Mice; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Oxides; Transcription, Genetic; Tretinoin

2015
p53 as an Effector or Inhibitor of Therapy Response.
    Cold Spring Harbor perspectives in medicine, 2015, Dec-04, Volume: 6, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Female; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Oxides; Treatment Outcome; Tretinoin; Tumor Suppressor Protein p53

2015
Acute myeloid leukemia in children and adolescents: identification of new molecular targets brings promise of new therapies.
    Hematology. American Society of Hematology. Education Program, 2015, Volume: 2015

    Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Clinical Trials as Topic; Down Syndrome; Epigenesis, Genetic; GATA1 Transcription Factor; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Medical Oncology; Molecular Medicine; Mutation; Oxides; ras Proteins; Receptor Protein-Tyrosine Kinases; Treatment Outcome; Tretinoin

2015
Current standard treatment of adult acute promyelocytic leukaemia.
    British journal of haematology, 2016, Volume: 172, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Early Diagnosis; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Stem Cell Transplantation; Tretinoin

2016
Swallowing a bitter pill-oral arsenic trioxide for acute promyelocytic leukemia.
    Blood reviews, 2016, Volume: 30, Issue:3

    Topics: Administration, Intravenous; Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Treatment Outcome

2016
The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy.
    Cancer, 2016, Apr-15, Volume: 122, Issue:8

    Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase III as Topic; Female; Follow-Up Studies; Forecasting; Hematologic Neoplasms; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Oxides; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome

2016
Acute promyelocytic leukemia with cryptic t(15;17) on isochromosome 17: a case report and review of literature.
    International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:11

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Examination; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Disease Progression; Fatal Outcome; Genetic Predisposition to Disease; Humans; In Situ Hybridization, Fluorescence; Isochromosomes; Karyotype; Leukemia, Promyelocytic, Acute; Male; Molecular Diagnostic Techniques; Mutation; Oncogene Proteins, Fusion; Oxides; Phenotype; Predictive Value of Tests; Time Factors; Translocation, Genetic; Treatment Outcome; Tretinoin; Young Adult

2015
Optimal treatment strategies for high-risk acute promyelocytic leukemia.
    Current opinion in hematology, 2016, Volume: 23, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation Disorders; Disease Management; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Treatment Outcome; Tretinoin

2016
Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
    Annals of hematology, 2016, Volume: 95, Issue:5

    Topics: Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Chromosome Aberrations; Disseminated Intravascular Coagulation; DNA-Binding Proteins; fms-Like Tyrosine Kinase 3; Hemorrhagic Disorders; Humans; Immunophenotyping; Leukemia, Promyelocytic, Acute; Leukocyte Count; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Prognosis; Risk Factors; Tandem Repeat Sequences; Treatment Outcome; Tretinoin; Tumor Protein p73; Tumor Suppressor Proteins

2016
Current management of newly diagnosed acute promyelocytic leukemia.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:8

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Promyelocytic, Acute; Oxides; Randomized Controlled Trials as Topic; Tretinoin

2016
All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis.
    PloS one, 2016, Volume: 11, Issue:7

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin

2016
Acute promyelocytic leukemia: preventing early complications and late toxicities.
    Hematology. American Society of Hematology. Education Program, 2016, Dec-02, Volume: 2016, Issue:1

    Topics: Adult; Age Factors; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Humans; Leukemia, Promyelocytic, Acute; Oxides; Survival Rate

2016
Arsenic trioxide.
    Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:10

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence

2008
The expanding role of arsenic in acute promyelocytic leukemia.
    Seminars in hematology, 2008, Volume: 45, Issue:3 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Cytarabine; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin

2008
Arsenic trioxide mechanisms of action--looking beyond acute promyelocytic leukemia.
    Leukemia & lymphoma, 2008, Volume: 49, Issue:10

    Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Proliferation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Reactive Oxygen Species

2008
What is the role of arsenic in newly diagnosed APL?
    Best practice & research. Clinical haematology, 2008, Volume: 21, Issue:4

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin

2008
Transcriptome and proteome analyses of drug interactions with natural products.
    Current drug metabolism, 2008, Volume: 9, Issue:10

    Topics: Animals; Arsenic Trioxide; Arsenicals; Benzamides; Drug Discovery; Drug Synergism; Gene Expression Profiling; Herb-Drug Interactions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Proteome; Pyrimidines; Tretinoin

2008
Interaction between arsenic trioxide and human primary cells: emphasis on human cells of myeloid origin.
    Inflammation & allergy drug targets, 2009, Volume: 8, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Degranulation; Cell Differentiation; Gene Expression Regulation; Humans; Inflammation; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; Myeloid Cells; NADPH Oxidases; Oxidative Stress; Oxides; Reactive Oxygen Species

2009
Beneficial and adverse effects of molecularly targeted therapies for acute promyelocytic leukemia in central nervous system.
    CNS & neurological disorders drug targets, 2009, Volume: 8, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Central Nervous System Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin

2009
[Efficacy of arsenic trioxide for acute promyelocytic leukemia: a systematic review and meta-analysis].
    Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine, 2009, Volume: 7, Issue:9

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides

2009
Acute promyelocytic leukemia in childhood.
    Current oncology reports, 2009, Volume: 11, Issue:6

    Topics: Anthracyclines; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Translocation, Genetic; Tretinoin

2009
[Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
    Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine, 2009, Volume: 7, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Tretinoin

2009
Acute promyelocytic leukemia: what are the treatment options?
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:4

    Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Secondary Prevention; Tretinoin

2010
Signal transduction pathways and transcription factors triggered by arsenic trioxide in leukemia cells.
    Toxicology and applied pharmacology, 2010, May-01, Volume: 244, Issue:3

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Reactive Oxygen Species; Signal Transduction; Transcription Factors

2010
Acute promyelocytic leukemia: a paradigm for differentiation therapy.
    Cancer treatment and research, 2010, Volume: 145

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Dyspnea; Fever; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Models, Biological; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Transcription, Genetic; Treatment Outcome; Tretinoin

2010
Arsenic trioxide as a treatment for myelodysplastic syndrome.
    Current hematologic malignancy reports, 2006, Volume: 1, Issue:1

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; DNA-Binding Proteins; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; MDS1 and EVI1 Complex Locus Protein; Multicenter Studies as Topic; Myelodysplastic Syndromes; Oxides; Proto-Oncogenes; Salvage Therapy; Thalidomide; Transcription Factors

2006
The impact of molecularly targeted therapies upon the understanding of leukemogenesis and the role of hematopoietic stem cell transplantation in acute promyelocytic leukemia.
    Current stem cell research & therapy, 2010, Volume: 5, Issue:4

    Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Survival; Cell Transformation, Neoplastic; Glutamates; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Myeloid Progenitor Cells; Neoplastic Stem Cells; Nuclear Proteins; Oxides; Prodrugs; Promyelocytic Leukemia Protein; Transcription Factors; Tretinoin; Tumor Suppressor Proteins

2010
Modern approaches to treating acute promyelocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Feb-10, Volume: 29, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin

2011
Differentiation syndrome in patients with acute promyelocytic leukemia.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2012, Volume: 18, Issue:1

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Glucocorticoids; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Oxides; Risk Factors; Syndrome; Time Factors; Tretinoin

2012
The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis.
    Leukemia research, 2011, Volume: 35, Issue:9

    Topics: Adolescent; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Clinical Trials as Topic; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Tretinoin; Young Adult

2011
Advances in therapies for acute promyelocytic leukemia.
    Cancer science, 2011, Volume: 102, Issue:11

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Differentiation; Clinical Trials as Topic; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Multicenter Studies as Topic; Oncogene Proteins, Fusion; Oxides; Risk; Salvage Therapy; Tretinoin

2011
[All-trans retinoic acid and arsenic trioxide: their molecular mechanisms of action and updated clinical progress in APL therapy].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2011, Volume: 52, Issue:7

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Tretinoin

2011
Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy.
    Oncology (Williston Park, N.Y.), 2011, Volume: 25, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin

2011
Acute promyelocytic leukemia can be treated successfully without cytotoxic chemotherapy.
    Oncology (Williston Park, N.Y.), 2011, Volume: 25, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin

2011
Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia.
    Leukemia, 2012, Volume: 26, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Treatment Outcome

2012
Arsenic trioxide in acute promyelocytic leukemia: potion not poison.
    Expert review of anticancer therapy, 2011, Volume: 11, Issue:9

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides

2011
Curing APL through PML/RARA degradation by As2O3.
    Trends in molecular medicine, 2012, Volume: 18, Issue:1

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Sumoylation; Treatment Outcome

2012
Current treatment strategy of acute promyelocytic leukemia.
    Frontiers of medicine, 2011, Volume: 5, Issue:4

    Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Secondary Prevention; Survival Rate; Tretinoin

2011
Pathogenesis and treatment of leukemia: an Asian perspective.
    Expert opinion on therapeutic targets, 2012, Volume: 16 Suppl 1

    Topics: Arsenic Trioxide; Arsenicals; Asian People; Cell Proliferation; Humans; Leukemia; Leukemia, Large Granular Lymphocytic; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin

2012
A new era for an ancient drug: arsenic trioxide and Hedgehog signaling.
    Vitamins and hormones, 2012, Volume: 88

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Cerebellar Neoplasms; Hedgehog Proteins; Humans; Leukemia, Promyelocytic, Acute; Medulloblastoma; Oncogene Proteins; Oxides; Sarcoma, Ewing

2012
How to manage acute promyelocytic leukemia.
    Leukemia, 2012, Volume: 26, Issue:8

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Transformation, Neoplastic; Central Nervous System Neoplasms; Consolidation Chemotherapy; Drug Synergism; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Oxides; Recurrence; Tretinoin

2012
Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease.
    Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:7

    Topics: Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin

2012
Bleeding and thrombosis in acute promyelocytic leukemia.
    American journal of hematology, 2012, Volume: 87, Issue:6

    Topics: Antifibrinolytic Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation Tests; Clinical Trials as Topic; Combined Modality Therapy; Cysteine Endopeptidases; Disseminated Intravascular Coagulation; Factor VIIa; Factor VIII; Fibrinogen; Fibrinolysis; Hemorrhage; Heparin; Humans; Leukemia, Promyelocytic, Acute; Multicenter Studies as Topic; Neoplasm Proteins; Oxides; Plasma; Platelet Count; Platelet Transfusion; Recombinant Proteins; Thromboplastin; Thrombosis; Treatment Failure; Tretinoin

2012
Targeted therapy: The new lease on life for acute promyelocytic leukemia, and beyond.
    IUBMB life, 2012, Volume: 64, Issue:8

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Core Binding Factor Alpha 2 Subunit; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Oxides; RUNX1 Translocation Partner 1 Protein; Translocation, Genetic; Tretinoin; Tumor Cells, Cultured

2012
Provocative pearls in diagnosing and treating acute promyelocytic leukemia.
    Oncology (Williston Park, N.Y.), 2012, Volume: 26, Issue:7

    Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Arsenic Trioxide; Arsenicals; Biopsy, Fine-Needle; Bone Marrow; Clinical Trials as Topic; Dexamethasone; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Oxides; Practice Guidelines as Topic; Prognosis; Pulmonary Edema; Remission Induction; Respiratory Insufficiency; Tretinoin

2012
Arsenic trioxide: an ancient drug revived.
    Chinese medical journal, 2012, Volume: 125, Issue:19

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Oxides; Reactive Oxygen Species

2012
Mechanisms of action of arsenic trioxide.
    Cancer research, 2002, Jul-15, Volume: 62, Issue:14

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides

2002
Liposomal-all-trans-retinoic acid in treatment of acute promyelocytic leukemia.
    Leukemia & lymphoma, 2002, Volume: 43, Issue:5

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Clinical Trials as Topic; Drug Carriers; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Liposomes; Oxides; Tretinoin

2002
Management of acute promyelocytic leukemia.
    Current oncology reports, 2002, Volume: 4, Issue:5

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Daunorubicin; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Tretinoin

2002
How acute promyelocytic leukaemia revived arsenic.
    Nature reviews. Cancer, 2002, Volume: 2, Issue:9

    Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Differentiation; China; Europe; Gene Expression Regulation, Neoplastic; History, 15th Century; History, 16th Century; History, 18th Century; History, 20th Century; History, 21st Century; History, Ancient; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Transcription Factors; Tumor Suppressor Proteins

2002
Arsenic trioxide: acute promyelocytic leukemia and beyond.
    Leukemia & lymphoma, 2002, Volume: 43, Issue:8

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species

2002
[A review of the research on malignant hemopathies treated with arsenium-containing Chinese drugs].
    Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2000, Volume: 25, Issue:8

    Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia; Leukemia, Promyelocytic, Acute; Materia Medica; Oxides; Sulfides; Tumor Cells, Cultured

2000
[Research advances on effect of arsenic trioxide on tumor].
    Ai zheng = Aizheng = Chinese journal of cancer, 2002, Volume: 21, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Gene Expression; Gene Expression Profiling; Humans; Leukemia, Promyelocytic, Acute; Oxides

2002
Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation.
    The oncologist, 2003, Volume: 8, Issue:2

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Combined Modality Therapy; Europe; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Regression, Spontaneous; Oxides; Practice Guidelines as Topic; Risk Factors; Tretinoin; United States

2003
Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies.
    International journal of hematology, 2003, Volume: 78, Issue:1

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides

2003
[Relationship of arsenic trioxide and tumor cell apoptosis].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2003, Volume: 23, Issue:8

    Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; HeLa Cells; Humans; Leukemia, Promyelocytic, Acute; Oxides

2003
[Expanding possibilities, strategic considerations, and novel methods in the diagnosis and chemotherapy of adult acute myeloid leukemia].
    Orvosi hetilap, 2003, Sep-07, Volume: 144, Issue:36

    Topics: Adult; Anthracyclines; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Oligonucleotide Array Sequence Analysis; Oxides; Palliative Care; Prognosis; Remission Induction; Tretinoin

2003
The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
    Leukemia & lymphoma, 2004, Volume: 45, Issue:4

    Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Delivery Systems; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tretinoin

2004
Acute promyelocytic leukemia as a paradigm for targeted therapy.
    Seminars in hematology, 2004, Volume: 41, Issue:2 Suppl 4

    Topics: Arsenic Trioxide; Arsenicals; Drug Delivery Systems; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin

2004
[Advances in the study on antineoplastic action of realgar].
    Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials, 2004, Volume: 27, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; K562 Cells; Leukemia; Leukemia, Promyelocytic, Acute; Materia Medica; Oxides; Tumor Cells, Cultured

2004
An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid.
    Hematological oncology, 2004, Volume: 22, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Remission Induction; Treatment Outcome; Tretinoin

2004
Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies.
    Current opinion in hematology, 2005, Volume: 12, Issue:1

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Models, Biological; Oncogene Proteins, Fusion; Oxides; Reactive Oxygen Species

2005
Arsenic trioxide as a treatment for myelodysplastic syndrome.
    Current hematology reports, 2005, Volume: 4, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cell Division; Clinical Trials as Topic; Dexamethasone; DNA-Binding Proteins; Drug Therapy, Combination; Glutathione; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; MDS1 and EVI1 Complex Locus Protein; Multicenter Studies as Topic; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Proto-Oncogenes; Transcription Factors

2005
Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside.
    Leukemia & lymphoma, 2004, Volume: 45, Issue:12

    Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Humans; Leukemia, Promyelocytic, Acute; Oxides

2004
Arsenic trioxide: an anti cancer missile with multiple warheads.
    Hematology (Amsterdam, Netherlands), 2005, Volume: 10, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Arsenic Trioxide; Arsenicals; Chromatin Assembly and Disassembly; DNA Fragmentation; Flavoproteins; Humans; Leukemia, Promyelocytic, Acute; Membrane Proteins; Mitosis; Oxides; Tumor Suppressor Protein p53

2005
[Pharmacological and clinical properties of arsenic trioxide (Trisenox) for relapse or refractory acute promyelocytic leukemia therapy].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2005, Volume: 125, Issue:6

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Mice; Oxides

2005
Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence.
    Haematologica, 2005, Volume: 90, Issue:9

    Topics: Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides

2005
Acute promyelocytic leukemia: a model of molecular target based therapy.
    Hematology (Amsterdam, Netherlands), 2005, Volume: 10 Suppl 1

    Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Delivery Systems; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin

2005
Treatment concepts of acute promyelocytic leukemia.
    Critical reviews in oncology/hematology, 2005, Volume: 56, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Prognosis; Recurrence; Risk Factors; Stem Cell Transplantation; Thrombosis; Translocation, Genetic; Transplantation, Homologous; Tretinoin

2005
Strategies for the treatment of acute promyelocytic leukemia.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2006, Volume: 4, Issue:1

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin

2006
Hypoxia inducible factor-1alpha and leukemic cell differentiation.
    Sheng li xue bao : [Acta physiologica Sinica], 2006, Feb-25, Volume: 58, Issue:1

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Transformation, Neoplastic; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia; Leukemia, Promyelocytic, Acute; Oxides

2006
Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin.
    Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:1

    Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides

2006
Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
    Hematological oncology, 2006, Volume: 24, Issue:4

    Topics: Administration, Oral; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Treatment Outcome

2006
[Therapeutic strategies for patients with relapsed acute promyelocytic leukemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2006, Volume: 47, Issue:8

    Topics: Aminoglycosides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Leukemia, Promyelocytic, Acute; Oxides; Practice Guidelines as Topic; Recurrence; Remission Induction; Tetrahydronaphthalenes; Tretinoin

2006
Recent advances in the treatment of APL.
    Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:10

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Diagnosis, Differential; History, 20th Century; History, 21st Century; Humans; Leukemia, Promyelocytic, Acute; Oxides; Translocation, Genetic

2006
Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide?
    Leukemia & lymphoma, 2006, Volume: 47, Issue:11

    Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Tretinoin

2006
Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.
    Current topics in microbiology and immunology, 2007, Volume: 313

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome

2007
The design of selective and non-selective combination therapy for acute promyelocytic leukemia.
    Current topics in microbiology and immunology, 2007, Volume: 313

    Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin

2007
Relationship between cytokines and leukocytosis in patients with APL induced by all-trans retinoic acid or arsenic trioxide.
    Cellular & molecular immunology, 2006, Volume: 3, Issue:6

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cytokines; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides; Tretinoin

2006
[Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
    Deutsche medizinische Wochenschrift (1946), 2007, Feb-16, Volume: 132, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Risk Factors; Time Factors

2007
Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
    Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2007, Jun-29, Volume: 362, Issue:1482

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin

2007
Treatment of relapsed or refractory acute promyelocytic leukemia.
    Best practice & research. Clinical haematology, 2007, Volume: 20, Issue:1

    Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Oxides; Transplantation, Autologous; Transplantation, Homologous

2007
Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
    The international journal of biochemistry & cell biology, 2007, Volume: 39, Issue:6

    Topics: Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Models, Biological; Oncogene Proteins, Fusion; Oxides; Tretinoin

2007
[Arsenic trioxide as a therapeutic agent in APL].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Jan-28, Volume: 65 Suppl 1

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides

2007
Arsenic trioxide and neuroblastoma cytotoxicity.
    Journal of bioenergetics and biomembranes, 2007, Volume: 39, Issue:1

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Brain Neoplasms; Cell Death; Cell Differentiation; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Neuroblastoma; Oxides

2007
Leukemia, an effective model for chemical biology and target therapy.
    Acta pharmacologica Sinica, 2007, Volume: 28, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Dasatinib; Growth Inhibitors; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Tretinoin

2007
PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia.
    International journal of clinical oncology, 2007, Volume: 12, Issue:5

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Tetrahydronaphthalenes; Tretinoin

2007
New data with arsenic trioxide in leukemias and myelodysplastic syndromes.
    Clinical lymphoma & myeloma, 2007, Volume: 8 Suppl 1

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Myelodysplastic Syndromes; Oxides

2007
Acute promyelocytic leukemia: from highly fatal to highly curable.
    Blood, 2008, Mar-01, Volume: 111, Issue:5

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; History, 20th Century; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin

2008
[Progresses in the study of hematology in China, 1997].
    Zhonghua yi xue za zhi, 1997, Volume: 77, Issue:12

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Oxides; Thrombophlebitis

1997
[Arsenic trioxide, a new drug for the treatment of acute promyelocytic leukemia resistant to tretinoine].
    Nederlands tijdschrift voor geneeskunde, 1999, Aug-21, Volume: 143, Issue:34

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin

1999
Arsenic-induced apoptosis in malignant cells in vitro.
    Leukemia & lymphoma, 2000, Volume: 37, Issue:1-2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Down-Regulation; Glutathione; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Leukemia; Leukemia, B-Cell; Leukemia, Promyelocytic, Acute; Leukocytes, Mononuclear; Neuroblastoma; Oxides; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured

2000
[Recent advances of differentiation-inducing therapy for leukemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2000, Volume: 41, Issue:3

    Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Differentiation; Histone Deacetylase Inhibitors; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Transcription, Genetic; Tretinoin

2000
Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
    Leukemia & lymphoma, 2000, Volume: 38, Issue:3-4

    Topics: Acute Kidney Injury; Antineoplastic Agents; Apoptosis; Arrhythmias, Cardiac; Arsenic Trioxide; Arsenicals; Cell Differentiation; Chemical and Drug Induced Liver Injury; Drug Evaluation; Drug Screening Assays, Antitumor; Gastrointestinal Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Life Tables; Medicine, Chinese Traditional; Mitochondria; Models, Biological; Neoplasm Proteins; Neoplastic Stem Cells; Neuromuscular Diseases; Oncogene Proteins, Fusion; Oxides; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured; Urinary Bladder Neoplasms

2000
Arsenicals and inhibitors of histone deacetylase as anticancer therapy.
    Haematologica, 1999, Volume: 84 Suppl EHA-4

    Topics: Acetylation; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; China; Chromatin; Drug Evaluation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gastrointestinal Diseases; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Melarsoprol; Neoplasm Proteins; Neoplasms; Nervous System Diseases; Oxides; Phenylbutyrates; Protein Processing, Post-Translational; Salvage Therapy; Tretinoin

1999
Arsenicals in hematologic cancers.
    Seminars in oncology, 2000, Volume: 27, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tumor Cells, Cultured

2000
Old, new drugs and new, new drugs for the new millennium.
    Current oncology reports, 2000, Volume: 2, Issue:2

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Clinical Trials as Topic; Female; Forecasting; Humans; Imatinib Mesylate; Leukemia, Promyelocytic, Acute; Male; Oxides; Piperazines; Prognosis; Pyrimidines; Sensitivity and Specificity; Treatment Outcome

2000
Differentiating agents in pediatric malignancies: all-trans-retinoic acid and arsenic in acute promyelocytic leukemia.
    Current oncology reports, 2000, Volume: 2, Issue:6

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Child; Disease Models, Animal; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin

2000
Acute progranulocytic leukemia.
    Current opinion in oncology, 2001, Volume: 13, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Clinical Trials as Topic; Cytarabine; Humans; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Oxides; Prognosis; Salvage Therapy; Survival Analysis; Tretinoin

2001
Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.
    Seminars in hematology, 2001, Volume: 38, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides

2001
Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia.
    The oncologist, 2001, Volume: 6 Suppl 2

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides

2001
Risk/benefit profile of arsenic trioxide.
    The oncologist, 2001, Volume: 6 Suppl 2

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides; Risk Assessment

2001
Histone deacetylases and transcriptional therapy with their inhibitors.
    Cancer chemotherapy and pharmacology, 2001, Volume: 48 Suppl 1

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Mice; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transcription, Genetic; Tretinoin

2001
APL, a model disease for cancer therapies?
    Oncogene, 2001, Oct-29, Volume: 20, Issue:49

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Nucleus; Cellular Senescence; Humans; Inclusion Bodies; Leukemia, Promyelocytic, Acute; Multigene Family; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Tretinoin

2001
Arsenic trioxide, a therapeutic agent for APL.
    Oncogene, 2001, Oct-29, Volume: 20, Issue:49

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Disease Models, Animal; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Mice; Mitochondria; Neoplasm Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Remission Induction; Survival Rate; Transcription Factors; Tretinoin; Tumor Suppressor Proteins

2001
Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission.
    Oncogene, 2001, Oct-29, Volume: 20, Issue:49

    Topics: Animals; Arsenic Trioxide; Arsenicals; Binding Sites; Caspases; Cell Differentiation; Cysteine Endopeptidases; Humans; Leukemia, Promyelocytic, Acute; Multienzyme Complexes; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Proteasome Endopeptidase Complex; Protein Structure, Tertiary; Remission Induction; Tretinoin

2001
Maturation sensitive and resistant t(15;17) NB4 cell lines as tools for APL physiopathology: nomenclature of cells and repertory of their known genetic alterations and phenotypes.
    Oncogene, 2001, Oct-29, Volume: 20, Issue:49

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Oxides; Phenotype; Retinoids; Terminology as Topic; Transgenes; Tumor Cells, Cultured

2001
Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies.
    Blood reviews, 2001, Volume: 15, Issue:3

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Survival Analysis

2001
Acute promyelocytic leukemia: evolving therapeutic strategies.
    Blood, 2002, Feb-01, Volume: 99, Issue:3

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Remission Induction; Tretinoin

2002
Advances in the treatment of relapsed acute promyelocytic leukemia.
    Acta haematologica, 2002, Volume: 107, Issue:1

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Combined Modality Therapy; Humans; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Oxides; Recurrence; Tretinoin

2002
Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.
    The oncologist, 2002, Volume: 7 Suppl 1

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Oxides; Recurrence; Remission Induction; Survival Analysis; Treatment Outcome; Tretinoin

2002
Molecular targets of arsenic trioxide in malignant cells.
    The oncologist, 2002, Volume: 7 Suppl 1

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Glutathione; Growth Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Oxides

2002
Introduction.
    Seminars in hematology, 2002, Volume: 39, Issue:2 Suppl 1

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Tretinoin

2002
Arsenic trioxide: mechanisms of action.
    Seminars in hematology, 2002, Volume: 39, Issue:2 Suppl 1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Division; Glutathione; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neovascularization, Pathologic; Oncogene Proteins, Fusion; Oxides; Recurrence

2002
Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy.
    Seminars in hematology, 2002, Volume: 39, Issue:2 Suppl 1

    Topics: Antineoplastic Agents; Antineoplastic Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Randomized Controlled Trials as Topic; Recurrence

2002
Expanding the use of arsenic trioxide: leukemias and beyond.
    Seminars in hematology, 2002, Volume: 39, Issue:2 Suppl 1

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Neoplasms; Oxides

2002

Trials

88 trial(s) available for arsenic trioxide and Acute Promyelocytic Leukemia

ArticleYear
Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy.
    Blood advances, 2021, 11-09, Volume: 5, Issue:21

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Quality of Life; Treatment Outcome

2021
Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 Trial.
    JAMA oncology, 2022, Jan-01, Volume: 8, Issue:1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Child; Child, Preschool; Disease-Free Survival; Humans; Infant; Leukemia, Promyelocytic, Acute; Male; Tretinoin; Young Adult

2022
The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia.
    Cancer chemotherapy and pharmacology, 2022, Volume: 90, Issue:1

    Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Child; Drugs, Chinese Herbal; Humans; Leukemia, Promyelocytic, Acute; Tretinoin

2022
An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial).
    Blood cancer journal, 2022, 11-21, Volume: 12, Issue:11

    Topics: Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin

2022
Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group.
    Blood cancer journal, 2023, Dec-05, Volume: 13, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic; Arsenic Trioxide; Arsenicals; Child; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin

2023
Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial.
    Leukemia, 2020, Volume: 34, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Female; Follow-Up Studies; Germany; Humans; Italy; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Prospective Studies; Treatment Outcome; Tretinoin; Young Adult

2020
The economic research of arsenic trioxide for the treatment of newly diagnosed acute promyelocytic leukemia in China.
    Cancer, 2020, 01-15, Volume: 126, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; China; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; Female; Hospitalization; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Markov Chains; Middle Aged; Neoplasm Recurrence, Local; Quality-Adjusted Life Years; Remission Induction; Treatment Failure; Tretinoin

2020
A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide.
    Cancer medicine, 2020, Volume: 9, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Biomarkers, Tumor; Bortezomib; Disease Management; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Non-Randomized Controlled Trials as Topic; Prognosis; Salvage Therapy; Survival Rate; Tumor Cells, Cultured; Young Adult

2020
Safety and efficacy of arsenic trioxide and all-trans retinoic acid therapy in acute promyelocytic leukemia patients with a high risk for early death.
    Annals of hematology, 2020, Volume: 99, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Retrospective Studies; Risk Factors; Survival Rate; Tretinoin

2020
A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535).
    Blood advances, 2020, 04-28, Volume: 4, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Tretinoin

2020
Younger age at diagnosis of acute promyelocytic leukaemia is associated with better long-term cognitive functioning.
    British journal of haematology, 2020, Volume: 190, Issue:5

    Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Child; Child, Preschool; Cognition; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Tretinoin

2020
[Therapies for newly diagnosed acute promyelocytic leukemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2020, Volume: 61, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Japan; Leukemia, Promyelocytic, Acute; Oxides; Prospective Studies; Treatment Outcome; Tretinoin

2020
Tissue factor-bearing microparticles are a link between acute promyelocytic leukemia cells and coagulation activation: a human subject study.
    Annals of hematology, 2021, Volume: 100, Issue:6

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Blood Coagulation; Cell-Derived Microparticles; Female; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Prospective Studies; Thromboplastin

2021
Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 10-01, Volume: 39, Issue:28

    Topics: Adolescent; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Child; Child, Preschool; China; Female; Humans; Infant; Leukemia, Promyelocytic, Acute; Male; Progression-Free Survival; Time Factors; Tretinoin

2021
PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study.
    British journal of haematology, 2021, Volume: 195, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Prognosis; Retrospective Studies; Tretinoin; Young Adult

2021
Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Sep-10, Volume: 35, Issue:26

    Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Female; Historically Controlled Study; Humans; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Methotrexate; Oxides; Young Adult

2017
Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide.
    Annals of hematology, 2017, Volume: 96, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Child; Creatinine; Female; Fibrin Fibrinogen Degradation Products; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides

2017
The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia.
    Leukemia research, 2018, Volume: 65

    Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Blood Transfusion; Disseminated Intravascular Coagulation; Drugs, Chinese Herbal; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Platelet Transfusion; Retrospective Studies; Tretinoin; Young Adult

2018
Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
    Leukemia research, 2018, Volume: 66

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Survival Rate; Tretinoin

2018
Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
    BMC cancer, 2018, 04-03, Volume: 18, Issue:1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Biomarkers; Case-Control Studies; Child; Child, Preschool; Consolidation Chemotherapy; Cytarabine; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Treatment Outcome; Tretinoin

2018
Characteristics of fibrinolytic disorders in acute promyelocytic leukemia.
    Hematology (Amsterdam, Netherlands), 2018, Volume: 23, Issue:10

    Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Blood Coagulation Disorders; Blood Proteins; Female; Fibrinolysis; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oxides

2018
Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial).
    Haematologica, 2018, Volume: 103, Issue:11

    Topics: Aged; Aged, 80 and over; Arsenic Trioxide; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Survival Rate

2018
Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial.
    Blood, 2018, 09-27, Volume: 132, Issue:13

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Tretinoin; Young Adult

2018
Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study.
    American journal of hematology, 2018, Volume: 93, Issue:12

    Topics: Adolescent; Arsenic Trioxide; Child; Child, Preschool; Disease-Free Survival; Drugs, Chinese Herbal; Humans; Infant; Length of Stay; Leukemia, Promyelocytic, Acute; Male; Treatment Outcome; Tretinoin

2018
Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
    Trials, 2018, Sep-05, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; China; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Tretinoin; Young Adult

2018
Efficacy and safety of early switching to an outpatient therapy model using oral arsenic plus retinoic acid based-regimen in newly diagnosed acute promyelocytic leukemia.
    Leukemia research, 2019, Volume: 83

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic; Arsenic Trioxide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Models, Biological; Survival Rate; Tretinoin

2019
Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia.
    Blood, 2013, Apr-18, Volume: 121, Issue:16

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Oxides; Remission Induction; Transcription, Genetic; Transplantation, Autologous; Young Adult

2013
[Clinical investigation of homoharringtonine in combination with all-transretinoic acid and arsenic trioxide for acute promyelocytic leukemia].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2013, Volume: 34, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Harringtonines; Homoharringtonine; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin

2013
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
    The New England journal of medicine, 2013, Jul-11, Volume: 369, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Middle Aged; Neutropenia; Oxides; Thrombocytopenia; Tretinoin; Young Adult

2013
Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy.
    Leukemia research, 2013, Volume: 37, Issue:11

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Chromosome Aberrations; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxides; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Translocation, Genetic; Tretinoin; Young Adult

2013
Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Nov-20, Volume: 31, Issue:33

    Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Drugs, Chinese Herbal; Female; Fever; Follow-Up Studies; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Liver; Maintenance Chemotherapy; Male; Middle Aged; Oxides; Remission Induction; Sulfides; Treatment Outcome; Tretinoin; Young Adult

2013
Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Female; fms-Like Tyrosine Kinase 3; Humans; Karyotype; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion; Oxides; Prognosis; Treatment Outcome; Young Adult

2014
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.
    British journal of haematology, 2014, Volume: 165, Issue:4

    Topics: Adult; Aged; Aminoglycosides; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Dogs; Female; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Mercaptopurine; Methotrexate; Middle Aged; Oncogene Proteins, Fusion; Oxides; Platelet Count; Remission Induction; Risk; Treatment Outcome; Tretinoin; Young Adult

2014
Arsenic trioxide and mannitol for the treatment of acute promyelocytic leukemia relapse in the central nervous system.
    Blood, 2014, Sep-18, Volume: 124, Issue:12

    Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Blood-Brain Barrier; Central Nervous System Neoplasms; Child; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Mannitol; Middle Aged; Oxides; Recurrence; Remission Induction; Young Adult

2014
Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.
    Bone marrow transplantation, 2015, Volume: 50, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autografts; Female; Graft Survival; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Peripheral Blood Stem Cell Transplantation

2015
Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Oct-20, Volume: 32, Issue:30

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prospective Studies; Quality of Life; Tretinoin

2014
Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis.
    British journal of haematology, 2015, Volume: 168, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukapheresis; Leukemia, Promyelocytic, Acute; Leukocyte Count; Leukocytosis; Male; Middle Aged; Oxides; Retrospective Studies; Survival Rate; Tretinoin

2015
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
    British journal of haematology, 2015, Volume: 171, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Biomarkers, Tumor; Cardiovascular Diseases; Cell Differentiation; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; Drug Resistance, Neoplasm; Febrile Neutropenia; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Salvage Therapy; Tetrahydronaphthalenes; Tretinoin

2015
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Denmark; Female; Humans; Idarubicin; Intention to Treat Analysis; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; New Zealand; Oncogene Proteins, Fusion; Oxides; Quality of Life; Real-Time Polymerase Chain Reaction; Time Factors; Treatment Outcome; Tretinoin; United Kingdom; Young Adult

2015
[Efficacy Analysis of Arsenic Trioxide Combined with All Trans Retinoic Acid for Acute Promyelocytic Leukemia].
    Zhongguo shi yan xue ye xue za zhi, 2015, Volume: 23, Issue:5

    Topics: Arsenic Trioxide; Arsenicals; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Tretinoin

2015
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
    The Lancet. Haematology, 2015, Volume: 2, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Australia; Consolidation Chemotherapy; Female; Humans; Leukemia, Promyelocytic, Acute; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Remission Induction; Treatment Outcome; Young Adult

2015
Arsenic trioxide-based therapy is suitable for patients with psoriasis-associated acute promyelocytic leukemia - A retrospective clinical study.
    Hematology (Amsterdam, Netherlands), 2016, Volume: 21, Issue:5

    Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Psoriasis; Retrospective Studies; Survival Rate

2016
PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.
    Leukemia, 2016, Volume: 30, Issue:10

    Topics: Adolescent; Adult; Aged; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Humans; Induction Chemotherapy; Italy; Kinetics; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion; Oxides; Prognosis; Tretinoin; Young Adult

2016
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Feb-20, Volume: 35, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prospective Studies; Risk Factors; Treatment Outcome; Tretinoin; Young Adult

2017
Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
    Cancer, 2008, Nov-01, Volume: 113, Issue:9

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prognosis; Remission Induction; Survival Rate

2008
Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients.
    Acta haematologica, 2009, Volume: 121, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Survival Rate; Time Factors; Tretinoin

2009
Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903).
    Clinical genitourinary cancer, 2009, Volume: 7, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium

2009
Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia.
    Blood, 2010, Mar-04, Volume: 115, Issue:9

    Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Karyotyping; Leukemia, Promyelocytic, Acute; Male; Neutropenia; Oxides; Remission Induction; Time Factors

2010
Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Feb-20, Volume: 28, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxides; Prognosis; Remission Induction; Survival Rate; Treatment Outcome; Tretinoin; Young Adult

2010
Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24

    Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Follow-Up Studies; Hair; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Nails; Oxides; Recurrence; Remission Induction; Time Factors; Treatment Outcome

2010
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.
    Blood, 2010, Nov-11, Volume: 116, Issue:19

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; North America; Oxides; Survival Analysis; Treatment Outcome; Tretinoin; Young Adult

2010
[Recurrences of acute promyelocytic leukemia in children: experience with arsenic trioxide therapy and autologous hematopoietic cell transplantation].
    Terapevticheskii arkhiv, 2010, Volume: 82, Issue:7

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Combined Modality Therapy; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Secondary Prevention; Transplantation Conditioning; Transplantation, Autologous

2010
Effect of arsenic trioxide on the treatment of children with newly diagnosed acute promyelocytic leukemia in China.
    International journal of hematology, 2011, Volume: 93, Issue:2

    Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; China; Cohort Studies; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Remission Induction; Survival Analysis; Tretinoin

2011
Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-10, Volume: 29, Issue:20

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Disease-Free Survival; Female; Follow-Up Studies; Humans; Iran; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Survival Analysis

2011
Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study.
    Blood, 2011, Dec-15, Volume: 118, Issue:25

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cytarabine; Daunorubicin; Disease-Free Survival; Dyspepsia; Female; Follow-Up Studies; Headache; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Remission Induction; Time Factors; Treatment Outcome; Tretinoin

2011
The early addition of arsenic trioxide versus high-dose arabinoside is more effective and safe as consolidation chemotherapy for risk-tailored patients with acute promyelocytic leukemia: multicenter experience.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin; Young Adult

2012
Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO era.
    Haematologica, 2012, Volume: 97, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation, Homologous; Tretinoin

2012
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
    Blood, 2012, Aug-23, Volume: 120, Issue:8

    Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Treatment Outcome; Tretinoin; Young Adult

2012
Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience.
    American journal of hematology, 2002, Volume: 70, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cause of Death; Child; Disease-Free Survival; Drug Monitoring; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Oxides; Remission Induction; Treatment Outcome

2002
Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.
    Cancer, 2003, May-01, Volume: 97, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Oxides; Polymerase Chain Reaction; Remission Induction; Safety; Salvage Therapy; Survival Rate; Treatment Outcome

2003
Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jun-15, Volume: 21, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Statistics, Nonparametric; Survival Rate; Treatment Outcome; Tretinoin

2003
Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia.
    Blood, 2003, Jul-01, Volume: 102, Issue:1

    Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Salvage Therapy; Treatment Outcome; Tretinoin

2003
Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
    Chemical research in toxicology, 2004, Volume: 17, Issue:1

    Topics: Adult; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Arsenites; Cacodylic Acid; Chromatography, High Pressure Liquid; Humans; Injections, Intravenous; Leukemia, Promyelocytic, Acute; Male; Methylation; Middle Aged; Oxidation-Reduction; Oxides

2004
All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.
    Proceedings of the National Academy of Sciences of the United States of America, 2004, Apr-13, Volume: 101, Issue:15

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; In Situ Nick-End Labeling; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Prospective Studies; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Tretinoin; Tumor Cells, Cultured

2004
[Clinical observation and following up of two administration methods of arsenic trioxide in treatment of acute promyelocytic leukemia].
    Zhonghua yi xue za zhi, 2004, Mar-02, Volume: 84, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Case-Control Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Oxides; Remission Induction; Treatment Outcome

2004
Comparing two arsenic trioxide administration methods in APL therapy.
    Chinese medical journal, 2004, Volume: 117, Issue:9

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides

2004
[Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 1997, Volume: 18, Issue:5

    Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Female; Hair; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Nails; Oxides; Treatment Outcome; Young Adult

1997
Increased erythropoietin level and reticulocyte count during arsenic trioxide therapy.
    Leukemia, 2005, Volume: 19, Issue:4

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Erythropoietin; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Reticulocyte Count

2005
Effects of administration styles of arsenic trioxide on intracellular arsenic concentration, cell differentiation and apoptosis.
    Haematologica, 2005, Volume: 90, Issue:9

    Topics: Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line; Drug Administration Schedule; Humans; Intracellular Fluid; Leukemia, Promyelocytic, Acute; Oxides

2005
Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies.
    International journal of hematology, 2005, Volume: 82, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Female; Humans; Japan; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Treatment Outcome

2005
Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia.
    Leukemia & lymphoma, 2006, Volume: 47, Issue:1

    Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Disease Progression; Female; Follow-Up Studies; Humans; Immunohistochemistry; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Neovascularization, Pathologic; Oxides; Recurrence; Remission Induction; Survival Rate; Time Factors; Treatment Outcome

2006
Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity.
    Blood, 2006, Apr-01, Volume: 107, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Partial Thromboplastin Time; Platelet Count; Remission Induction; Survival Analysis; Treatment Outcome

2006
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
    Blood, 2006, May-01, Volume: 107, Issue:9

    Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Polymerase Chain Reaction; Remission Induction; Tretinoin

2006
Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety.
    Blood, 2006, Jul-01, Volume: 108, Issue:1

    Topics: Administration, Oral; Adult; Aged; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Electrocardiography; Electrocardiography, Ambulatory; Female; Heart Conduction System; Heart Rate; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Treatment Outcome

2006
Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity.
    Leukemia, 2006, Volume: 20, Issue:5

    Topics: Adult; Arsenic Trioxide; Arsenicals; Chemical and Drug Induced Liver Injury; Cohort Studies; Disease-Free Survival; Female; Follow-Up Studies; Genetic Predisposition to Disease; Humans; Incidence; Leukemia, Promyelocytic, Acute; Liver; Liver Function Tests; Male; Methylenetetrahydrofolate Reductase (NADPH2); Oxides; Polymorphism, Genetic; Remission Induction; Risk Factors; Survival Rate; Treatment Outcome

2006
Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials).
    Leukemia, 2006, Volume: 20, Issue:5

    Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Europe; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prognosis; Recurrence; Risk Factors; Treatment Outcome; Tretinoin

2006
Effects of arsenic trioxide administration styles on leukocytosis.
    Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih, 2006, Volume: 21, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Humans; Infusions, Intravenous; K562 Cells; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides

2006
Arrhythmogenic effects of arsenic trioxide in patients with acute promyelocytic leukemia and an electrophysiological study in isolated guinea pig papillary muscles.
    Circulation journal : official journal of the Japanese Circulation Society, 2006, Volume: 70, Issue:11

    Topics: Action Potentials; Animals; Antineoplastic Agents; Antioxidants; Arrhythmias, Cardiac; Arsenic Trioxide; Arsenicals; Butylated Hydroxytoluene; Electrocardiography; Electrophysiology; Guinea Pigs; Humans; Leukemia, Promyelocytic, Acute; Lipid Peroxidation; Long QT Syndrome; Myocardial Contraction; Oxides; Papillary Muscles; Poisons; Reactive Oxygen Species; Tetrodotoxin

2006
Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.
    Blood, 2008, Jan-15, Volume: 111, Issue:2

    Topics: Abdominal Pain; Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Constipation; Dermatitis; Dose-Response Relationship, Drug; Female; Headache; Humans; Hyperglycemia; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Lymphoma; Male; Nausea; Oxides; Pancreatitis; Pneumonia; Recurrence; Time Factors; Vomiting; Water-Electrolyte Balance

2008
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.
    Blood, 1997, May-01, Volume: 89, Issue:9

    Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Metabolic Clearance Rate; Middle Aged; Neutrophils; Oxides; Receptors, Retinoic Acid; Recurrence; Remission Induction; Retinoic Acid Receptor alpha; Survival Rate; Time Factors

1997
New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
    Cancer chemotherapy and pharmacology, 1997, Volume: 40 Suppl

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Retinoids; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured

1997
Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents.
    Leukemia, 1999, Volume: 13, Issue:7

    Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation; Daunorubicin; Drug Screening Assays, Antitumor; Endothelium, Vascular; Female; Fibrinolysis; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Thromboplastin; Tretinoin

1999
Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.
    Blood, 1999, Nov-15, Volume: 94, Issue:10

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Disease-Free Survival; Drug Monitoring; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Oxides; Recurrence; Remission Induction; Translocation, Genetic

1999
Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.
    International journal of hematology, 1999, Volume: 70, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Survival Rate; Tretinoin

1999
Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide.
    Blood, 2001, Jul-15, Volume: 98, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Death, Sudden; Female; Humans; Kinetics; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence

2001
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Sep-15, Volume: 19, Issue:18

    Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Electrocardiography; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Nervous System Diseases; Oxides; Pilot Projects; Platelet Count; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Syndrome

2001
[An analysis of the therapeutic effects and reactions in treating acute promyelocytic leukemia with intravenous arsenic trioxide or all-trans retinoic acid].
    Zhonghua nei ke za zhi, 1999, Volume: 38, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Child; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin

1999
Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation.
    Haematologica, 2002, Volume: 87, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Oxides; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Therapeutic Equivalency; Treatment Outcome

2002

Other Studies

682 other study(ies) available for arsenic trioxide and Acute Promyelocytic Leukemia

ArticleYear
Diagnosis of Acute Promyelocytic Leukemia After Presentation to Neuro-Ophthalmology.
    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2022, 03-01, Volume: 42, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Ophthalmology; Papilledema; Retrospective Studies; Treatment Outcome; Tretinoin; Young Adult

2022
Impact of sociodemographic factors on early mortality in acute promyelocytic leukemia in the United States: A time-trend analysis.
    Cancer, 2022, 01-15, Volume: 128, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Sociodemographic Factors; Treatment Outcome; Tretinoin; United States

2022
Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia.
    Blood advances, 2022, 01-25, Volume: 6, Issue:2

    Topics: Animals; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Leukemia, Promyelocytic, Acute; Mice; Oxides; Tretinoin

2022
The pharmacokinetics of therapeutic arsenic trioxide in acute promyelocytic leukemia patients.
    Leukemia & lymphoma, 2022, Volume: 63, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin

2022
Bone marrow necrosis as complication of treatment with all-trans retinoic acid and arsenic trioxide: case report and implications for treatment.
    Annals of hematology, 2022, Volume: 101, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Humans; Leukemia, Promyelocytic, Acute; Necrosis; Tretinoin

2022
Relapsed/refractory acute promyelocytic leukemia with RARA-LBD region mutation was salvaged by venetoclax: A case report.
    Medicine, 2021, Dec-03, Volume: 100, Issue:48

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Ecchymosis; Female; Humans; Leukemia, Promyelocytic, Acute; Mutation; Proto-Oncogene Proteins c-bcl-2; Recurrence; Salvage Therapy; Sulfonamides; Treatment Outcome; Tretinoin

2021
Gemtuzumab Ozogamicin Followed by Unrelated Cord Blood Transplantation With Reduced-intensity Conditioning for a Child With Refractory Acute Promyelocytic Leukemia.
    Journal of pediatric hematology/oncology, 2022, 05-01, Volume: 44, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cord Blood Stem Cell Transplantation; Female; Gemtuzumab; Humans; Infant; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin

2022
Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia.
    Blood cancer journal, 2022, 01-31, Volume: 12, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Treatment Outcome; Tretinoin

2022
Venetoclax for arsenic-resistant acute promyelocytic leukaemia.
    British journal of haematology, 2022, Volume: 197, Issue:5

    Topics: Arsenic; Arsenic Trioxide; Arsenicals; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Sulfonamides; Tretinoin

2022
Cup-shaped nuclei in acute promyelocytic leukaemia.
    British journal of haematology, 2022, Volume: 197, Issue:4

    Topics: Arsenic Trioxide; Cell Nucleus; Humans; Leukemia, Promyelocytic, Acute; Tretinoin

2022
Alternate application of all-trans-retinoic acid and arsenic trioxide combined with idarubicin/daunorubicin in treatment of acute promyelocytic leukemia.
    Pakistan journal of pharmaceutical sciences, 2022, Volume: 35, Issue:1

    Topics: Antineoplastic Agents; Arsenic Trioxide; Cohort Studies; Daunorubicin; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Prospective Studies; Tretinoin

2022
A Novel NUP98/RARG Gene Fusion in Pediatric Acute Myeloid Leukemia Resembling Acute Promyelocytic Leukemia.
    Journal of pediatric hematology/oncology, 2022, 04-01, Volume: 44, Issue:3

    Topics: Adult; Arsenic Trioxide; Child; Chromosome Aberrations; Gene Fusion; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Nuclear Pore Complex Proteins

2022
Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia.
    Blood advances, 2022, 06-14, Volume: 6, Issue:11

    Topics: Arsenic Trioxide; Chromosome Aberrations; Humans; Karyotype; Leukemia, Promyelocytic, Acute; Prognosis

2022
Extracellular Traps Increase Burden of Bleeding by Damaging Endothelial Cell in Acute Promyelocytic Leukaemia.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Arsenic Trioxide; Endothelial Cells; Extracellular Traps; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Tretinoin

2022
Do high-mobility group box 1 gene polymorphisms affect the incidence of differentiation syndrome in acute promyelocytic leukemia?
    Molecular biology reports, 2022, Volume: 49, Issue:7

    Topics: Arsenic Trioxide; Cytokines; HMGB1 Protein; Humans; Incidence; Leukemia, Promyelocytic, Acute; Polymorphism, Genetic; Syndrome; Tretinoin

2022
Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia.
    The Korean journal of internal medicine, 2022, Volume: 37, Issue:4

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Cytarabine; Follow-Up Studies; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Recurrence; Remission Induction; Treatment Outcome; Tretinoin

2022
p53 as a unique target of action of cisplatin in acute leukaemia cells.
    Journal of cellular and molecular medicine, 2022, Volume: 26, Issue:17

    Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Cisplatin; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Mice; Ovarian Neoplasms; Tumor Suppressor Protein p53

2022
[Acute Myeloid Leukemia - Update 2022].
    Deutsche medizinische Wochenschrift (1946), 2022, Volume: 147, Issue:17

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Tretinoin

2022
Subcellular Partitioning of Arsenic Trioxide Revealed by Label-Free Imaging.
    Analytical chemistry, 2022, 10-11, Volume: 94, Issue:40

    Topics: Antineoplastic Agents; Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Protein Aggregates; Sulfur; Tretinoin

2022
Hyperthermia promotes degradation of the acute promyelocytic leukemia driver oncoprotein ZBTB16/RARα.
    Acta pharmacologica Sinica, 2023, Volume: 44, Issue:4

    Topics: Antineoplastic Agents; Arsenic Trioxide; HeLa Cells; Humans; Hyperthermia, Induced; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Promyelocytic Leukemia Zinc Finger Protein; Tretinoin

2023
CPSF6-RARG-positive acute myeloid leukaemia resembles acute promyelocytic leukaemia but is insensitive to retinoic acid and arsenic trioxide.
    Pathology, 2023, Volume: 55, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Retinoic Acid Receptor gamma; Tretinoin

2023
Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia.
    Journal of hematology & oncology, 2022, 10-18, Volume: 15, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin

2022
Higher than normal mitochondrial DNA content associated with better outcome in acute promyelocytic leukaemia? Maybe.
    British journal of haematology, 2023, Volume: 200, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; DNA, Mitochondrial; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin

2023
Multimodal approach to characterize the tetrameric form of human PML-RBCC domain and ATO-mediated conformational changes.
    International journal of biological macromolecules, 2022, Dec-31, Volume: 223, Issue:Pt A

    Topics: Arsenic Trioxide; Humans; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Promyelocytic Leukemia Protein; Transcription Factors; Tumor Suppressor Proteins

2022
The characteristics and long-term outcomes of acute promyelocytic leukemia patients with early intracranial hemorrhage.
    International journal of hematology, 2023, Volume: 117, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Humans; Intracranial Hemorrhages; Leukemia, Promyelocytic, Acute; Prospective Studies; Retrospective Studies; Tretinoin

2023
Long-term real-world outcomes of patients with acute promyelocytic leukaemia treated with arsenic trioxide and all-trans retinoic acid without chemotherapy-a retrospective, single-centre study.
    British journal of haematology, 2023, Volume: 201, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin

2023
Long-term retrospective study of retinoic acid combined with arsenic and chemotherapy for acute promyelocytic leukemia.
    International journal of hematology, 2023, Volume: 117, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin

2023
Pyrrolidine Dithiocarbamate Enhances the Cytotoxic Effect of Arsenic Trioxide on Acute Promyelocytic Leukemia Cells.
    Combinatorial chemistry & high throughput screening, 2023, Volume: 26, Issue:11

    Topics: Antineoplastic Agents; Arsenic Trioxide; Cell Line, Tumor; Humans; Leukemia, Promyelocytic, Acute

2023
A global study for acute myeloid leukemia with RARG rearrangement.
    Blood advances, 2023, 07-11, Volume: 7, Issue:13

    Topics: Arsenic Trioxide; HLA-DR Antigens; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Tretinoin

2023
Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα.
    Cell death and differentiation, 2023, Volume: 30, Issue:5

    Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oxides; Transcription Factors; Tretinoin; Ubiquitination

2023
Tocotrienols-enriched Self-nanoemulsifying Drug Delivery System Enhances the Antileukemic Activity of All-trans Retinoic Acid but not Electrocardiogram Alterations Evoked by Its Combination with Arsenic Trioxide.
    AAPS PharmSciTech, 2023, Mar-14, Volume: 24, Issue:3

    Topics: Animals; Arsenic Trioxide; Electrocardiography; Leukemia, Promyelocytic, Acute; Mice; Oxides; Tocotrienols; Tretinoin

2023
[Devil with angel wings - when vitamin A saves lives].
    Deutsche medizinische Wochenschrift (1946), 2023, Volume: 148, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Disseminated Intravascular Coagulation; Humans; Leukemia, Promyelocytic, Acute; Male; Tretinoin; Vitamin A

2023
Transglutaminase 2 associated with PI3K and PTEN in a membrane-bound signalosome platform blunts cell death.
    Cell death & disease, 2023, 03-28, Volume: 14, Issue:3

    Topics: Arsenic Trioxide; Arsenicals; Cell Death; Humans; Integrins; Leukemia, Promyelocytic, Acute; Mechanistic Target of Rapamycin Complex 2; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Protein Glutamine gamma Glutamyltransferase 2; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; TOR Serine-Threonine Kinases; Tretinoin

2023
Monomethylarsonous acid binds to Cys-104α and Cys-112β of hemoglobin in acute promyelocytic leukemia patients treated with arsenic trioxide.
    Toxicology letters, 2023, May-01, Volume: 380

    Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Hemoglobins; Humans; Leukemia, Promyelocytic, Acute; Oxides

2023
Report of PRPF19 as a novel partner of RARG and the recurrence of interposition-type fusion in variant acute promyelocytic leukemia.
    Hematological oncology, 2023, Volume: 41, Issue:4

    Topics: Arsenic Trioxide; DNA Repair Enzymes; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Receptors, Retinoic Acid; RNA Splicing Factors; Tretinoin

2023
Type 2 diabetes affects arsenic metabolism via transporters in arsenic trioxide treated acute promyelocytic leukemia patients.
    Environmental toxicology and pharmacology, 2023, Volume: 100

    Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Diabetes Mellitus, Type 2; Glucose; HEK293 Cells; Humans; Leukemia, Promyelocytic, Acute; Oxides

2023
Torsemide increases arsenic concentrations by inhibition of multidrug resistance protein 4 in arsenic trioxide treated acute promyelocytic leukemia patients.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 163

    Topics: Animals; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Drug Resistance, Multiple; HEK293 Cells; Humans; Leukemia, Promyelocytic, Acute; Multidrug Resistance-Associated Proteins; Oxides; Rats; Torsemide

2023
Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all-trans retinoic acid and arsenic trioxide sensitivity.
    British journal of haematology, 2023, Volume: 202, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Repressor Proteins; Retinoic Acid Receptor alpha; Tretinoin

2023
Intracranial bleeding in acute promyelocytic leukemia treated with arsenic trioxide based regimens is associated with induction mortality but not with relapse.
    Blood cancer journal, 2023, 06-22, Volume: 13, Issue:1

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin

2023
The clinically relevant CHK1 inhibitor MK-8776 induces the degradation of the oncogenic protein PML-RARα and overcomes ATRA resistance in acute promyelocytic leukemia cells.
    Biochemical pharmacology, 2023, Volume: 214

    Topics: Arsenic Trioxide; Caspase 3; Caspases; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Tretinoin

2023
ATO Increases ROS Production and Apoptosis of Cells by Enhancing Calpain-Mediated Degradation of the Cancer Survival Protein TG2.
    International journal of molecular sciences, 2023, Jun-30, Volume: 24, Issue:13

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Calpain; Humans; Leukemia, Promyelocytic, Acute; Leukocytes, Mononuclear; Oxides; Protein Glutamine gamma Glutamyltransferase 2; Reactive Oxygen Species; Tretinoin

2023
Angiogenesis, coagulation, and fibrinolytic markers in acute promyelocytic leukemia (NB4): An evaluation of melatonin effects.
    Journal of pineal research, 2023, Volume: 75, Issue:3

    Topics: Arsenic Trioxide; Endothelial Cells; Humans; Leukemia, Promyelocytic, Acute; Melatonin; Tretinoin

2023
Utility of end of induction bone marrow biopsy and survival outcomes in acute promyelocytic leukemia treated with fixed-dose induction regimen.
    Leukemia & lymphoma, 2023, Volume: 64, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Retrospective Studies; Treatment Outcome; Tretinoin

2023
miR-603 promotes cell proliferation and differentiation by targeting TrkB in acute promyelocytic leukemia.
    Annals of hematology, 2023, Volume: 102, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Proliferation; Humans; Leukemia, Promyelocytic, Acute; MicroRNAs; Oxides

2023
Factors associated with thrombo-hemorrhagic deaths in patients with Acute Promyelocytic leukemia treated with Arsenic Trioxide and all-trans retinoic acid.
    Leukemia research, 2023, Volume: 134

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Thrombosis; Tretinoin

2023
Arsenic trioxide inhibits angiogenesis in vitro and in vivo by upregulating FoxO3a.
    Toxicology letters, 2019, Oct-15, Volume: 315

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Arsenic Trioxide; Cell Enlargement; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Epithelial Cells; Forkhead Box Protein O3; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Mice; Umbilical Veins; Up-Regulation

2019
CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic acid receptor alpha degradation in acute promyelocytic leukemia.
    Anti-cancer drugs, 2020, Volume: 31, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Biomarkers, Tumor; Caspases; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Prognosis; Quinazolines; Retinoic Acid Receptor alpha; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2020
[Effect of Chromosomal Karyotype on the Prognosis of Patients with Acute Promyelocytic Leukemia in Condition of the Maintenance Treatment Based on Arsenic Trioxide].
    Zhongguo shi yan xue ye xue za zhi, 2019, Volume: 27, Issue:5

    Topics: Arsenic Trioxide; Humans; Karyotype; Leukemia, Promyelocytic, Acute; Prognosis; Remission Induction; Retrospective Studies; Treatment Outcome; Tretinoin

2019
Outcomes of high-risk acute promyelocytic leukemia patients treated with arsenic trioxide (ATO)/all trans retinoic acid (ATRA) based induction and consolidation without maintenance phase: A case Series.
    Hematology/oncology and stem cell therapy, 2020, Volume: 13, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Retrospective Studies; Risk Factors; Survival Rate; Tretinoin

2020
Involvement of PML-I in reformation of PML nuclear bodies in acute promyelocytic leukemia cells by leptomycin B.
    Toxicology and applied pharmacology, 2019, 12-01, Volume: 384

    Topics: Antineoplastic Agents; Arsenic Trioxide; Cell Line, Tumor; Cell Nucleus; Drug Screening Assays, Antitumor; Drug Synergism; Fatty Acids, Unsaturated; Humans; Leukemia, Promyelocytic, Acute; Leukocytes, Mononuclear; Oncogene Proteins, Fusion; Primary Cell Culture; Promyelocytic Leukemia Protein; Protein Isoforms; Proteolysis

2019
Irreversibility of arsenic trioxide induced PML/RARα fusion protein solubility changes.
    Metallomics : integrated biometal science, 2019, 12-11, Volume: 11, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Cell Differentiation; Cell Line, Tumor; HEK293 Cells; HeLa Cells; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Solubility

2019
Comparative analysis of causes and predictors of early death in elderly and young patients with acute promyelocytic leukemia treated with arsenic trioxide.
    Journal of cancer research and clinical oncology, 2020, Volume: 146, Issue:2

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Child; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Prognosis; Retrospective Studies; Young Adult

2020
[All-trans retinoic acid/arsenic trioxide combination therapy for a patient with acute promyelocytic leukemia on dialysis].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2019, Volume: 60, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Polycystic Kidney Diseases; Remission Induction; Renal Dialysis; Treatment Outcome; Tretinoin

2019
Replacing chemotherapy with arsenic trioxide for the treatment of acute promyelocytic leukemia in the frontline setting: Is it cost-effective?
    Cancer, 2020, 01-15, Volume: 126, Issue:2

    Topics: Arsenic Trioxide; Arsenicals; China; Cost-Benefit Analysis; Humans; Leukemia, Promyelocytic, Acute; Tretinoin

2020
Ventricular repolarization dynamics in arsenic trioxide treatment of acute promyelocytic leukemia.
    International journal of cardiology, 2020, 05-01, Volume: 306

    Topics: Arsenic Trioxide; Arsenicals; Electrocardiography; Heart Rate; Humans; Leukemia, Promyelocytic, Acute; Long QT Syndrome; Oxides

2020
Acute Promyelocytic Leukemia With Sudden Vision Loss.
    JAMA ophthalmology, 2020, 02-01, Volume: 138, Issue:2

    Topics: Arsenic Trioxide; Blindness; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Retinal Detachment; Tretinoin

2020
Tolerance to arsenic trioxide combined with all-trans-retinoic acid in children with acute promyelocytic leukaemia in France.
    British journal of haematology, 2020, Volume: 188, Issue:1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Child; Child, Preschool; Disease-Free Survival; Drug Tolerance; Female; France; Humans; Infant; Leukemia, Promyelocytic, Acute; Male; Retrospective Studies; Survival Rate; Tretinoin

2020
Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide.
    British journal of haematology, 2020, Volume: 189, Issue:2

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Cost-Benefit Analysis; Humans; Leukemia, Promyelocytic, Acute; Retrospective Studies

2020
[Efficacy of Arsenic Trioxide Combined with ATRA and Chemotherapy for Relapsed Acute Promyelocytic Leukemia Patients].
    Zhongguo shi yan xue ye xue za zhi, 2020, Volume: 28, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Treatment Outcome; Tretinoin

2020
Activation of PPARγ intensified the effects of arsenic trioxide in acute promyelocytic leukemia through the suppression of PI3K/Akt pathway: Proposing a novel anticancer effect for pioglitazone.
    The international journal of biochemistry & cell biology, 2020, Volume: 122

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Cell Cycle; Cell Line, Tumor; Drug Synergism; Humans; Hypoglycemic Agents; Leukemia, Promyelocytic, Acute; Phosphatidylinositol 3-Kinases; Pioglitazone; PPAR gamma; Proto-Oncogene Proteins c-akt; Signal Transduction

2020
7‑Difluoromethyl‑5,4'‑dimethoxygenistein exerts anti‑angiogenic effects on acute promyelocytic leukemia HL‑60 cells by inhibiting the TLR4/NF‑κB signaling pathway.
    Molecular medicine reports, 2020, Volume: 21, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Arsenic Trioxide; Chick Embryo; Genistein; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Neovascularization, Pathologic; NF-kappa B; Signal Transduction; Toll-Like Receptor 4

2020
Two successful deliveries of healthy children by a young woman diagnosed and treated during induction and relapsed therapy for acute promyelocytic leukemia.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Pregnancy; Recurrence; Tretinoin; Young Adult

2020
Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic Leukemia.
    Clinical lymphoma, myeloma & leukemia, 2020, Volume: 20, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Prognosis; Retrospective Studies; Risk Factors; Treatment Outcome; Young Adult

2020
JSH practical guidelines for hematological malignancies, 2018: I. Leukemia-2. Acute promyelocytic leukemia (APL).
    International journal of hematology, 2020, Volume: 111, Issue:6

    Topics: Antineoplastic Agents; Arsenic Trioxide; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Practice Guidelines as Topic; Tretinoin

2020
Acute promyelocytic leukaemia lying under the mask of COVID-19-a diagnostic and therapeutic conundrum.
    British journal of haematology, 2020, Volume: 190, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; COVID-19; COVID-19 Drug Treatment; Humans; Leukemia, Promyelocytic, Acute; Male; SARS-CoV-2; Tretinoin

2020
Second cancers in adults with acute promyelocytic leukemia treated with or without arsenic trioxide: a SEER-medicare analysis.
    Leukemia, 2020, Volume: 34, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Female; Humans; Incidence; Leukemia, Promyelocytic, Acute; Male; Medicare; Neoplasms, Second Primary; Prognosis; SEER Program; United States

2020
c-Myc Inhibition Using 10058-F4 Increased the Sensitivity of Acute Promyelocytic Leukemia Cells to Arsenic Trioxide Via Blunting PI3K/NF-κB Axis.
    Archives of medical research, 2020, Volume: 51, Issue:7

    Topics: Antineoplastic Agents; Arsenic Trioxide; Cell Line, Tumor; Genes, myc; Humans; Leukemia, Promyelocytic, Acute; NF-kappa B; Proto-Oncogene Proteins c-myc; Thiazoles

2020
First report of successful management of acute promyelocytic leukemia in a pregnant female with All-Trans-Retinoic Acid and Arsenic Trioxide-based induction regimen.
    Blood cells, molecules & diseases, 2020, Volume: 85

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Female; Humans; Leukemia, Promyelocytic, Acute; Pregnancy; Pregnancy Complications, Neoplastic; Treatment Outcome; Tretinoin; Young Adult

2020
Probing arsenic trioxide (ATO) treated leukemia cell elasticities using atomic force microscopy.
    Analytical methods : advancing methods and applications, 2020, 10-15, Volume: 12, Issue:39

    Topics: Arsenic Trioxide; Cell Line, Tumor; Elasticity; Humans; Leukemia, Promyelocytic, Acute; Microscopy, Atomic Force

2020
Peroxiredoxin 3 Has Important Roles on Arsenic Trioxide Induced Apoptosis in Human Acute Promyelocytic Leukemia Cell Line via Hyperoxidation of Mitochondrial Specific Reactive Oxygen Species.
    Molecules and cells, 2020, Sep-30, Volume: 43, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Cell Line, Tumor; Humans; Leukemia, Promyelocytic, Acute; Mitochondria; Peroxiredoxin III; Reactive Oxygen Species; Transfection

2020
Severe Wernicke encephalopathy and acute pancreatitis due to all-trans-retinoic acid and arsenic trioxide during treatment of acute promyelocytic leukaemia: a case report.
    The Journal of international medical research, 2020, Volume: 48, Issue:9

    Topics: Acute Disease; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Pancreatitis; Tretinoin; Wernicke Encephalopathy

2020
JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML.
    The Journal of experimental medicine, 2021, 02-01, Volume: 218, Issue:2

    Topics: Animals; Arsenic Trioxide; Cell Line; Cell Line, Tumor; Disease Models, Animal; Humans; Interferon-alpha; Janus Kinase 2; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myeloproliferative Disorders; Promyelocytic Leukemia Protein

2021
Herpes zoster during arsenic trioxide therapy for acute promyelocytic leukemia.
    Leukemia & lymphoma, 2021, Volume: 62, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Herpes Zoster; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin

2021
Role of cofilin‑1 in arsenic trioxide‑induced apoptosis of NB4‑R1 cells.
    Molecular medicine reports, 2020, Volume: 22, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Cell Death; Cofilin 1; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Mitochondria; Oxides; Proteomics; Proto-Oncogene Proteins c-bcl-2; Receptors, Retinoic Acid; Tretinoin; Tumor Cells, Cultured

2020
Effects of different autophagy inhibitors on sensitizing KG-1 and HL-60 leukemia cells to chemotherapy.
    IUBMB life, 2021, Volume: 73, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Autophagy; Cell Proliferation; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Tretinoin; Tumor Cells, Cultured

2021
Autologous stem cell transplantation finds a place in acute promyelocytic leukaemia.
    British journal of haematology, 2021, Volume: 192, Issue:2

    Topics: Arsenic Trioxide; Arsenicals; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Transplantation, Autologous; Tretinoin

2021
Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens.
    British journal of haematology, 2021, Volume: 192, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Child; Child, Preschool; Disease Management; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Treatment Outcome; Young Adult

2021
[Acute promyelocytic leukemia recurrence diagnosed due to granulocytic sarcoma of the external auditory canal].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2020, Volume: 61, Issue:11

    Topics: Arsenic Trioxide; Ear Canal; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Recurrence; Sarcoma, Myeloid; Tretinoin

2020
Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site.
    Cancer cell, 2021, 02-08, Volume: 39, Issue:2

    Topics: A549 Cells; Allosteric Site; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Cell Line; Cell Line, Tumor; Female; HCT116 Cells; HEK293 Cells; Humans; Leukemia, Promyelocytic, Acute; MCF-7 Cells; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Mutation; PC-3 Cells; Tumor Suppressor Protein p53

2021
Suppression of proteasome induces apoptosis in APL cells and increases chemo-sensitivity to arsenic trioxide: Proposing a perception in APL treatment.
    Cancer treatment and research communications, 2021, Volume: 26

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Autophagy; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; G2 Phase Cell Cycle Checkpoints; Humans; Leukemia, Promyelocytic, Acute; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors

2021
Analysis of gamma-glutamyltransferase in acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
    Hematology (Amsterdam, Netherlands), 2021, Volume: 26, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Female; gamma-Glutamyltransferase; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Liver; Male; Middle Aged; Retrospective Studies; Young Adult

2021
Arsenic trioxide and all-trans retinoic acid in the treatment of children with newly diagnosed acute promyelocytic leukemia.
    Leukemia & lymphoma, 2021, Volume: 62, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin

2021
Towards Optimizing Risk-adapted Treatment of APML in ATRA/ATO Era: How Can Prediction of Early Mortality Help?
    Journal of pediatric hematology/oncology, 2021, 05-01, Volume: 43, Issue:4

    Topics: Antineoplastic Agents; Arsenic Trioxide; Humans; Leukemia, Promyelocytic, Acute; Prognosis; Risk Assessment; Risk Factors; Tretinoin

2021
Safety and efficacy of different doses of anthracyclines combined with arsenic trioxide and all-trans retinoic acid in the treatment of de novo acute promyelocytic leukemia.
    Hematology (Amsterdam, Netherlands), 2021, Volume: 26, Issue:1

    Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Biomarkers, Tumor; Bone Marrow; Disease Management; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Prognosis; Treatment Outcome; Tretinoin; Young Adult

2021
Characteristics of arsenic species in cerebrospinal fluid (CSF) of acute promyelocytic leukaemia (APL) patients treated with arsenic trioxide plus mannitol.
    British journal of clinical pharmacology, 2021, Volume: 87, Issue:10

    Topics: Arsenic; Arsenic Trioxide; Chromatography, High Pressure Liquid; Humans; Leukemia, Promyelocytic, Acute; Mannitol; Neoplasm Recurrence, Local

2021
Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
    Expert review of clinical pharmacology, 2021, Volume: 14, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Child; Chromatography, High Pressure Liquid; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Spectrometry, Fluorescence; Treatment Outcome; Young Adult

2021
Arsenic trioxide therapy predisposes to herpes zoster reactivation despite minimally myelosuppressive therapy.
    Leukemia research, 2021, Volume: 106

    Topics: Antineoplastic Agents; Arsenic Trioxide; Disease Susceptibility; Herpes Zoster; Herpesvirus 3, Human; Humans; Immunosuppressive Agents; Leukemia, Promyelocytic, Acute; Retrospective Studies; Virus Activation

2021
Monomethylated arsenic was the Major methylated arsenic in Red blood cells of acute promyelocytic leukemia patients treated with arsenic trioxide.
    Toxicology letters, 2021, Sep-01, Volume: 347

    Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biotransformation; Cacodylic Acid; Child; Child, Preschool; Chromatography, High Pressure Liquid; Erythrocytes; Female; Hemoglobins; Humans; Infant; Infant, Newborn; Leukemia, Promyelocytic, Acute; Male; Methylation; Middle Aged; Protein Binding; Spectrometry, Fluorescence; Spectrophotometry, Atomic; Young Adult

2021
Acute promyelocytic leukemia drug - arsenic trioxide in the presence of eugenol shows differential action on leukemia cells (HL-60) and cardiomyocytes (H9c2) - inference from NMR study.
    Toxicology mechanisms and methods, 2021, Volume: 31, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Eugenol; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Magnetic Resonance Spectroscopy; Myocytes, Cardiac; Pharmaceutical Preparations

2021
A call to action for the treatment of acute promyelocytic leukemia in the modern era: It is no longer just about the ATRA and arsenic.
    Cancer, 2021, 08-15, Volume: 127, Issue:16

    Topics: Arsenic; Arsenic Trioxide; Humans; Leukemia, Promyelocytic, Acute; Tretinoin

2021
Impact of insurance status on the survival of younger patients diagnosed with acute promyelocytic leukemia in the United States.
    Cancer, 2021, 08-15, Volume: 127, Issue:16

    Topics: Adult; Arsenic Trioxide; Humans; Insurance Coverage; Leukemia, Promyelocytic, Acute; Male; Medicaid; Medically Uninsured; United States

2021
Gene mutations in acute promyelocytic leukemia early death in patients treated with arsenic trioxide alone.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021, Volume: 23, Issue:10

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Cause of Death; Child; Female; GATA2 Transcription Factor; Genes, ras; Genetic Markers; High-Throughput Nucleotide Sequencing; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Mutation; Platelet Count; Prothrombin Time; Regression Analysis; Retrospective Studies; Risk Factors; Survival Rate; Time Factors; Young Adult

2021
Multidisciplinary corroboration in differentiation syndrome: a case report.
    Journal of medical case reports, 2021, May-05, Volume: 15, Issue:1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Leukemia, Promyelocytic, Acute; Syndrome; Tretinoin

2021
Successful Treatment of Acute Promyelocytic Leukemia Complicated with Endometrial Cancer by Arsenic Trioxide.
    Acta medica Okayama, 2021, Volume: 75, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Arsenic Trioxide; Endometrial Neoplasms; Female; Humans; Leukemia, Promyelocytic, Acute

2021
Arsenic trioxide reduces the expression of E2F1, cyclin E, and phosphorylation of PI3K signaling molecules in acute leukemia cells.
    Environmental toxicology, 2021, Volume: 36, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cyclin E; E2F1 Transcription Factor; Humans; Leukemia, Promyelocytic, Acute; Oxides; Phosphatidylinositol 3-Kinases; Phosphorylation

2021
Mutational profile of ZBTB16-RARA-positive acute myeloid leukemia.
    Cancer medicine, 2021, Volume: 10, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Bone Marrow; Child; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Disseminated Intravascular Coagulation; DNA Helicases; DNA-Binding Proteins; Female; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Nuclear Proteins; Oncogene Proteins, Fusion; Prognosis; Promyelocytic Leukemia Zinc Finger Protein; Retinoic Acid Receptor alpha; Transcription Factors; Translocation, Genetic; Tretinoin

2021
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study.
    Haematologica, 2021, 12-01, Volume: 106, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Prospective Studies; Remission Induction; Risk Assessment; Treatment Outcome; Tretinoin; Young Adult

2021
Arsenic and all-
    Haematologica, 2021, 12-01, Volume: 106, Issue:12

    Topics: Arsenic; Arsenic Trioxide; Humans; Leukemia, Promyelocytic, Acute; Tretinoin

2021
Crosstalk between hnRNP K and SET in ATRA-induced differentiation in acute promyelocytic leukemia.
    FEBS open bio, 2021, Volume: 11, Issue:7

    Topics: Animals; Arsenic Trioxide; Heterogeneous-Nuclear Ribonucleoprotein K; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, Nude; Tretinoin

2021
A novel fusion protein TBLR1-RARα acts as an oncogene to induce murine promyelocytic leukemia: identification and treatment strategies.
    Cell death & disease, 2021, 06-11, Volume: 12, Issue:6

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Cell Differentiation; Cell Transformation, Neoplastic; Cells, Cultured; Female; HEK293 Cells; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Male; Mice; Mice, Inbred C57BL; Oncogene Proteins, Fusion; Receptors, Cytoplasmic and Nuclear; Repressor Proteins; Retinoic Acid Receptor alpha; Xenograft Model Antitumor Assays

2021
Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin

2022
Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients - a 25-year Italian experience.
    British journal of haematology, 2021, Volume: 195, Issue:2

    Topics: Adolescent; Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Immunological; Arsenic Trioxide; Case-Control Studies; Child; Child, Preschool; Combined Modality Therapy; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Italy; Leukemia, Promyelocytic, Acute; Male; Neoplasm Recurrence, Local; Prognosis; Progression-Free Survival; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult

2021
All-trans Retinoic Acid, Arsenic Trioxide, and Anthracycline-based Chemotherapy Improves Outcome in Newly Diagnosed Acute Promyelocytic Leukemia Regardless of FLT3-ITD Mutation Status.
    Current medical science, 2021, Volume: 41, Issue:3

    Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Mutation; Prognosis; Tretinoin; Young Adult

2021
PML/RARA destabilization by hyperthermia: a new model for oncogenic fusion protein degradation?
    Blood cancer discovery, 2021, 06-10, Volume: 2, Issue:4

    Topics: Arsenic Trioxide; Arsenicals; Humans; Hyperthermia, Induced; Leukemia, Promyelocytic, Acute; Oxides; Proteolysis

2021
Effects of co-administration of arsenic trioxide and Schiff base oxovanadium complex on the induction of apoptosis in acute promyelocytic leukemia cells.
    Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine, 2021, Volume: 34, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Schiff Bases

2021
Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study.
    Blood advances, 2021, 07-27, Volume: 5, Issue:14

    Topics: Arsenic Trioxide; Hospitals; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Tretinoin

2021
Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.
    Leukemia, 2017, Volume: 31, Issue:11

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Oxides; Remission Induction; Survival Analysis; Treatment Outcome; Young Adult

2017
Bruising and abnormal leucocytes on a blood film--a haematological emergency.
    BMJ (Clinical research ed.), 2017, 03-23, Volume: 356

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Contusions; Gingival Hemorrhage; Humans; Lethargy; Leukemia, Promyelocytic, Acute; Leukocytes; Male; Oxides; Tretinoin; Young Adult

2017
Effect of ATRA and ATO on the expression of tissue factor in NB4 acute promyelocytic leukemia cells and regulatory function of the inflammatory cytokines TNF and IL-1β.
    Annals of hematology, 2017, Volume: 96, Issue:6

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; CD11c Antigen; Cell Line, Tumor; Enzyme Inhibitors; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Imidazoles; Interleukin-1beta; JNK Mitogen-Activated Protein Kinases; Leukemia, Promyelocytic, Acute; NF-kappa B; Oxides; p38 Mitogen-Activated Protein Kinases; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thromboplastin; Time Factors; Tretinoin; Tumor Necrosis Factor-alpha; U937 Cells

2017
Arsenic trioxide induced rhabdomyolysis, a rare but severe side effect, in an APL patient: a case report.
    Frontiers of medicine, 2017, Volume: 11, Issue:2

    Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Creatinine; Dyspnea; Female; Humans; Leukemia, Promyelocytic, Acute; Medicine, Chinese Traditional; Oxides; Rhabdomyolysis

2017
High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro.
    Oncotarget, 2017, May-16, Volume: 8, Issue:20

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Oxides; Reactive Oxygen Species; Survival Analysis; Tumor Cells, Cultured

2017
All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells.
    Cell death & disease, 2017, 05-11, Volume: 8, Issue:5

    Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Female; Humans; Interferon Regulatory Factors; Leukemia, Promyelocytic, Acute; Male; Monocytes; Neoplasm Proteins; Oxides; Tretinoin

2017
Mechanism of As2O3-Induced Action Potential Prolongation and Using hiPS-CMs to Evaluate the Rescue Efficacy of Drugs With Different Rescue Mechanism.
    Toxicological sciences : an official journal of the Society of Toxicology, 2017, 08-01, Volume: 158, Issue:2

    Topics: Action Potentials; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ERG1 Potassium Channel; HEK293 Cells; Humans; Induced Pluripotent Stem Cells; Leukemia, Promyelocytic, Acute; Long QT Syndrome; Lysosomes; Myocytes, Cardiac; Oxides; Patch-Clamp Techniques; Proteolysis; Resveratrol; Stilbenes; Terfenadine

2017
Infections caused by resistant organisms: Could organic arsenic compounds be an effective treatment?
    Medical hypotheses, 2017, Volume: 104

    Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Arsphenamine; Drug Resistance, Bacterial; Haptens; Humans; Inhibitory Concentration 50; Leukemia, Promyelocytic, Acute; Lyme Disease; Methicillin-Resistant Staphylococcus aureus; Models, Theoretical; Molecular Weight; Oxides; Staphylococcal Infections; Syphilis; Treatment Outcome

2017
Arsenic trioxide decreases the amount and inhibits the function of regulatory T cells, which may contribute to its efficacy in the treatment of acute promyelocytic leukemia.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Case-Control Studies; Cell Proliferation; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Prognosis; T-Lymphocytes, Regulatory

2018
Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress.
    Leukemia, 2018, Volume: 32, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Cell Differentiation; Cell Line; Cell Line, Tumor; Endoplasmic Reticulum Stress; HEK293 Cells; Humans; Leukemia, Promyelocytic, Acute; Tretinoin

2018
Arsenic trioxide consolidation in APL.
    The Lancet. Oncology, 2017, Volume: 18, Issue:9

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase III as Topic; Consolidation Chemotherapy; Disease-Free Survival; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome

2017
Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report.
    Hematology/oncology and stem cell therapy, 2019, Volume: 12, Issue:3

    Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Promyelocytic, Acute; Male; Rituximab; Tretinoin

2019
Distinct TP73-DAPK2-ATG5 pathway involvement in ATO-mediated cell death versus ATRA-mediated autophagy responses in APL.
    Journal of leukocyte biology, 2017, Volume: 102, Issue:6

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Autophagy-Related Protein 12; Autophagy-Related Protein 5; Cell Line, Tumor; Cell Nucleus; Death-Associated Protein Kinases; Gene Knockdown Techniques; HEK293 Cells; Humans; Leukemia, Promyelocytic, Acute; Models, Biological; Oxides; Promoter Regions, Genetic; Protein Binding; Protein Isoforms; Protein Stability; Signal Transduction; Transcription, Genetic; Tretinoin; Tumor Protein p73

2017
A new ETV6-NTRK3 cell line model reveals MALAT1 as a novel therapeutic target - a short report.
    Cellular oncology (Dordrecht), 2018, Volume: 41, Issue:1

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line; Cell Proliferation; Humans; Leukemia, Promyelocytic, Acute; Mitogen-Activated Protein Kinase 1; Models, Biological; Oncogene Proteins, Fusion; Oxides; Pyrimidines; RNA, Long Noncoding

2018
Redistribution of cell cycle by arsenic trioxide is associated with demethylation and expression changes of cell cycle related genes in acute promyelocytic leukemia cell line (NB4).
    Annals of hematology, 2018, Volume: 97, Issue:1

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Division; Cell Line, Tumor; Demethylation; DNA Methylation; Gene Expression Regulation, Leukemic; Genes, cdc; Humans; Leukemia, Promyelocytic, Acute; Oxides

2018
Severe myopericarditis following induction therapy with idarubicin and transretinoic acid in a patient with acute promyelocytic leukemia.
    Medicina clinica, 2018, 06-22, Volume: 150, Issue:12

    Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Cardiovascular Agents; Chest Pain; Drug Substitution; Echocardiography; Electrocardiography; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Myocarditis; Pericarditis; Remission Induction; Tretinoin

2018
[Comparison of Curative Effect between Fu Fang Huang Dai Pian and Arsenic Trioxide in Treatment of 45 Patients with Acute Promyelocytic Leukaemia].
    Zhongguo shi yan xue ye xue za zhi, 2017, Volume: 25, Issue:6

    Topics: Arsenic Trioxide; Arsenicals; Child; Humans; Leukemia, Promyelocytic, Acute; Medicine, Chinese Traditional; Oxides; Remission Induction; Retrospective Studies; Treatment Outcome; Tretinoin

2017
Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia.
    European journal of haematology, 2018, Volume: 100, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation; Female; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Middle Aged; Oxides; Platelet Adhesiveness; Platelet Aggregation; Platelet Function Tests; Remission Induction; Treatment Outcome; Young Adult

2018
Antileukemic effect of paclitaxel in combination with metformin in HL-60 cell line.
    Gene, 2018, Mar-20, Volume: 647

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Drug Therapy, Combination; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Metformin; NF-kappa B; Oxides; Paclitaxel; Signal Transduction

2018
[Successful treatment of acute promyelocytic leukaemia without chemotherapy and blood transfusion].
    Ugeskrift for laeger, 2018, 01-15, Volume: 180, Issue:3

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Female; Humans; Leukemia, Promyelocytic, Acute; Religion and Medicine; Treatment Outcome; Treatment Refusal; Tretinoin

2018
Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy.
    Cell death & disease, 2018, 01-23, Volume: 9, Issue:2

    Topics: Adolescent; Adult; Animals; Apoptosis; Arsenic Trioxide; Autophagy; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Mice, SCID; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Reactive Oxygen Species; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tumor Burden; Young Adult

2018
Relapse of acute promyelocytic leukemia in the external auditory canal confirmed by PML/RARA dual-fusion and RARA break-apart fluorescence in situ hybridization.
    Annals of hematology, 2018, Volume: 97, Issue:5

    Topics: Abnormal Karyotype; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; DNA Probes; Ear Canal; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Positron-Emission Tomography; Recurrence; RNA, Messenger; RNA, Neoplasm; Tomography, X-Ray Computed; WT1 Proteins

2018
[Acute Promyelocytic Leukemia - A Rare, Life-Threatening Disease with High Healing Chance].
    Deutsche medizinische Wochenschrift (1946), 2018, Volume: 143, Issue:3

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Rare Diseases; Tretinoin

2018
Case report: Purulent transformation of granulocytic sarcoma: An unusual pattern of differentiation in acute promyelocytic leukemia.
    Medicine, 2018, Volume: 97, Issue:8

    Topics: Abdomen; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Differentiation; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Sarcoma, Myeloid; Suppuration; Tretinoin

2018
ZYH005, a novel DNA intercalator, overcomes all-trans retinoic acid resistance in acute promyelocytic leukemia.
    Nucleic acids research, 2018, 04-20, Volume: 46, Issue:7

    Topics: Animals; Apoptosis; Arsenic Trioxide; Caspases; Cell Line, Tumor; Cell Proliferation; DNA Damage; Drug Resistance, Neoplasm; Humans; Intercalating Agents; Leukemia, Promyelocytic, Acute; Mice; Molecular Docking Simulation; Oncogene Proteins, Fusion; Phenanthridines; Promyelocytic Leukemia Protein; Proteolysis; Retinoic Acid Receptor alpha; Tretinoin; Xenograft Model Antitumor Assays

2018
Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study.
    Cancer, 2018, 06-01, Volume: 124, Issue:11

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Ascorbic Acid; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Disease-Free Survival; Female; Headache; Hematopoietic Stem Cell Transplantation; Hong Kong; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Risk Factors; Severity of Illness Index; Survival Analysis; Time Factors; Transplantation, Autologous; Tretinoin; Young Adult

2018
Influence of acute promyelocytic leukemia therapeutic drugs on nuclear pore complex density and integrity.
    Biochemical and biophysical research communications, 2018, 05-15, Volume: 499, Issue:3

    Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line; Cell Nucleus; Humans; Kinetics; Leukemia, Promyelocytic, Acute; Mitosis; Nuclear Envelope; Nuclear Pore; Oxides; Permeability; Tretinoin

2018
Early detection of differentiation syndrome by chest ultrasound in acute promyelocytic leukaemia.
    British journal of haematology, 2019, Volume: 184, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Point-of-Care Systems; Prospective Studies; Syndrome; Tretinoin; Ultrasonography

2019
Switching from all-trans retinoic acid to arsenic trioxide for newly diagnosed acute promyelocytic leukemia.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Disease Progression; Disseminated Intravascular Coagulation; Drug Substitution; Humans; Leukemia, Promyelocytic, Acute; Male; Treatment Outcome; Tretinoin

2018
Arsenic speciation in hair and nails of acute promyelocytic leukemia (APL) patients undergoing arsenic trioxide treatment.
    Talanta, 2018, Jul-01, Volume: 184

    Topics: Adult; Arsenic; Arsenic Trioxide; Arsenicals; Chromatography, High Pressure Liquid; Female; Hair; Humans; Leukemia, Promyelocytic, Acute; Male; Mass Spectrometry; Middle Aged; Nails; Oxides; Young Adult

2018
Cutaneous herald: leukaemia cutis as presenting manifestation of relapse in acute promyelocytic leukaemia.
    BMJ case reports, 2018, May-02, Volume: 2018

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biopsy; Consolidation Chemotherapy; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Oxides; Skin; Tretinoin

2018
Role of arsenic (+3 oxidation state) methyltransferase in arsenic mediated APL treatment: an in vitro investigation.
    Metallomics : integrated biometal science, 2018, 06-20, Volume: 10, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Arsenic; Arsenic Trioxide; Cell Differentiation; Cell Proliferation; Hep G2 Cells; Humans; In Vitro Techniques; Leukemia, Promyelocytic, Acute; Methyltransferases; Oncogene Proteins, Fusion; Tumor Cells, Cultured

2018
Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia.
    Nature communications, 2018, 05-24, Volume: 9, Issue:1

    Topics: 5'-Nucleotidase; Animals; Antineoplastic Agents; Arsenic Trioxide; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Promyelocytic, Acute; Male; Mice; Mutation; Promyelocytic Leukemia Protein; Recurrence; Retinoic Acid Receptor alpha; Tretinoin

2018
[Relationship between the Therapeutic Dose of Arsenic Trioxide and Relapse in Acute Promyelocytic Leukemia].
    Zhongguo shi yan xue ye xue za zhi, 2018, Volume: 26, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Retrospective Studies; Tretinoin

2018
Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.
    Annals of hematology, 2018, Volume: 97, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Proportional Hazards Models; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult

2018
Salinomycin induces apoptosis and differentiation in human acute promyelocytic leukemia cells.
    Oncology reports, 2018, Volume: 40, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imides; Leukemia, Promyelocytic, Acute; Oxides; Pyrans; Quinolines; Tretinoin; Wnt Signaling Pathway

2018
Arsenic trioxide and all-trans retinoic acid treatment for childhood acute promyelocytic leukaemia.
    British journal of haematology, 2019, Volume: 185, Issue:2

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Child; Child, Preschool; Female; Hematologic Diseases; Humans; Leukemia, Promyelocytic, Acute; Male; Tretinoin

2019
Trisenox induces cytotoxicity through phosphorylation of mitogen-activated protein kinase molecules in acute leukemia cells.
    Journal of biochemical and molecular toxicology, 2018, Volume: 32, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Cell Cycle; Cell Line, Tumor; Humans; L-Lactate Dehydrogenase; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Phosphorylation

2018
Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells.
    Nature communications, 2018, 08-09, Volume: 9, Issue:1

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Cell Proliferation; Female; Fibroblasts; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred BALB C; Mice, Knockout; Neoplasm Transplantation; Neoplasms; NIMA-Interacting Peptidylprolyl Isomerase; Proteomics; Signal Transduction; Tretinoin

2018
Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-κB axis: Shedding new light on resistance to Aprepitant.
    The international journal of biochemistry & cell biology, 2018, Volume: 103

    Topics: Antineoplastic Agents; Aprepitant; Arsenic Trioxide; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Neurokinin-1 Receptor Antagonists; NF-kappa B; Receptors, Neurokinin-1

2018
Multiple Bowen's diseases and basal cell carcinomas in a patient with acute promyelocytic leukemia treated with arsenic trioxide: A case report and effective treatment with photodynamic therapy.
    Dermatologic therapy, 2018, Volume: 31, Issue:6

    Topics: Antineoplastic Agents; Arsenic Trioxide; Biopsy; Bowen's Disease; Carcinoma, Basal Cell; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Photochemotherapy; Skin Neoplasms; Treatment Outcome

2018
Diffuse Pulmonary Alveolar Hemorrhage Secondary to All-Trans-Retinoic Acid in Acute Promyelocytic Leukemia.
    Chinese medical journal, 2018, 10-05, Volume: 131, Issue:19

    Topics: Adult; Arsenic Trioxide; Female; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Leukocytes; Tretinoin

2018
Inhibition of PI3K signaling pathway enhances the chemosensitivity of APL cells to ATO: Proposing novel therapeutic potential for BKM120.
    European journal of pharmacology, 2018, Dec-15, Volume: 841

    Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Caspase 3; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Drug Interactions; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Intracellular Space; Leukemia, Promyelocytic, Acute; Morpholines; Phosphatidylinositol 3-Kinases; Reactive Oxygen Species; Signal Transduction

2018
Chloroquine aggravates the arsenic trioxide (As2O3)-induced apoptosis of acute promyelocytic leukemia NB4 cells via inhibiting lysosomal degradation in vitro.
    European review for medical and pharmacological sciences, 2018, Volume: 22, Issue:19

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Autophagy; Cell Line, Tumor; Chloroquine; Dose-Response Relationship, Drug; Humans; Leukemia, Promyelocytic, Acute; Lysosomes; Microtubule-Associated Proteins

2018
AS3MT Polymorphisms, Arsenic Metabolism, and the Hematological and Biochemical Values in APL Patients Treated with Arsenic Trioxide.
    Toxicological sciences : an official journal of the Society of Toxicology, 2018, 11-01, Volume: 166, Issue:1

    Topics: Antineoplastic Agents; Arsenic Trioxide; DNA; Female; Genotype; Humans; Leukemia, Promyelocytic, Acute; Male; Methyltransferases; Middle Aged; Polymorphism, Single Nucleotide

2018
Long-term effect of all-trans retinoic acid and arsenic trioxide sequential maintenance in patients with acute promyelocytic leukemia.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Consolidation Chemotherapy; Female; Humans; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Prognosis; Recurrence; Retreatment; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Tretinoin

2019
Microgranular variant of acute promyelocytic leukemia with cytoplasmic projections resembling micromegakaryocytes.
    Blood, 2018, 11-22, Volume: 132, Issue:21

    Topics: Aged, 80 and over; Antigens, CD; Antineoplastic Agents; Arsenic Trioxide; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Male; Megakaryocytes; Tretinoin

2018
In vitro stability of arsenic trioxide-liposome encapsulates for acute promyelocytic leukemia treatment.
    Leukemia research, 2019, Volume: 76

    Topics: Antineoplastic Agents; Arsenic Trioxide; Cell Line, Tumor; Chromatography, Liquid; Drug Stability; Humans; Leukemia, Promyelocytic, Acute; Liposomes; Mass Spectrometry

2019
Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:5

    Topics: Abnormal Karyotype; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Child; Child, Preschool; Chromosome Aberrations; Cytogenetic Analysis; Female; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Prognosis; Recurrence; Treatment Outcome; Young Adult

2019
Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Blood Transfusion; Hospitalization; Humans; Leukemia, Promyelocytic, Acute; Treatment Outcome; Tretinoin

2019
Acute promyelocytic leukaemia presenting as necrotising fasciitis of the perineum (Fournier gangrene).
    BMJ case reports, 2018, 12-07, Volume: 11, Issue:1

    Topics: Adult; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Fasciitis, Necrotizing; Fournier Gangrene; Humans; Leukemia, Promyelocytic, Acute; Male; Perineum; Remission Induction; Treatment Outcome; Tretinoin

2018
Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia.
    Leukemia, 2019, Volume: 33, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Promyelocytic Leukemia Protein

2019
Flexural Eruption Associated With Arsenic Trioxide Therapy in a Patient With Acute Promyelocytic Leukemia.
    JAMA dermatology, 2019, Mar-01, Volume: 155, Issue:3

    Topics: Aged; Arsenic Trioxide; Biopsy, Needle; Drug Eruptions; Follow-Up Studies; Humans; Immunohistochemistry; Leukemia, Promyelocytic, Acute; Male; Remission, Spontaneous; Risk Assessment; Treatment Outcome; Tretinoin

2019
The Cardiotoxicity Induced by Arsenic Trioxide is Alleviated by Salvianolic Acid A via Maintaining Calcium Homeostasis and Inhibiting Endoplasmic Reticulum Stress.
    Molecules (Basel, Switzerland), 2019, Feb-02, Volume: 24, Issue:3

    Topics: Animals; Apoptosis; Arsenic Trioxide; Caffeic Acids; Calcium; Cardiotoxicity; Disease Models, Animal; Endoplasmic Reticulum Stress; Gene Expression Regulation; Homeostasis; Humans; Lactates; Leukemia, Promyelocytic, Acute; Mice; Myocytes, Cardiac; Rats; Sarcoplasmic Reticulum; Sarcoplasmic Reticulum Calcium-Transporting ATPases

2019
Toward Candidate Proteomic Biomarkers in Clinical Monitoring of Acute Promyelocytic Leukemia Treatment with Arsenic Trioxide.
    Omics : a journal of integrative biology, 2019, Volume: 23, Issue:2

    Topics: Arsenic Trioxide; Biomarkers; Filaggrin Proteins; Humans; Leukemia, Promyelocytic, Acute; Precision Medicine; Proteomics; Retrospective Studies

2019
Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide.
    Expert review of clinical pharmacology, 2019, Volume: 12, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Cacodylic Acid; Child; Chromatography, High Pressure Liquid; Erythrocytes; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Mass Spectrometry; Middle Aged; Time Factors; Young Adult

2019
Influence of bcr-3 PML-RARα transcript on outcome in Acute Promyelocytic Leukemia patients of Kashmir treated with all-trans retinoic acid and/or arsenic tri-oxide.
    Cancer genetics, 2019, Volume: 231-232

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Child; Chromosome Breakpoints; Disease-Free Survival; Female; Humans; India; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Multivariate Analysis; Oncogene Proteins, Fusion; RNA, Messenger; Treatment Outcome; Tretinoin; Young Adult

2019
Successful Treatment With ATRA and Arsenic Trioxide for a Child With Down Syndrome and Acute Promyelocytic Leukemia.
    Journal of pediatric hematology/oncology, 2020, Volume: 42, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Child; Down Syndrome; Female; Humans; Leukemia, Promyelocytic, Acute; Tretinoin

2020
Identification of a point mutation PML
    Biochemical and biophysical research communications, 2019, 04-09, Volume: 511, Issue:3

    Topics: Antineoplastic Agents; Arsenic Trioxide; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Point Mutation; Sumoylation; Tretinoin

2019
An extracellular pH-driven targeted multifunctional manganese arsenite delivery system for tumor imaging and therapy.
    Biomaterials science, 2019, May-28, Volume: 7, Issue:6

    Topics: Animals; Arsenic Trioxide; Cell Line, Tumor; Cell Transformation, Neoplastic; Drug Carriers; Drug Liberation; Extracellular Space; Humans; Hydrogen-Ion Concentration; Leukemia, Promyelocytic, Acute; Magnetic Resonance Imaging; Manganese; Mice; Nanoparticles; Peptides; Silicon Dioxide

2019
A novel NPM1-RARG-NPM1 chimeric fusion in acute myeloid leukaemia resembling acute promyelocytic leukaemia but resistant to all-trans retinoic acid and arsenic trioxide.
    British journal of cancer, 2019, Volume: 120, Issue:11

    Topics: Aged; Arsenic Trioxide; Drug Resistance, Neoplasm; Gene Fusion; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Nuclear Proteins; Nucleophosmin; Receptors, Retinoic Acid; Retinoic Acid Receptor gamma; Tretinoin

2019
Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy.
    Cell research, 2019, Volume: 29, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Disease Models, Animal; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Neoplasms, Experimental; Tretinoin; Tumor Cells, Cultured; U937 Cells

2019
Effect of combination of all-trans retinoic acid and arsenic trioxide on apoptosis of acute promyelocytic leukemia cells.
    Cellular and molecular biology (Noisy-le-Grand, France), 2019, Apr-30, Volume: 65, Issue:4

    Topics: Apoptosis; Arsenic Trioxide; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Humans; Interleukin-6; Leukemia, Promyelocytic, Acute; Prognosis; Quality of Life; Tretinoin; Tumor Necrosis Factor-alpha

2019
NDRG2 Sensitizes Myeloid Leukemia to Arsenic Trioxide via GSK3β-NDRG2-PP2A Complex Formation.
    Cells, 2019, 05-22, Volume: 8, Issue:5

    Topics: Antineoplastic Agents; Arsenic Trioxide; Carboxylic Ester Hydrolases; Glycogen Synthase Kinase 3 beta; Humans; Leukemia, Promyelocytic, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Tumor Suppressor Proteins; U937 Cells

2019
Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia.
    Cancer, 2019, 09-15, Volume: 125, Issue:18

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Blood Component Transfusion; Female; Gemtuzumab; Humans; Induction Chemotherapy; Intensive Care Units; Intubation, Intratracheal; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Patient Transfer; Retrospective Studies; Risk Factors; Serum Albumin; Tretinoin; Water-Electrolyte Imbalance; Young Adult

2019
Retinoic acid and arsenic trioxide induce lasting differentiation and demethylation of target genes in APL cells.
    Scientific reports, 2019, 07-01, Volume: 9, Issue:1

    Topics: Apoptosis; Arsenic Trioxide; Cell Differentiation; Cell Line, Tumor; Chemokine CCL2; CpG Islands; Demethylation; GTP-Binding Proteins; Humans; Leukemia, Promyelocytic, Acute; Promoter Regions, Genetic; Protein Glutamine gamma Glutamyltransferase 2; Receptors, Retinoic Acid; Transcriptome; Transglutaminases; Tretinoin

2019
Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse.
    American journal of hematology, 2019, Volume: 94, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bone Marrow; Clone Cells; Disease Progression; Drug Resistance, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Promyelocytic, Acute; Mutation; Neoplasm Proteins; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Promyelocytic Leukemia Protein; Protein Domains; Recurrence; Remission Induction; Reproducibility of Results; Retinoic Acid Receptor alpha; RNA, Messenger; RNA, Neoplasm; Tretinoin

2019
Multicenter evaluation of arsenic trioxide dosing in obese patients with low-intermediate risk acute promyelocytic leukemia.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Long QT Syndrome; Male; Middle Aged; Obesity; Prognosis; Retrospective Studies; Young Adult

2019
Bone Marrow Findings in Patients With Acute Promyelocytic Leukemia Treated With Arsenic Trioxide.
    American journal of clinical pathology, 2019, 10-07, Volume: 152, Issue:5

    Topics: Adolescent; Adult; Aged; Arsenic Trioxide; Biopsy; Bone Marrow; Bone Marrow Cells; Erythroid Cells; Female; Humans; Karyotype; Leukemia, Promyelocytic, Acute; Male; Megakaryocytes; Middle Aged; Myeloid Cells; Myeloid Progenitor Cells; Treatment Outcome; Tretinoin; Young Adult

2019
[Acute kidney failure in differentiation syndrome: a possible complication during therapy with differentiating agents for acute promyelocytic leukemia. A case report].
    Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2019, Jul-24, Volume: 36, Issue:4

    Topics: Acute Kidney Injury; Adult; Antineoplastic Agents; Arsenic Trioxide; Dexamethasone; Edema; Fever of Unknown Origin; Humans; Hypotension; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Renal Dialysis; Respiratory Distress Syndrome; Syndrome; Tretinoin

2019
Hepatotoxicity from arsenic trioxide for pediatric acute promyelocytic leukemia.
    Journal of pediatric hematology/oncology, 2013, Volume: 35, Issue:2

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Hodgkin Disease; Humans; Leukemia, Promyelocytic, Acute; Liver; Male; Oxides

2013
The novel arsenical Darinaparsin circumvents BRG1-dependent, HO-1-mediated cytoprotection in leukemic cells.
    Leukemia, 2013, Volume: 27, Issue:11

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Blast Crisis; Blotting, Western; Cell Cycle; Cell Proliferation; Chromatin Immunoprecipitation; Cytoprotection; DNA Helicases; Flow Cytometry; Glutathione; Heme Oxygenase-1; Humans; Leukemia, Promyelocytic, Acute; NF-E2-Related Factor 2; Nuclear Proteins; Oxides; Phosphorylation; Promoter Regions, Genetic; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription Factors; Tumor Cells, Cultured

2013
Myocardial toxicity of acute promyelocytic leukaemia drug-arsenic trioxide.
    European review for medical and pharmacological sciences, 2013, Volume: 17 Suppl 1

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Body Burden; Catalase; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Glutathione Transferase; Heart Diseases; Leukemia, Promyelocytic, Acute; Lipid Peroxidation; Male; Myocytes, Cardiac; Oxides; Rats; Rats, Wistar; Superoxide Dismutase; Time Factors

2013
Arsenic: an old enemy now turned friend.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:9

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides

2013
Aquaporin 9, a promising predictor for the cytocidal effects of arsenic trioxide in acute promyelocytic leukemia cell lines and primary blasts.
    Oncology reports, 2013, Volume: 29, Issue:6

    Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; Aquaporins; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression; HL-60 Cells; Humans; Jurkat Cells; K562 Cells; Leukemia, Promyelocytic, Acute; Oxides

2013
Arsenic methylation metabolism and liver injury of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
    Environmental toxicology, 2013, Volume: 28, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Liver; Liver Function Tests; Male; Methylation; Middle Aged; Oxides; Sex Factors; Young Adult

2013
Mees lines and Beau lines.
    Cutis, 2013, Volume: 91, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Nail Diseases; Oxides; Remission Induction; Tretinoin

2013
Arsenic reverses glioblastoma resistance to mTOR-targeted therapies.
    Cell cycle (Georgetown, Tex.), 2013, May-15, Volume: 12, Issue:10

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Leukemia, Promyelocytic, Acute; Oxides; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases

2013
Acute promyelocytic leukemia complicated by massive intracerebral hemorrhage: safety and efficacy of replacing conventional chemotherapy with arsenic trioxide in an adolescent.
    Klinische Padiatrie, 2013, Volume: 225, Issue:3

    Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cerebral Hemorrhage; Drug Administration Schedule; Drug Substitution; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Long-Term Care; Oxides; Remission Induction; Tomography, X-Ray Computed

2013
Azidothymidine hinders arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells by induction of p21 and attenuation of G2/M arrest.
    Annals of hematology, 2013, Volume: 92, Issue:9

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; G2 Phase Cell Cycle Checkpoints; Humans; Leukemia, Promyelocytic, Acute; M Phase Cell Cycle Checkpoints; Oxides; Zidovudine

2013
Complete remission of acute promyelocytic leukemia in a very elderly patient after treatment with low dose arsenic trioxide and sequential retinoic acid: a case report.
    Annals of hematology, 2014, Volume: 93, Issue:2

    Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Remission Induction; Tretinoin

2014
Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with acute promyelocytic leukemia treated with arsenic trioxide.
    Annals of hematology, 2014, Volume: 93, Issue:2

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; DNA, Viral; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Virus Activation

2014
Urothelial cell intracytoplasmic inclusions after treatment of promyelocytic leukemia with arsenic trioxide.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 134, Issue:2

    Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Case-Control Studies; Female; Humans; Inclusion Bodies; Leukemia, Promyelocytic, Acute; Male; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Middle Aged; Oxides; Urothelium

2013
Coordinated regulation of the immunoproteasome subunits by PML/RARα and PU.1 in acute promyelocytic leukemia.
    Oncogene, 2014, May-22, Volume: 33, Issue:21

    Topics: Antigen Presentation; Arsenic Trioxide; Arsenicals; Cysteine Endopeptidases; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Immunologic Factors; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oxides; Promoter Regions, Genetic; Promyelocytic Leukemia Protein; Proteasome Endopeptidase Complex; Protein Binding; Protein Subunits; Proto-Oncogene Proteins; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Trans-Activators; Transcription Factors; Transcriptional Activation; Transcriptome; Tretinoin; Tumor Escape; Tumor Suppressor Proteins

2014
BCR/ABL fusion gene detected in acute promyelocytic leukemia: a case study of clinical and laboratory results.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Piperazines; Pyrimidines; Translocation, Genetic; Treatment Outcome; Tretinoin

2014
Acute promyelocytic leukemia with Flt3-TKD and WT1 mutations relapsing in a testicle and followed by systemic relapse.
    Acta haematologica, 2013, Volume: 130, Issue:4

    Topics: Adult; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Daunorubicin; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Promyelocytic, Acute; Male; Neoplasm Recurrence, Local; Oxides; Salvage Therapy; Sarcoma, Myeloid; Testicular Neoplasms; Testis; Tretinoin; WT1 Proteins

2013
Effect of therapeutic arsenic exposure on pulmonary function.
    Respiratory medicine, 2013, Volume: 107, Issue:9

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Case-Control Studies; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Forced Expiratory Volume; Humans; Leukemia, Promyelocytic, Acute; Lung Diseases; Male; Middle Aged; Oxides; Uteroglobin; Vital Capacity

2013
Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: a retrospective analysis of JALSG-APL97.
    Cancer science, 2013, Volume: 104, Issue:10

    Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Combined Modality Therapy; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Japan; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Retrospective Studies; Salvage Therapy; Tetrahydronaphthalenes; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Tretinoin; Young Adult

2013
Targeting agents alone to cure acute promyelocytic leukemia.
    The New England journal of medicine, 2013, Jul-11, Volume: 369, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin

2013
Arsenic trioxide inhibits the Hedgehog pathway which is aberrantly activated in acute promyelocytic leukemia.
    Acta haematologica, 2013, Volume: 130, Issue:4

    Topics: Adolescent; Adult; Aged; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Female; Hedgehog Proteins; Humans; Kruppel-Like Transcription Factors; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Nuclear Proteins; Oxides; Patched Receptors; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Smoothened Receptor; Transcription Factors; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2

2013
A single course of all-trans retinoic acid plus arsenic trioxide reached a long-term survival in a patient with newly diagnosed acute promyelocytic leukemia: a suggestion for reduction of treatment courses?
    European journal of haematology, 2013, Volume: 91, Issue:5

    Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Treatment Outcome; Tretinoin

2013
3Omics: a web-based systems biology tool for analysis, integration and visualization of human transcriptomic, proteomic and metabolomic data.
    BMC systems biology, 2013, Jul-23, Volume: 7

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Gene Expression Profiling; Humans; Internet; Leukemia, Promyelocytic, Acute; Metabolomics; Oxides; Proteomics; Statistics as Topic; Systems Biology; Tretinoin; Urinalysis

2013
Retinoic acid plus arsenic trioxide, the ultimate panacea for acute promyelocytic leukemia?
    Blood, 2013, Sep-19, Volume: 122, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin

2013
Overcoming treatment resistance in acute promyelocytic leukemia and beyond.
    Oncotarget, 2013, Volume: 4, Issue:8

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Tretinoin

2013
Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
    Hematological oncology, 2014, Volume: 32, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; China; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Dexamethasone; Drug Evaluation; Female; Harringtonines; Homoharringtonine; Humans; Idarubicin; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult

2014
Thyroid arsenic content and papillary thyroid carcinoma arising 10 years after oral arsenic trioxide therapy for refractory acute promyelocytic leukemia.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:5

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma; Carcinoma, Papillary; Female; Humans; Leukemia, Promyelocytic, Acute; Neoplasms, Second Primary; Oxides; Thyroid Cancer, Papillary; Thyroid Gland; Thyroid Neoplasms; Young Adult

2014
Importance of ERK activation in As2O3-induced differentiation and promyelocytic leukemia nuclear bodies formation in neuroblastoma cells.
    Pharmacological research, 2013, Volume: 77

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Intranuclear Inclusion Bodies; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; N-Myc Proto-Oncogene Protein; Neurites; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; Oxides; Promyelocytic Leukemia Protein; Transcription Factors; Tumor Suppressor Proteins

2013
Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
    European journal of haematology, 2013, Volume: 91, Issue:6

    Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Consolidation Chemotherapy; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Neoplasm, Residual; Oxides; Prognosis; Treatment Outcome; Tretinoin

2013
Arsenic trioxide combination improves survival in APL.
    The Lancet. Oncology, 2013, Volume: 14, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Remission Induction; Survival Rate; Tretinoin

2013
High frequency of varicella zoster virus reactivation associated with the use of arsenic trioxide in patients with acute promyelocytic leukemia.
    Acta haematologica, 2014, Volume: 131, Issue:2

    Topics: Acyclovir; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Incidence; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Retrospective Studies; Valacyclovir; Valine; Virus Activation

2014
Carcinogenic risk of retained arsenic after successful treatment of acute promyelocytic leukemia with arsenic trioxide: a cause for concern?
    Leukemia & lymphoma, 2014, Volume: 55, Issue:5

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma; Carcinoma, Papillary; Female; Humans; Leukemia, Promyelocytic, Acute; Neoplasms, Second Primary; Oxides; Thyroid Cancer, Papillary; Thyroid Neoplasms

2014
Prognostic significance of additional cytogenetic abnormalities and FLT3 mutations in acute promyelocytic leukemia.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:7

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; fms-Like Tyrosine Kinase 3; Humans; Karyotype; Leukemia, Promyelocytic, Acute; Male; Mutation; Oxides

2014
MicroRNAs contribute to promyelocyte apoptosis in As2O3-treated APL cells.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2013, Volume: 32, Issue:6

    Topics: 3' Untranslated Regions; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Base Sequence; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cell Survival; DNA Fragmentation; Down-Regulation; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; MicroRNAs; Oxides; RNA, Messenger; Sequence Alignment; Up-Regulation

2013
Outcomes and prognostic factors of first relapsed acute promyelocytic leukemia patients undergoing salvage therapy with intravenous arsenic trioxide and chemotherapy.
    Annals of hematology, 2014, Volume: 93, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Drug Evaluation; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prognosis; Proportional Hazards Models; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult

2014
Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure.
    Nature medicine, 2014, Volume: 20, Issue:2

    Topics: Animals; Arsenic Trioxide; Arsenicals; Computational Biology; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Mice; Microarray Analysis; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Proteolysis; Receptors, Retinoic Acid; Recombinant Fusion Proteins; Retinoic Acid Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Transcription Factors; Tretinoin; Tumor Suppressor Protein p53; Tumor Suppressor Proteins

2014
Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child.
    Pediatric hematology and oncology, 2014, Volume: 31, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin

2014
Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia.
    European journal of haematology, 2014, Volume: 93, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Retrospective Studies; Survival Analysis; Tretinoin

2014
PML nuclear bodies mediate the therapeutic response of APL cells.
    Cancer discovery, 2014, Volume: 4, Issue:3

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Cycle; Humans; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Signal Transduction; Tretinoin

2014
The acute promyelocytic leukaemia success story: curing leukaemia through targeted therapies.
    Journal of internal medicine, 2014, Volume: 276, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Transformation, Neoplastic; Epigenesis, Genetic; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Retinoid X Receptor alpha; Signal Transduction; Tretinoin

2014
Normal CYP3A activity during arsenic trioxide therapy.
    Annals of hematology, 2014, Volume: 93, Issue:11

    Topics: Arsenic Trioxide; Arsenicals; Cytochrome P-450 CYP3A; Enzyme Activation; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides

2014
Resistance to arsenic therapy in acute promyelocytic leukemia.
    The New England journal of medicine, 2014, May-08, Volume: 370, Issue:19

    Topics: Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Mutation; Neoplasm Proteins; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha

2014
cAMP protects acute promyelocytic leukemia cells from arsenic trioxide-induced caspase-3 activation and apoptosis.
    European journal of pharmacology, 2014, Aug-05, Volume: 736

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-Associated Death Protein; Caspase 3; Cell Line, Tumor; Cell Proliferation; Colforsin; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; DNA; G1 Phase Cell Cycle Checkpoints; Humans; Leukemia, Promyelocytic, Acute; Oxides; Proto-Oncogene Mas; Tumor Suppressor Protein p53

2014
Metabolism of arsenic trioxide in acute promyelocytic leukemia cells.
    Journal of cellular biochemistry, 2014, Volume: 115, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cacodylic Acid; Cell Line, Tumor; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; DNA Methyltransferase 3B; Glutathione; Humans; Leukemia, Promyelocytic, Acute; Methyltransferases; Oxides; S-Adenosylhomocysteine; S-Adenosylmethionine

2014
Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells.
    Journal of experimental & clinical cancer research : CR, 2014, May-16, Volume: 33

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspase 3; Cytochromes c; DNA Damage; Drug Screening Assays, Antitumor; Glutathione; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Lipid Peroxidation; Membrane Potential, Mitochondrial; Mitochondria; Oxidative Stress; Oxides; Protein Transport; Single-Cell Analysis

2014
Guest editorial: acute promyelocytic leukemia: change from "highly fatal to highly curable" leukemia.
    International journal of hematology, 2014, Volume: 100, Issue:1

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disseminated Intravascular Coagulation; Forkhead Box Protein O3; Forkhead Transcription Factors; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Tretinoin

2014
Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.
    Leukemia research, 2014, Volume: 38, Issue:8

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; CD11b Antigen; Cell Differentiation; Cell Line, Tumor; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Pyrimidines; Tretinoin; Up-Regulation

2014
Pregnancy in acute promyelocytic leukaemia after front-line therapy with arsenic trioxide and all-trans retinoic acid.
    British journal of haematology, 2014, Volume: 167, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Fetus; Humans; Infant, Newborn; Leukemia, Promyelocytic, Acute; Oxides; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Tretinoin; Young Adult

2014
Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells.
    British journal of cancer, 2014, Aug-26, Volume: 111, Issue:5

    Topics: Arsenic Trioxide; Arsenicals; Cell Survival; Drug Synergism; Glutathione; Heme Oxygenase-1; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; NF-E2-Related Factor 2; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Tretinoin; Tumor Cells, Cultured

2014
Torsade de Pointes during oral arsenic trioxide therapy for acute promyelocytic leukemia in a patient with heart failure.
    Annals of hematology, 2015, Volume: 94, Issue:3

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Heart Failure; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Torsades de Pointes

2015
Targeting catalase but not peroxiredoxins enhances arsenic trioxide-induced apoptosis in K562 cells.
    PloS one, 2014, Volume: 9, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Catalase; Cell Line, Tumor; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Peroxiredoxins; Reactive Oxygen Species

2014
Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Incidence; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Oxides; Tretinoin; Young Adult

2015
ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia.
    PloS one, 2014, Volume: 9, Issue:8

    Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Consolidation Chemotherapy; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Remission Induction; Retrospective Studies; Treatment Outcome; Tretinoin; Young Adult

2014
Arsenic trioxide and resveratrol show synergistic anti-leukemia activity and neutralized cardiotoxicity.
    PloS one, 2014, Volume: 9, Issue:8

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Myocytes, Cardiac; Neoplasm Proteins; Oxides; Rats; Reactive Oxygen Species; Resveratrol; Stilbenes; Superoxide Dismutase

2014
A prospective, observational study of added medium-dose cytosine arabinoside versus As2O3 for elderly patients with acute promyelocytic leukemia.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:10

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Polymerase Chain Reaction; Prospective Studies; Survival Rate; Tretinoin

2014
Acute promyelocytic leukaemia with a PML-RARA insertional translocation and a chromosome 21 abnormality in XYY syndrome: case report.
    The Journal of international medical research, 2014, Volume: 42, Issue:6

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chromosomes, Human, Pair 21; Humans; In Situ Hybridization, Fluorescence; Karyotype; Leukemia, Promyelocytic, Acute; Male; Mutagenesis, Insertional; Oncogene Proteins, Fusion; Oxides; Sex Chromosome Disorders; Translocation, Genetic; Treatment Outcome; Tretinoin; XYY Karyotype

2014
Resistance to therapy in acute promyelocytic leukemia.
    The New England journal of medicine, 2014, Sep-18, Volume: 371, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Mutation; Oncogene Proteins, Fusion; Oxides; Recurrence; Tretinoin

2014
Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation.
    Blood, 2014, Dec-11, Volume: 124, Issue:25

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Transformation, Neoplastic; Cells, Cultured; Chlorocebus aethiops; COS Cells; Gene Expression Profiling; Humans; Leukemia, Promyelocytic, Acute; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Nude; Mice, Transgenic; Oncogene Proteins, Fusion; Oxides; Promoter Regions, Genetic; Protein Binding; Retinoid X Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sumoylation; Transcriptional Activation; Tretinoin

2014
Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada.
    European journal of haematology, 2015, Volume: 95, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Canada; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Leukemia, Promyelocytic, Acute; Male; Markov Chains; Middle Aged; Monte Carlo Method; Oxides; Quality-Adjusted Life Years; Recurrence; Treatment Failure; Treatment Outcome; Tretinoin

2015
Economic evaluation of arsenic trioxide for treatment of newly diagnosed acute promyelocytic leukaemia in Canada.
    Hematological oncology, 2015, Volume: 33, Issue:4

    Topics: Arsenic Trioxide; Arsenicals; Canada; Cost-Benefit Analysis; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides

2015
Extramedullary relapse in RARA rearrangement-negative acute promyelocytic leukemia successfully treated in combination with chemotherapy, local radiotherapy, and cord blood transplantation.
    Journal of pediatric hematology/oncology, 2015, Volume: 37, Issue:4

    Topics: Allografts; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Female; Gene Rearrangement; Humans; Infant; Leukemia, Promyelocytic, Acute; Oxides; Receptors, Retinoic Acid; Recurrence; Retinoic Acid Receptor alpha

2015
Real-life experience of a brief arsenic trioxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: favorable outcomes with limited anthracycline exposure and shorter consolidation therapy.
    Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:5

    Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Young Adult

2015
Dose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure.
    European journal of haematology, 2015, Volume: 95, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Monitoring; Female; Humans; Kidney Failure, Chronic; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Pilot Projects; Treatment Outcome

2015
Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet.
    Leukemia, 2015, Volume: 29, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Child; Child, Preschool; Disease-Free Survival; Europe; Female; Humans; International Cooperation; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prospective Studies; Recurrence; Registries; Treatment Outcome; Young Adult

2015
Arsenic Trioxide and Icariin Show Synergistic Anti-leukemic Activity.
    Cell biochemistry and biophysics, 2015, Volume: 73, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Flavonoids; Humans; Leukemia, Promyelocytic, Acute; Membrane Potential, Mitochondrial; Oxides; Reactive Oxygen Species

2015
Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance.
    PloS one, 2015, Volume: 10, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Prospective Studies; Recurrence; Transcription Factors; Tretinoin; Tumor Suppressor Proteins; Young Adult

2015
Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Aug-15, Volume: 21, Issue:16

    Topics: Animals; Arsenic Trioxide; Arsenicals; Camptothecin; Cell Differentiation; Cell Movement; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia, Promyelocytic, Acute; Mice; Mutation; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Polyethylene Glycols; Tretinoin

2015
Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2016, Volume: 22, Issue:4

    Topics: Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Monitoring; Humans; Kidney Failure, Chronic; Leukemia, Promyelocytic, Acute; Male; Oxides; Renal Dialysis

2016
[The clinical efficacy of all-trans retinoic acid plus arsenic trioxide in 177 newly diagnosed acute promyelocytic leukemia patients].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Tretinoin

2015
The influence of joint application of arsenic trioxide and daunorubicin on primary acute promyelocytic leukaemia cells and apoptosis and blood coagulation of cell strain.
    Pakistan journal of pharmaceutical sciences, 2015, Volume: 28, Issue:3 Suppl

    Topics: Adult; Annexin A2; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Blood Coagulation; Cell Line, Tumor; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Thrombomodulin; Thromboplastin; Time Factors; Tumor Cells, Cultured; Young Adult

2015
Tetraarsenictetrasulfide and Arsenic Trioxide Exert Synergistic Effects on Induction of Apoptosis and Differentiation in Acute Promyelocytic Leukemia Cells.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oxides; Reactive Oxygen Species; Sulfides

2015
Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy.
    Leukemia research, 2015, Volume: 39, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; CD56 Antigen; Chromosome Duplication; Female; fms-Like Tyrosine Kinase 3; Gene Expression; Humans; Injections, Intravenous; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Multivariate Analysis; Oncogene Proteins, Fusion; Oxides; Prognosis; Retrospective Studies; Risk Factors; Survival Analysis

2015
Lessons taught by acute promyelocytic leukemia cure.
    Lancet (London, England), 2015, Jul-18, Volume: 386, Issue:9990

    Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Mice; Oncogene Proteins, Fusion; Oxides; Tretinoin; Tumor Suppressor Protein p53

2015
Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
    Oncotarget, 2015, Sep-22, Volume: 6, Issue:28

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Biotransformation; Cacodylic Acid; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; HEK293 Cells; HeLa Cells; Humans; Leukemia, Promyelocytic, Acute; Methylation; Nuclear Proteins; Oncogene Proteins, Fusion; Organometallic Compounds; Oxides; Promyelocytic Leukemia Protein; Proteasome Endopeptidase Complex; Protein Binding; Protein Interaction Domains and Motifs; Proteolysis; Sumoylation; Time Factors; Transcription Factors; Tumor Suppressor Proteins

2015
Budgetary impact of treating acute promyelocytic leukemia patients with first-line arsenic trioxide and retinoic acid from an Italian payer perspective.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Italy; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin

2015
Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide.
    EBioMedicine, 2015, Volume: 2, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Disease-Free Survival; DNA Mutational Analysis; Epigenesis, Genetic; Female; Genes, Modifier; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mutation; Nucleophosmin; Oxides; Prognosis; Treatment Outcome; Tretinoin; Young Adult

2015
Epigenetic Gene Mutations Impact on Outcome in Acute Myeloid Leukaemia.
    EBioMedicine, 2015, Volume: 2, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin

2015
Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.
    Annals of hematology, 2015, Volume: 94, Issue:11

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Frequency; Humans; Leukemia, Promyelocytic, Acute; Longitudinal Studies; Male; Middle Aged; Mutation, Missense; Oncogene Proteins, Fusion; Oxides; Recurrence; Young Adult

2015
Induction, consolidation, and maintenance therapies with arsenic as a single agent for acute promyelocytic leukaemia in a 11-year follow-up.
    Hematological oncology, 2017, Volume: 35, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Neoplasm Recurrence, Local; Oxides; Remission Induction; Time Factors; Treatment Outcome; Young Adult

2017
Chemotherapy-free treatment of acute promyelocytic leukemia.
    Clinical advances in hematology & oncology : H&O, 2015, Volume: 13, Issue:8

    Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin

2015
Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States.
    Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:12

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Case-Control Studies; Cost-Benefit Analysis; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Markov Chains; Models, Economic; Oxides; Treatment Outcome; Tretinoin; United States

2015
Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia.
    Leukemia research, 2015, Volume: 39, Issue:12

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; China; Cost Savings; Cost-Benefit Analysis; Direct Service Costs; Female; Health Care Costs; Hospitals, University; Humans; Length of Stay; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Middle Aged; Oxides; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Tretinoin; Young Adult

2015
Time to improve health-related quality of life outcomes in patients with acute promyelocytic leukemia.
    Blood, 2015, Nov-26, Volume: 126, Issue:22

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Quality of Life; Survival Rate; Tretinoin

2015
Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
    Cancer genetics, 2015, Volume: 208, Issue:11

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Chromosomes, Human, Pair 17; Female; Humans; Isochromosomes; Leukemia, Promyelocytic, Acute; Middle Aged; Oncogene Proteins, Fusion; Oxides; Remission Induction; Treatment Outcome; Tretinoin

2015
Is There Still a Role for Low-Dose All-Transretinoic Acid in the Treatment of Acute Promyelocytic Leukemia in the Arsenic Trioxide Era?
    Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:12

    Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Idarubicin; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Oxides; Proportional Hazards Models; Treatment Outcome; Tretinoin; Young Adult

2015
Varying responses of PML-RARA with different genetic mutations to arsenic trioxide.
    Blood, 2016, Jan-14, Volume: 127, Issue:2

    Topics: Active Transport, Cell Nucleus; Arsenic Trioxide; Arsenicals; Cell Nucleus; Cells, Cultured; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; HeLa Cells; Hematopoietic Stem Cells; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Point Mutation; Prognosis; Sumoylation; U937 Cells

2016
Identification of Arsenic Direct-Binding Proteins in Acute Promyelocytic Leukaemia Cells.
    International journal of molecular sciences, 2015, Nov-10, Volume: 16, Issue:11

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biotin; Biotinylation; Carrier Proteins; Cell Line, Tumor; Chromatography, Liquid; Glutathione S-Transferase pi; HSP70 Heat-Shock Proteins; Humans; Leukemia, Promyelocytic, Acute; Membrane Proteins; Mitochondrial Proteins; Neoplasm Proteins; Oxides; Protein Binding; Streptavidin; Tandem Mass Spectrometry; Thyroid Hormone-Binding Proteins; Thyroid Hormones

2015
pVAX14DNA-mediated add-on immunotherapy combined with arsenic trioxide and all-trans retinoic acid targeted therapy effectively increases the survival of acute promyelocytic leukemia mice.
    Blood cancer journal, 2015, Dec-11, Volume: 5

    Topics: Adjuvants, Immunologic; Animals; Arsenic Trioxide; Arsenicals; Disease Models, Animal; DNA; Immunotherapy; Leukemia, Promyelocytic, Acute; Mice; Oxides; Tretinoin

2015
Exceptions in patterns of arsenic compounds in urine of acute promyelocytic leukaemia patients treated with As2O3.
    Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine, 2016, Volume: 29, Issue:1

    Topics: Adult; Arsenic Trioxide; Arsenicals; Cacodylic Acid; Female; Humans; Inactivation, Metabolic; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides

2016
Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia.
    British journal of haematology, 2016, Volume: 172, Issue:6

    Topics: Adult; Aged; Alleles; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Gene Rearrangement; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mutation; Neoplasm Proteins; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transcription Factors; Tumor Suppressor Proteins; Young Adult

2016
[History of acute promyelocytic leukemia].
    La Revue du praticien, 2015, Volume: 65, Issue:8

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; History, 20th Century; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin

2015
Genital vasculitis secondary to all-trans-retinoic-acid.
    BMJ case reports, 2016, Jan-20, Volume: 2016

    Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Genitalia; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin; Vasculitis

2016
Tamoxifen enhances the differentiation-inducing and growth-inhibitory effects of all-trans retinoic acid in acute promyelocytic leukemia cells.
    International journal of oncology, 2016, Volume: 48, Issue:3

    Topics: Animals; Anthracyclines; Antineoplastic Agents, Hormonal; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; CD11b Antigen; Cell Differentiation; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Male; Mice; Mice, Inbred BALB C; Middle Aged; Oxides; Tamoxifen; Tretinoin

2016
Microgranular acute promyelocytic leukemia presenting with leukopenia and an unusual immunophenotype.
    Hematology/oncology and stem cell therapy, 2017, Volume: 10, Issue:1

    Topics: Arsenic Trioxide; Arsenicals; Bone Marrow; Disseminated Intravascular Coagulation; Flow Cytometry; Humans; Immunophenotyping; Leukemia, Promyelocytic, Acute; Leukopenia; Male; Oxides; Treatment Outcome; Tretinoin; Young Adult

2017
Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia.
    PloS one, 2016, Volume: 11, Issue:1

    Topics: Adolescent; Adult; Aged; Arsenic Trioxide; Arsenicals; Blood Coagulation; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Fibrinolysis; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Platelet Count; Prothrombin Time; Retrospective Studies; Tretinoin; Young Adult

2016
A facile route to core-shell nanoparticulate formation of arsenic trioxide for effective solid tumor treatment.
    Nanoscale, 2016, Feb-21, Volume: 8, Issue:7

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Liberation; Female; Humans; Leukemia, Promyelocytic, Acute; Liver Neoplasms; Mice; Mice, Inbred ICR; Microscopy, Electron, Transmission; Nanoparticles; Oxides; Porosity; Silicon Dioxide; Surface Properties; Transplantation, Heterologous

2016
Carnosic Acid-combined Arsenic Trioxide Antileukaemia Cells in the Establishment of NB4/SCID Mouse Model.
    Basic & clinical pharmacology & toxicology, 2016, Volume: 119, Issue:3

    Topics: Abietanes; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Mice; Mice, SCID; Oxides; PTEN Phosphohydrolase; RNA, Messenger

2016
Targeted Therapy Alone for Acute Promyelocytic Leukemia.
    The New England journal of medicine, 2016, Mar-24, Volume: 374, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Follow-Up Studies; Humans; Intention to Treat Analysis; Leukemia, Promyelocytic, Acute; Oxides; Randomized Controlled Trials as Topic; Tretinoin

2016
Role of Signal Regulatory Protein α in Arsenic Trioxide-induced Promyelocytic Leukemia Cell Apoptosis.
    Scientific reports, 2016, Mar-24, Volume: 6

    Topics: Antigens, Differentiation; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Humans; Leukemia, Promyelocytic, Acute; MicroRNAs; Oxides; Receptors, Immunologic

2016
[Relapse of acute promyelocytic leukemia in the central nervous system revealed by isolated dementia].
    La Revue de medecine interne, 2016, Volume: 37, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Dementia; Female; Humans; Leukemia, Promyelocytic, Acute; Meningeal Neoplasms; Neoplasm Recurrence, Local; Oxides; Recurrence; Remission Induction

2016
PCGF2 negatively regulates arsenic trioxide-induced PML-RARA protein degradation via UBE2I inhibition in NB4 cells.
    Biochimica et biophysica acta, 2016, Volume: 1863, Issue:7 Pt A

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Fluorescent Antibody Technique; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Immunoprecipitation; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Polycomb Repressive Complex 1; Protein Binding; Proteolysis; RNA Interference; Signal Transduction; Sumoylation; Time Factors; Transfection; Ubiquitin-Conjugating Enzymes; Ubiquitination

2016
Autologous transplant remains the preferred therapy for relapsed APL in CR2.
    Bone marrow transplantation, 2016, Volume: 51, Issue:9

    Topics: Adolescent; Adult; Aged; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Infant; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Young Adult

2016
PHA-Induced Peripheral Blood Cytogenetics and Molecular Analysis: a Valid Diagnostic and Follow-up Modality for Acute Promyelocytic Leukemia Patients Treated with ATRA and/or Arsenic Tri-oxide.
    Asian Pacific journal of cancer prevention : APJCP, 2016, Volume: 17, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Blood Cells; Child; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cytogenetic Analysis; Female; Follow-Up Studies; Gene Rearrangement; Humans; In Situ Hybridization, Fluorescence; India; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oncogene Proteins, Fusion; Oxides; Phytohemagglutinins; Prognosis; Translocation, Genetic; Tretinoin

2016
Nrf2 activation ameliorates cytotoxic effects of arsenic trioxide in acute promyelocytic leukemia cells through increased glutathione levels and arsenic efflux from cells.
    Toxicology and applied pharmacology, 2016, 08-15, Volume: 305

    Topics: Abietanes; Arsenic; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cytotoxins; Glutathione; Humans; Leukemia, Promyelocytic, Acute; NF-E2-Related Factor 2; Oxides; RNA, Small Interfering

2016
Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, in vitro and in vivo.
    Oncotarget, 2016, Jul-19, Volume: 7, Issue:29

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred BALB C; Mice, Nude; Oxides; Polysaccharides; Tretinoin; Xenograft Model Antitumor Assays

2016
The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia.
    Blood, 2016, 09-15, Volume: 128, Issue:11

    Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Case-Control Studies; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Quality of Life; Survival Analysis

2016
Oxidative stress-mediated intrinsic apoptosis in human promyelocytic leukemia HL-60 cells induced by organic arsenicals.
    Scientific reports, 2016, 07-19, Volume: 6

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Proliferation; Cytochromes c; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; MCF-7 Cells; Membrane Potential, Mitochondrial; Oxidative Stress; Oxides; Reactive Oxygen Species; Signal Transduction

2016
Successful treatment of acute promyelocytic leukemia with arsenic trioxide and all-trans retinoic acid in a double lung and kidney transplanted patient.
    Annals of hematology, 2016, Volume: 95, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Squamous Cell; Humans; Immunocompromised Host; Kidney Transplantation; Leukemia, Promyelocytic, Acute; Lung Transplantation; Male; Middle Aged; Neoplasms, Second Primary; Oxides; Postoperative Complications; Skin Neoplasms; Tretinoin

2016
PML at Mitochondria-Associated Membranes Is Critical for the Repression of Autophagy and Cancer Development.
    Cell reports, 2016, 08-30, Volume: 16, Issue:9

    Topics: Adenine; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Calcium; Cell Line, Tumor; Disease Progression; Fibroblasts; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Membrane Potential, Mitochondrial; Mice; Mice, Knockout; Mitochondria; Mitochondrial Membranes; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Signal Transduction; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2016
Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia.
    Leukemia, 2016, Volume: 30, Issue:11

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Autophagy; Bortezomib; Cell Line, Tumor; Cell Transplantation; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Mice; NF-kappa B; Oxides; Proteasome Inhibitors; Reactive Oxygen Species; Transplantation, Heterologous; Tumor Cells, Cultured; Unfolded Protein Response

2016
Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission: outcomes before and after the introduction of arsenic trioxide.
    Leukemia & lymphoma, 2017, Volume: 58, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Japan; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult

2017
Induction treatments for acute promyelocytic leukemia: a network meta-analysis.
    Oncotarget, 2016, Nov-01, Volume: 7, Issue:44

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Humans; Induction Chemotherapy; Infant; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Network Meta-Analysis; Oxides; Randomized Controlled Trials as Topic; Tretinoin; Young Adult

2016
Survivin isoform expression in arsenic trioxide-treated acute promyelocytic leukemia cell line and patients: The odd expression pattern of survivin-2α.
    Asia-Pacific journal of clinical oncology, 2017, Volume: 13, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow; Case-Control Studies; Caspase 3; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Protein Isoforms; Survivin

2017
Recurrent acute myopericarditis without effusion during ATRA induction and ATO salvage of APL: a variant form of the differentiation syndrome?
    Leukemia & lymphoma, 2017, Volume: 58, Issue:7

    Topics: Acute Disease; Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Electrocardiography; Humans; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Oxides; Pericarditis; Remission Induction; Tretinoin

2017
First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid.
    Pediatric blood & cancer, 2017, Volume: 64, Issue:8

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Humans; Infant; Leukemia, Promyelocytic, Acute; Male; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin

2017
[Very Severe Differentiation Syndrome in Low Risk Acute Promyelocytic Leukemia - A Peril of Differentiating Therapy].
    Deutsche medizinische Wochenschrift (1946), 2017, Volume: 142, Issue:2

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Diagnosis, Differential; Dyspnea; Female; Fever; Humans; Hypotension; Leukemia, Promyelocytic, Acute; Leukocytosis; Lung Diseases; Oxides; Risk Factors; Severity of Illness Index; Syndrome; Treatment Outcome; Tretinoin

2017
RXRα ligand Z-10 induces PML-RARα cleavage and APL cell apoptosis through disrupting PML-RARα/RXRα complex in a cAMP-independent manner.
    Oncotarget, 2017, Feb-14, Volume: 8, Issue:7

    Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Caspases; Cell Line, Tumor; Chlorocebus aethiops; COS Cells; Cyclic AMP; Flow Cytometry; HEK293 Cells; Humans; Leukemia, Promyelocytic, Acute; Ligands; Naphthalenes; Nitro Compounds; Oncogene Proteins, Fusion; Oxides; Protein Binding; Proteolysis; Retinoid X Receptor alpha; Styrenes; Tretinoin

2017
Resistance to arsenic trioxide and retinoic acid therapy in acute promyelocytic leukemia.
    Annals of hematology, 2017, Volume: 96, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Leukemia, Promyelocytic, Acute; Male; Mutation, Missense; Oncogene Proteins, Fusion; Oxides; Tretinoin

2017
Poisoning the Devil.
    Cell, 2017, 02-09, Volume: 168, Issue:4

    Topics: Arsenic Trioxide; Arsenicals; China; France; History, 20th Century; History, 21st Century; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin

2017
Clinical impact of galectin-3 in newly diagnosed t (15;17)(q22;q21)/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens.
    Annals of hematology, 2017, Volume: 96, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Case-Control Studies; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Female; Galectin 3; Humans; Immunophenotyping; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Analysis; Translocation, Genetic; Treatment Outcome; Tretinoin; Young Adult

2017
Arsenic trioxide and all-trans-retinoic acid selectively exert synergistic cytotoxicity against FLT3-ITD AML cells via co-inhibition of FLT3 signaling pathways.
    Leukemia & lymphoma, 2017, Volume: 58, Issue:10

    Topics: Apoptosis; Arsenic Trioxide; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Signal Transduction; Tretinoin

2017
Cucurbitacin B synergistically enhances the apoptosis-inducing effect of arsenic trioxide by inhibiting STAT3 phosphorylation in lymphoma Ramos cells.
    Leukemia & lymphoma, 2017, Volume: 58, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Humans; Leukemia, Promyelocytic, Acute; Phosphorylation; STAT3 Transcription Factor; Triterpenes; Tumor Cells, Cultured

2017
Delayed hematological recovery following autologous transplantation utilizing peripheral blood stem cells harvested after treatment with arsenic trioxide.
    Pathology oncology research : POR, 2008, Volume: 14, Issue:4

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Peripheral Blood Stem Cell Transplantation; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Autologous

2008
Telomerase activity and telomere length in patients with acute promyelocytic leukemia: indicative of proliferative activity, disease progression, and overall survival.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Growth Processes; Disease Progression; Enzyme Activation; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Survival Rate; Telomerase; Telomere

2008
Arsenic trioxide and auranofin inhibit selenoprotein synthesis: implications for chemotherapy for acute promyelocytic leukaemia.
    British journal of pharmacology, 2008, Volume: 154, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Arsenites; Auranofin; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Oxides; Protein Biosynthesis; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Messenger; RNA, Small Interfering; Selenium Radioisotopes; Selenoproteins; Sodium Compounds; Sodium Selenite; Thioredoxin Reductase 1

2008
PML/RARalpha fusion protein mediates the unique sensitivity to arsenic cytotoxicity in acute promyelocytic leukemia cells: Mechanisms involve the impairment of cAMP signaling and the aberrant regulation of NADPH oxidase.
    Journal of cellular physiology, 2008, Volume: 217, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Survival; Cyclic AMP; Dose-Response Relationship, Drug; Humans; Leukemia, Promyelocytic, Acute; NADPH Oxidases; Oncogene Proteins, Fusion; Oxides; Reactive Oxygen Species; Signal Transduction; Time Factors; Transfection; U937 Cells

2008
Acute promyelocytic leukemia: recent advances in diagnosis and management.
    Seminars in oncology, 2008, Volume: 35, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Salvage Therapy; Treatment Outcome; Tretinoin

2008
Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy.
    Blood, 2008, Nov-01, Volume: 112, Issue:9

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Cytarabine; Female; Humans; Injections, Spinal; Leukemia, Promyelocytic, Acute; Male; Methotrexate; Middle Aged; Oxides; Recurrence

2008
Arsenic trioxide stimulates SUMO-2/3 modification leading to RNF4-dependent proteolytic targeting of PML.
    FEBS letters, 2008, Sep-22, Volume: 582, Issue:21-22

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Down-Regulation; Humans; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oxides; Proteasome Endopeptidase Complex; Small Ubiquitin-Related Modifier Proteins; Transcription Factors; Ubiquitination; Ubiquitins

2008
Arsenic trioxide mutational spectrum analysis in the mouse lymphoma assay.
    Mutation research, 2008, Nov-10, Volume: 646, Issue:1-2

    Topics: Animals; Arsenic Trioxide; Arsenicals; Biological Assay; Cell Line, Tumor; Leukemia L5178; Leukemia, Promyelocytic, Acute; Mice; Mutagenicity Tests; Oxides; Spectrum Analysis; Thymidine Kinase

2008
Oral arsenic treatment of leukemia and the risk of porphyria.
    Leukemia research, 2009, Volume: 33, Issue:4

    Topics: Administration, Oral; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Oxides; Porphyrias; Porphyrins

2009
Catalase activity and arsenic sensitivity in acute leukemia.
    Leukemia & lymphoma, 2008, Volume: 49, Issue:10

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Catalase; Cell Line, Tumor; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Oxides; Tumor Cells, Cultured

2008
Histopathological response of transitional cell carcinoma to arsenic trioxide during the treatment of concurrently diagnosed acute promyelocytic leukaemia.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2008, Volume: 20, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Transitional Cell; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasms, Multiple Primary; Oxides; Remission Induction; Tretinoin; Urinary Bladder Neoplasms

2008
Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia.
    Analytical and bioanalytical chemistry, 2009, Volume: 393, Issue:2

    Topics: Arsenic Trioxide; Arsenicals; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Leukemia, Promyelocytic, Acute; Male; Mass Spectrometry; Middle Aged; Oxides; Recurrence; Remission Induction; Time Factors; Tretinoin

2009
Apoptosis induction by (+)alpha-tocopheryl succinate in the absence or presence of all-trans retinoic acid and arsenic trioxide in NB4, NB4-R2 and primary APL cells.
    Leukemia research, 2009, Volume: 33, Issue:7

    Topics: alpha-Tocopherol; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Lipid Peroxidation; Oxides; Tretinoin

2009
[Can As2O3 improve the prognosis of childhood acute promyelocytic leukemia?--A single center experience].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2008, Volume: 29, Issue:7

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oncogene Proteins, Fusion; Oxides; Prognosis; Retrospective Studies; Treatment Outcome; Tretinoin

2008
Evidence for basophilic differentiation of acute promyelocytic leukaemia cells during arsenic trioxide therapy.
    British journal of haematology, 2009, Volume: 144, Issue:5

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Basophils; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides

2009
[New therapeutic perspectives for arsenic: from acute promyelocytic leukemia to autoimmune diseases].
    Medecine sciences : M/S, 2008, Volume: 24, Issue:11

    Topics: Animals; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Autoimmune Diseases; Disease Models, Animal; Growth Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders; Mice; Oxides

2008
Curative strategies in acute promyelocytic leukemia.
    Hematology. American Society of Hematology. Education Program, 2008

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Cytarabine; Daunorubicin; Disease-Free Survival; Growth Inhibitors; History, 20th Century; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasm Recurrence, Local; Oxides; Tretinoin

2008
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Feb-01, Volume: 27, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Female; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Polymerase Chain Reaction; Remission Induction; Survival Rate; Treatment Outcome; Tretinoin

2009
[Effects of PML-RARalpha on cAMP-induced AML cell differentiation].
    Zhongguo shi yan xue ye xue za zhi, 2008, Volume: 16, Issue:6

    Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cyclic AMP; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Signal Transduction; Transfection

2008
Curing APL: differentiation or destruction?
    Cancer cell, 2009, Jan-06, Volume: 15, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Tretinoin

2009
Characterization of cytotoxicity induced by arsenic trioxide (a potent anti-APL drug) in rat cardiac myocytes.
    Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS), 2009, Volume: 23, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium; Cell Line, Tumor; Cell Survival; Leukemia, Promyelocytic, Acute; Myocytes, Cardiac; Oxides; Rats; Rats, Wistar; Reactive Oxygen Species

2009
Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.
    Proceedings of the National Academy of Sciences of the United States of America, 2009, Mar-03, Volume: 106, Issue:9

    Topics: Aquaporins; Arsenic Trioxide; Arsenicals; Gene Expression Regulation, Leukemic; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Prognosis; Survival Rate; Time Factors; Tretinoin

2009
[Role of P27(Kip1) and TGF-beta1 in APL cell apoptosis induced by As(2)O(3)].
    Zhongguo shi yan xue ye xue za zhi, 2009, Volume: 17, Issue:2

    Topics: Adolescent; Adult; Aged; Apoptosis; Arsenic Trioxide; Arsenicals; Cyclin-Dependent Kinase Inhibitor p27; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Transforming Growth Factor beta1; Tumor Cells, Cultured; Young Adult

2009
Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells.
    The Journal of biological chemistry, 2009, Jun-12, Volume: 284, Issue:24

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bacterial Proteins; Cell Line; Fluorescence Resonance Energy Transfer; Humans; In Vitro Techniques; Kidney; Leukemia, Promyelocytic, Acute; Luciferases, Renilla; Luminescent Measurements; Luminescent Proteins; Mutagenesis, Site-Directed; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Protein Binding; Protein Structure, Tertiary; SUMO-1 Protein; Transcription Factors; Transfection; Tumor Suppressor Proteins

2009
[The significance of combined therapy of arsenic trioxide and all-trans retinoic acid in treating acute promyelocytic leukemia].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2009, Volume: 29, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Retrospective Studies; Tretinoin; Young Adult

2009
Downregulation of the c-MYC target gene, peroxiredoxin III, contributes to arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
    International journal of cancer, 2009, Jul-15, Volume: 125, Issue:2

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Base Sequence; Cell Line, Tumor; Chromatin Immunoprecipitation; DNA Primers; Down-Regulation; Genes, myc; Humans; Leukemia, Promyelocytic, Acute; Oxides; Peroxiredoxins; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering

2009
Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation.
    Cancer letters, 2009, Nov-01, Volume: 284, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; G2 Phase; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Metaphase; Neoplasm Proteins; Oxides; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-cbl; Signal Transduction; Stomach Neoplasms; Tumor Suppressor Protein p53; Ubiquitination; Up-Regulation

2009
[Construction of subtractive cDNA library of apoptosis-related genes in NB4 cells treated by arsenic trioxide].
    Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2009, Volume: 34, Issue:4

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; DNA, Complementary; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Library; Humans; Leukemia, Promyelocytic, Acute; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis; Oxides; Sequence Analysis, DNA

2009
Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:7

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Enzyme Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Male; Mitoxantrone; Multiple Sclerosis; Oxides; Remission Induction; Topoisomerase II Inhibitors; Treatment Outcome

2009
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Aug-01, Volume: 27, Issue:22

    Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Blood Chemical Analysis; Bone Marrow; Cohort Studies; Confidence Intervals; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Monitoring, Physiologic; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Predictive Value of Tests; Probability; Prognosis; Proportional Hazards Models; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Severity of Illness Index; Survival Analysis; Treatment Outcome; Tretinoin

2009
Arsenic trioxide associated toothache.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2010, Volume: 16, Issue:2

    Topics: Arsenic Trioxide; Arsenicals; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Toothache; Tretinoin

2010
Successful pregnancy after arsenic trioxide therapy for relapsed acute promyelocytic leukaemia.
    British journal of haematology, 2009, Volume: 146, Issue:3

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Infant, Newborn; Leukemia, Promyelocytic, Acute; Male; Oxides; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Recurrence

2009
[Influence of As(2)O(3) on proteasome beta(1)-subunit in NB4 cells].
    Zhongguo shi yan xue ye xue za zhi, 2009, Volume: 17, Issue:3

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Proteasome Endopeptidase Complex; Tumor Cells, Cultured

2009
Therapy-related acute promyelocytic leukemia: further insights into the molecular basis of the disease and showing the way forward in therapy.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:7

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Medical Oncology; Neoplasms, Second Primary; Oxides; Translocation, Genetic; Treatment Outcome; Tretinoin

2009
[Clinical study on the fibrinolytic activity in patients with acute promyelocytic leukemia].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2009, Volume: 30, Issue:3

    Topics: Adolescent; Adult; Aged; Annexin A2; Arsenic Trioxide; Arsenicals; Female; Fibrinolysis; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; RNA, Messenger; Tretinoin; Urokinase-Type Plasminogen Activator; Young Adult

2009
Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
    American journal of hematology, 2009, Volume: 84, Issue:10

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blindness; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Treatment Outcome

2009
Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia.
    Leukemia research, 2010, Volume: 34, Issue:3

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chromatography, High Pressure Liquid; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides

2010
Arsenic-induced pericardial and pleural effusion without acute promyelocytic leukemia differentiation syndrome.
    Leukemia research, 2010, Volume: 34, Issue:1

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Pericardial Effusion; Pleural Effusion

2010
Arsenic trioxide downregulates the expression of annexin II in bone marrow cells from patients with acute myelogenous leukemia.
    Chinese medical journal, 2009, Sep-05, Volume: 122, Issue:17

    Topics: Adult; Annexin A2; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Cell Survival; Cells, Cultured; Down-Regulation; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Reverse Transcriptase Polymerase Chain Reaction; Young Adult

2009
How I treat acute promyelocytic leukemia.
    Blood, 2009, Dec-10, Volume: 114, Issue:25

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Examination; Dose-Response Relationship, Drug; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Outcome Assessment, Health Care; Oxides; Practice Guidelines as Topic; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin

2009
Mobilization of PML/RARalpha negative peripheral blood stem cells with a combination of G-CSF and CXCR4 blockade in relapsed acute promyelocytic leukemia pre-treated with arsenic trioxide.
    Haematologica, 2010, Volume: 95, Issue:1

    Topics: Adult; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oxides; Peripheral Blood Stem Cell Transplantation; Promyelocytic Leukemia Protein; Receptors, CXCR4; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Secondary Prevention; Transcription Factors; Tumor Suppressor Proteins

2010
Arsenic trioxide in a hemodialytic patient with acute promyelocytic leukemia.
    Acta haematologica, 2009, Volume: 122, Issue:1

    Topics: Acute Kidney Injury; Aged; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Renal Dialysis

2009
Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:11

    Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Child; Combined Modality Therapy; Female; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Myeloablative Agonists; Oncogene Proteins, Fusion; Oxides; Peripheral Blood Stem Cell Transplantation; Recurrence; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Tretinoin; Young Adult

2009
Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome.
    Blood, 2009, Dec-24, Volume: 114, Issue:27

    Topics: Anti-Inflammatory Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Chemokine CCL2; Chemokine CCL24; Chemokine CCL7; Chemokines; Dexamethasone; Enzyme-Linked Immunosorbent Assay; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Oligonucleotide Array Sequence Analysis; Oxides; Receptors, Retinoic Acid; Reverse Transcriptase Polymerase Chain Reaction; Syndrome; Tretinoin; Tumor Cells, Cultured

2009
Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2009, Nov-01, Volume: 66, Issue:21

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin

2009
Evaluation of adverse cardiac effects induced by arsenic trioxide, a potent anti-APL drug.
    Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer, 2009, Volume: 28, Issue:3

    Topics: Action Potentials; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Dose-Response Relationship, Drug; Drug Antagonism; Edema, Cardiac; Guinea Pigs; Heart; Leukemia, Promyelocytic, Acute; Male; Membrane Transport Modulators; Myocardium; Oxidants; Oxides; Oxidoreductases; Vasodilator Agents

2009
[Apoptosis of MR2 cells induced by Tanshinone II A combined with arsenic trioxide].
    Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2009, Volume: 40, Issue:5

    Topics: Abietanes; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Phenanthrenes; Tretinoin

2009
[Comparison of efficacy and adverse effects between arsenic trioxide and all-trans retinoic acid in patients with acute promyelocytic leukemia].
    Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2009, Volume: 31, Issue:5

    Topics: Adolescent; Adult; Aged; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Retrospective Studies; Treatment Outcome; Tretinoin; Young Adult

2009
Arsenic trioxide and olanzapine co-administration: case analysis.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2011, Volume: 17, Issue:3

    Topics: Adult; Antineoplastic Agents; Antipsychotic Agents; Arsenic Trioxide; Arsenicals; Benzodiazepines; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Electrocardiography; Humans; Leukemia, Promyelocytic, Acute; Long QT Syndrome; Male; Mental Disorders; Olanzapine; Oxides; Patient Safety; Risk Factors

2011
[Retrospective analysis of 76 children with acute promyelocytic leukemia].
    Zhonghua er ke za zhi = Chinese journal of pediatrics, 2009, Volume: 47, Issue:9

    Topics: Adolescent; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Retrospective Studies; Survival Rate; Treatment Outcome

2009
Successful post-remission therapy with a combination of all-trans retinoic acid and arsenic trioxide in an elderly Japanese patient newly diagnosed with acute promyelocytic leukemia.
    International journal of hematology, 2010, Volume: 91, Issue:1

    Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Asian People; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Tretinoin

2010
Gangrenous cheilitis associated with all-trans retinoic acid therapy for acute promyelocytic leukemia.
    International journal of hematology, 2010, Volume: 91, Issue:1

    Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biopsy; Cheilitis; Female; Gangrene; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin

2010
Potent reducing effects of vitamin D3 on the frequency of apoptosis induced by arsenic trioxide in NB4 cell line.
    Archives of Iranian medicine, 2010, Volume: 13, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Cholecalciferol; Dose-Response Relationship, Drug; Humans; Leukemia, Promyelocytic, Acute; Oxides

2010
Phosphatidylserine exposure and procoagulant activity in acute promyelocytic leukemia.
    Journal of thrombosis and haemostasis : JTH, 2010, Volume: 8, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation; Blood Coagulation Tests; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Survival; Daunorubicin; Etoposide; Factor Xa; Female; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Male; Membrane Glycoproteins; Microscopy, Confocal; Milk Proteins; Oxides; Phosphatidylserines; Thrombin; Thromboplastin; Tretinoin; Young Adult

2010
Autophagy modification augmented the treatment effects initiated by arsenic trioxide in NB4 cells.
    Medical oncology (Northwood, London, England), 2011, Volume: 28, Issue:1

    Topics: Adenine; Antibiotics, Antineoplastic; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Cell Line, Tumor; Cell Survival; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Oxides; Sirolimus

2011
Arsenic trioxide-mediated antiplatelet activity: pivotal role of the phospholipase C gamma 2-protein kinase C-p38 MAPK cascade.
    Translational research : the journal of laboratory and clinical medicine, 2010, Volume: 155, Issue:2

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Platelets; Cell Adhesion Molecules; Collagen; Enzyme Activation; Humans; Hydroxyl Radical; In Vitro Techniques; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; Microfilament Proteins; Oxides; p38 Mitogen-Activated Protein Kinases; Phospholipase C gamma; Phosphoproteins; Phosphorylation; Platelet Activation; Platelet Aggregation Inhibitors; Protein Kinase C

2010
Non-lethal bone marrow necrosis under first-line arsenic trioxide therapy in acute promyelocytic leukaemia.
    Acta haematologica, 2010, Volume: 123, Issue:3

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Necrosis; Oxides; Treatment Outcome

2010
The expression of p38, ERK1 and Bax proteins has increased during the treatment of newly diagnosed acute promyelocytic leukemia with arsenic trioxide.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:9

    Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Blotting, Western; Bone Marrow; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitogen-Activated Protein Kinase 3; Neoplasm Staging; Oxides; p38 Mitogen-Activated Protein Kinases; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Treatment Outcome; Young Adult

2010
External auditory canal and middle ear relapse of acute promyelocytic leukemia treated with arsenic trioxide: case report and review of the literature.
    Journal of pediatric hematology/oncology, 2010, Volume: 32, Issue:3

    Topics: Arsenic Trioxide; Arsenicals; Child; Ear Canal; Ear Neoplasms; Ear, Middle; Female; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides; Treatment Outcome

2010
Gefitinib enhances arsenic trioxide (AS2O3)-induced differentiation of acute promyelocytic leukemia cell line.
    Leukemia research, 2010, Volume: 34, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Leukemia, Promyelocytic, Acute; Oxides; Quinazolines

2010
Treatment of therapy related acute promyelocytic leukemia with the combination of all trans retinoic acid and arsenic trioxide without chemotherapy: a series of three patients.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Choriocarcinoma; Female; Humans; Kidney Neoplasms; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neuroectodermal Tumors; Ovarian Neoplasms; Oxides; Prognosis; Tretinoin

2010
[Apoptosis of NB4 cells induced by Tanshinone II A combined with arsenic trioxide].
    Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2010, Volume: 41, Issue:1

    Topics: Abietanes; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides

2010
Medicine. Poisonous contacts.
    Science (New York, N.Y.), 2010, Apr-09, Volume: 328, Issue:5975

    Topics: Arsenic; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Mutant Proteins; Mutation; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Protein Multimerization; Transcription Factors; Tumor Suppressor Proteins; Zinc Fingers

2010
Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.
    Science (New York, N.Y.), 2010, Apr-09, Volume: 328, Issue:5975

    Topics: Arsenic; Arsenic Trioxide; Arsenicals; Cell Line; Humans; Leukemia, Promyelocytic, Acute; Mutant Proteins; Mutation; Nuclear Proteins; Oncogene Proteins, Fusion; Oxazines; Oxides; Promyelocytic Leukemia Protein; Protein Conformation; Protein Multimerization; Protein Structure, Secondary; Protein Structure, Tertiary; Receptors, Retinoic Acid; Recombinant Fusion Proteins; Retinoic Acid Receptor alpha; Small Ubiquitin-Related Modifier Proteins; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Transcription Factors; Tumor Suppressor Proteins; Ubiquitination; Zinc Fingers

2010
Relapsed APL patient with variant NPM-RARalpha fusion responded to arsenic trioxide-based therapy and achieved long-term survival.
    International journal of hematology, 2010, Volume: 91, Issue:4

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction

2010
All-trans retinoic acid and arsenic rescue patients with acute promyelocytic leukemia from a potential 'perfect storm'.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Neoplasms; Oxides; Prognosis; Tretinoin

2010
Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.
    International journal of hematology, 2010, Volume: 91, Issue:5

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Transformation, Neoplastic; Gene Expression Regulation, Neoplastic; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Mice; Oncogene Proteins, Fusion; Oncogenes; Oxides; Tretinoin

2010
Retrospective study of arsenic trioxide for childhood acute promyelocytic leukemia in China: a single-center experience.
    International journal of hematology, 2010, Volume: 91, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Child; Child, Preschool; China; Disseminated Intravascular Coagulation; Female; Humans; Incidence; Leukemia, Promyelocytic, Acute; Male; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin

2010
Sweet fruit from a poisonous kiss.
    Journal of hematology & oncology, 2010, May-28, Volume: 3

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides

2010
CNS relapse in acute promyeloctyic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Neoplasms; Brain Neoplasms; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cranial Irradiation; Cytarabine; Drug Administration Schedule; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Magnetic Resonance Imaging; Mercaptopurine; Methotrexate; Mutation; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Recurrence; Remission Induction; Retinoic Acid Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factors; Translocation, Genetic; Transplantation, Autologous; Treatment Outcome; Tretinoin; Tumor Suppressor Proteins

2010
Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein.
    Blood, 2010, Sep-30, Volume: 116, Issue:13

    Topics: Arsenic Trioxide; Arsenicals; Autophagy; Cell Differentiation; Cell Line, Tumor; HeLa Cells; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Protein Serine-Threonine Kinases; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; RNA, Small Interfering; Solubility; TOR Serine-Threonine Kinases; Transcription Factors; Tretinoin; Tumor Suppressor Proteins

2010
Arsenic trioxide promotes mitochondrial DNA mutation and cell apoptosis in primary APL cells and NB4 cell line.
    Science China. Life sciences, 2010, Volume: 53, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Base Sequence; Cell Line, Tumor; DNA Mutational Analysis; DNA, Mitochondrial; Humans; Leukemia, Promyelocytic, Acute; Molecular Sequence Data; Mutation; Oxides; Polymerase Chain Reaction; Tumor Cells, Cultured

2010
[Arsenic trioxide treatment in a patient with recurrent acute promyelocytic leukemia (APL)].
    Anales de pediatria (Barcelona, Spain : 2003), 2010, Volume: 73, Issue:1

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence

2010
PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.
    Cancer cell, 2010, Jul-13, Volume: 18, Issue:1

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, Western; Chlorocebus aethiops; CHO Cells; COS Cells; Cricetinae; Cricetulus; Disulfides; Embryo, Mammalian; Fibroblasts; Hematopoietic Stem Cells; Humans; Intranuclear Inclusion Bodies; Leukemia, Promyelocytic, Acute; Mice; Mice, Knockout; Mutation; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Reactive Oxygen Species; Signal Transduction; Small Ubiquitin-Related Modifier Proteins; Transcription Factors; Tumor Suppressor Proteins

2010
Arsenic trioxide cooperates with all trans retinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PML-RARalpha negative human myeloblastic leukemia cells.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Cycle; Cell Differentiation; Cell Proliferation; Drug Synergism; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Mitogen-Activated Protein Kinases; Oncogene Proteins, Fusion; Oxides; Tretinoin; Tumor Cells, Cultured

2010
The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel.
    BMC medical genomics, 2010, Aug-13, Volume: 3

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Cell Line, Tumor; Humans; Leukemia, Promyelocytic, Acute; National Cancer Institute (U.S.); NF-E2-Related Factor 2; Oxidative Stress; Oxides; RNA Interference; United States

2010
Clinical efficacy of arsenic trioxide in a patient with acute promyelocytic leukemia with recurrent central nervous system involvement.
    Annals of hematology, 2011, Volume: 90, Issue:5

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Central Nervous System; Central Nervous System Neoplasms; Female; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Meningeal Neoplasms; Oxides; Recurrence; Treatment Outcome

2011
Autophagic degradation of an oncoprotein.
    Autophagy, 2010, Volume: 6, Issue:7

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Proteasome Endopeptidase Complex; Tretinoin

2010
Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy.
    Cancer, 2011, Jan-01, Volume: 117, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Radiation-Induced; Oxides; Treatment Outcome; Tretinoin

2011
Synergistic apoptosis induction in leukemic cells by miR-15a/16-1 and arsenic trioxide.
    Biochemical and biophysical research communications, 2010, Dec-10, Volume: 403, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Drug Synergism; Fusion Proteins, bcr-abl; Humans; K562 Cells; Leukemia, Promyelocytic, Acute; MicroRNAs; Mitochondria; Oxides

2010
Long-term survey of outcome in acute promyelocytic leukemia: a single center experience in 340 patients.
    Medical oncology (Northwood, London, England), 2011, Volume: 28 Suppl 1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Survival Rate; Time Factors; Treatment Outcome; Tretinoin; Young Adult

2011
Treatment of patients with acute promyelocytic leukemia: a consensus statement on risk-adapted approaches to therapy.
    Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10 Suppl 3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Risk Assessment; Treatment Outcome; Tretinoin

2010
Utilization of molecular phenotypes to detect relapse and optimize the management of acute promyelocytic leukemia.
    Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10 Suppl 3

    Topics: Adaptor Proteins, Signal Transducing; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Phenotype; Prognosis; Recurrence; Translocation, Genetic; Tretinoin

2010
The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia.
    Leukemia research, 2011, Volume: 35, Issue:7

    Topics: Adolescent; Adult; Aged; Annexin A2; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation Tests; Blotting, Western; Cell Proliferation; Female; Fibrinolysin; Fibrinolysis; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Plasminogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tissue Plasminogen Activator; Tretinoin; Young Adult

2011
Don't just stand there, do something: strategies for the prevention of early death in acute promyelocytic leukemia: a commentary.
    Blood cells, molecules & diseases, 2011, Feb-15, Volume: 46, Issue:2

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disseminated Intravascular Coagulation; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Secondary Prevention; Survival Rate; Time Factors; Treatment Failure; Tretinoin

2011
[A successful case of tanshinone II A treatment for relapsed acute promyelocytic leukemia after maintainance therapy of all-trans retinoic acid and arsenic trioxide].
    Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2010, Volume: 41, Issue:6

    Topics: Abietanes; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Methotrexate; Neoplasm Recurrence, Local; Oxides; Tretinoin; Young Adult

2010
Long-term remission after first-line single-agent treatment with arsenic trioxide of relapsed acute promyelocytic leukemia in an 8-year-old boy.
    Pediatric hematology and oncology, 2011, Volume: 28, Issue:4

    Topics: Arsenic Trioxide; Arsenicals; Child; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence; Remission Induction; Time Factors

2011
Treatment of acute promyelocytic leukemia for older patients.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2011, Volume: 9, Issue:3

    Topics: Age Factors; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Prognosis; Treatment Outcome; Tretinoin

2011
Arsenic trioxide may improve the prognosis of APL with ider(17)(q10): report of a rare adult case of acute promyelocytic leukemia with ider(17)(q10)t(15;17) showing poor response to all-trans retinoic acid.
    Annals of hematology, 2011, Volume: 90, Issue:12

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Prognosis; Recombinant Fusion Proteins; Tretinoin

2011
Therapy-related acute promyelocytic leukemia.
    Haematologica, 2011, Volume: 96, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Neoplasms, Second Primary; Oxides; Radiotherapy, Computer-Assisted

2011
Successful treatment of relapsed and refractory extramedullary acute promyelocytic leukemia with tamibarotene.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-20, Volume: 29, Issue:18

    Topics: Adult; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Bone Marrow; Bone Neoplasms; Combined Modality Therapy; Doxorubicin; Drug Resistance, Neoplasm; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Male; Mercaptopurine; Methotrexate; Oxides; Radionuclide Imaging; Remission Induction; Salvage Therapy; Sarcoma, Myeloid; Soft Tissue Neoplasms; Tetrahydronaphthalenes; Tretinoin

2011
Treatment of relapsed acute promyelocytic leukemia by arsenic trioxide in Iran.
    Archives of Iranian medicine, 2011, Volume: 14, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Cohort Studies; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Iran; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Remission Induction; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult

2011
Characterization of arsenic-induced cytogenetic alterations in acute promyelocytic leukemia cell line, NB4.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Survival; Chromosome Aberrations; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides; Tumor Cells, Cultured

2012
[Mechanism of apoptosis induced by bortezomib and As2O3 in APL cell line NB4].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2011, Volume: 32, Issue:4

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Leukemia, Promyelocytic, Acute; Oxides; Pyrazines

2011
Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.
    Blood, 2011, Aug-11, Volume: 118, Issue:6

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Binding Sites; Cytoplasm; Drug Resistance, Neoplasm; Female; HeLa Cells; Humans; Immunoblotting; Leukemia, Promyelocytic, Acute; Male; Microscopy, Fluorescence; Middle Aged; Mutation, Missense; Neoplasm Recurrence, Local; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; Sumoylation; Transcription Factors; Transcription, Genetic; Tumor Suppressor Proteins; U937 Cells; Young Adult

2011
Newly diagnosed acute promyelocytic leukemia: arsenic moves front and center.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-10, Volume: 29, Issue:20

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Developing Countries; Humans; Leukemia, Promyelocytic, Acute; Oxides; Survival Analysis; Tretinoin

2011
Arsenic trioxide for the treatment of a relapsed acute promyelocytic leukemia with acute renal failure.
    Pediatric blood & cancer, 2011, Dec-01, Volume: 57, Issue:6

    Topics: Acute Kidney Injury; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Fatal Outcome; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence

2011
Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia.
    Haematologica, 2011, Volume: 96, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Treatment Outcome; Tretinoin

2011
Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia.
    The journal of the Royal College of Physicians of Edinburgh, 2011, Volume: 41, Issue:2

    Topics: Adult; Anti-Arrhythmia Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Electrocardiography; Female; Humans; Leukemia, Promyelocytic, Acute; Magnesium; Manitoba; Metoprolol; Oxides; Potassium; Tachycardia, Ventricular

2011
[Mechanism of apoptosis of NB4 cells induced by arsenic trioxide and cyclooxygenase-2 expression].
    Zhongguo shi yan xue ye xue za zhi, 2011, Volume: 19, Issue:3

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cyclooxygenase 2; Humans; Leukemia, Promyelocytic, Acute; Membrane Potential, Mitochondrial; Oxides

2011
(+)α-Tocopheryl succinate inhibits the mitochondrial respiratory chain complex I and is as effective as arsenic trioxide or ATRA against acute promyelocytic leukemia in vivo.
    Leukemia, 2012, Volume: 26, Issue:3

    Topics: alpha-Tocopherol; Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Line, Tumor; Cytochromes c; Disease Models, Animal; Electron Transport Complex I; Electron Transport Complex II; Humans; Leukemia, Promyelocytic, Acute; Membrane Potential, Mitochondrial; Mice; Mice, Transgenic; Mitochondria; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Oxides; Protein Stability; Rats; Reactive Oxygen Species; Transplantation, Isogeneic; Tretinoin

2012
Arsenic trioxide in the management of APL: proceed with caution.
    Oncology (Williston Park, N.Y.), 2011, Volume: 25, Issue:8

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides

2011
Oral arsenic trioxide for relapsed acute promyelocytic leukemia in pediatric patients.
    Pediatric blood & cancer, 2012, Volume: 58, Issue:4

    Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence; Time Factors

2012
Epstein - Barr virus Latent Membrane Protein 1 suppresses reporter activity through modulation of promyelocytic leukemia protein-nuclear bodies.
    Virology journal, 2011, Oct-05, Volume: 8

    Topics: Arsenic Trioxide; Arsenicals; beta-Galactosidase; Cell Line; Dose-Response Relationship, Drug; Epstein-Barr Virus Infections; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Viral; Gene Silencing; Genes, Reporter; Herpesvirus 4, Human; Humans; Intranuclear Inclusion Bodies; Leukemia, Promyelocytic, Acute; Luciferases; Nuclear Proteins; Oxides; Plasmids; Promyelocytic Leukemia Protein; RNA, Small Interfering; Transcription Factors; Transcription, Genetic; Transfection; Tumor Suppressor Proteins; Viral Matrix Proteins

2011
Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2012, Volume: 33, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression; Humans; Leukemia, Promyelocytic, Acute; MicroRNAs; Oxides

2012
Promyelocytic leukemia nuclear bodies support a late step in DNA double-strand break repair by homologous recombination.
    Journal of cellular biochemistry, 2012, Volume: 113, Issue:5

    Topics: Arsenic Trioxide; Arsenicals; Cell Nucleus; DNA Breaks, Double-Stranded; DNA End-Joining Repair; DNA, Neoplasm; Genomic Instability; Histones; Humans; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Phosphorylation; Promyelocytic Leukemia Protein; Rad51 Recombinase; Recombinational DNA Repair; RNA Interference; Transcription Factors; Tretinoin; Tumor Suppressor Proteins

2012
Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient.
    Journal of hematology & oncology, 2012, Jan-24, Volume: 5

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Chromatography, High Pressure Liquid; Drug Monitoring; Female; Humans; Leukemia, Promyelocytic, Acute; Mass Spectrometry; Middle Aged; Neoplasm Recurrence, Local; Oxides; Prognosis; Remission Induction; Salvage Therapy; Tissue Distribution

2012
Sustained molecular remission after arsenic trioxide and gemutuzumab ozogamicin in a pediatric patient with relapsed acute promyelocytic leukemia.
    Pediatric hematology and oncology, 2012, Volume: 29, Issue:2

    Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Benzoates; Child; Drug Administration Schedule; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence; Remission Induction; Tetrahydronaphthalenes; Tretinoin

2012
Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy.
    Blood, 2012, Apr-12, Volume: 119, Issue:15

    Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Molecular Diagnostic Techniques; Monitoring, Physiologic; Neoadjuvant Therapy; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Predictive Value of Tests; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Young Adult

2012
Long-term remission in a case of acute promyelocytic leukemia patient with marked myelofibrosis treated with arsenic trioxide, all-trans retinoic acid and consolidation therapy with daunorubicin plus cytarabine.
    Leukemia research, 2012, Volume: 36, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Primary Myelofibrosis; Remission Induction; Survivors; Tretinoin

2012
[Regulation of all-trans retinoic acid and arsenic trioxide on CD44v6 expression in NB4 cells].
    Zhongguo shi yan xue ye xue za zhi, 2012, Volume: 20, Issue:1

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Gene Expression Regulation, Leukemic; Humans; Hyaluronan Receptors; Leukemia, Promyelocytic, Acute; Oxides; Signal Transduction; Tretinoin

2012
Quantification of PML/RARa transcript after induction predicts outcome in children with acute promyelocytic leukemia.
    International journal of hematology, 2012, Volume: 95, Issue:5

    Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Multivariate Analysis; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Prognosis; Real-Time Polymerase Chain Reaction; Remission Induction; Transcription, Genetic; Treatment Outcome; Tretinoin

2012
Mitochondrial myopathy caused by arsenic trioxide therapy.
    Blood, 2012, May-03, Volume: 119, Issue:18

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; DNA Mutational Analysis; Female; Humans; Leukemia, Promyelocytic, Acute; Mitochondria, Muscle; Mitochondrial Myopathies; Oxides; Tretinoin

2012
Parenthood in patients with acute promyelocytic leukemia after treatment with arsenic trioxide: a case series.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:11

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Fertility; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Pregnancy; Pregnancy Outcome

2012
Does arsenic trioxide impact fertility?
    Leukemia & lymphoma, 2012, Volume: 53, Issue:11

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Fertility; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Pregnancy

2012
Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks.
    Leukemia research, 2012, Volume: 36, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Staging; Oxides; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Treatment Outcome; Tretinoin; Young Adult

2012
Cardiac conduction block at multiple levels caused by arsenic trioxide therapy.
    The Canadian journal of cardiology, 2013, Volume: 29, Issue:1

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chelating Agents; Dimercaprol; Electrocardiography; Female; Follow-Up Studies; Growth Inhibitors; Heart Block; Heart Conduction System; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides

2013
The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.
    Blood, 2012, Jul-26, Volume: 120, Issue:4

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Nucleus; Cytoplasm; Fluorescent Antibody Technique; Humans; Leukemia, Promyelocytic, Acute; Mutation; Nuclear Pore Complex Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Recycling; Sumoylation; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins

2012
Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008.
    Cancer, 2012, Dec-01, Volume: 118, Issue:23

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Female; Humans; Incidence; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; SEER Program; Time Factors; Tretinoin; United States

2012
The organic arsenic derivative GMZ27 induces PML-RARα-independent apoptosis in myeloid leukemia cells.
    Anticancer research, 2012, Volume: 32, Issue:7

    Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 9; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Activation; Female; HL-60 Cells; Humans; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Mice; Oncogene Proteins, Fusion; Oxides; Oxygen

2012
[Effect of arsenic trioxide and daunorubicin on procoagulant activity of acute promyelocytic leukemia cells].
    Zhonghua yi xue za zhi, 2012, Apr-24, Volume: 92, Issue:16

    Topics: Adult; Arsenic Trioxide; Arsenicals; Blood Coagulation; Blood Coagulation Tests; Case-Control Studies; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Phosphatidylserines; Thromboplastin; Tumor Cells, Cultured; Young Adult

2012
Kidney transplantation in a patient with end stage renal disease after complete remission of acute promyelocytic leukemia.
    Journal of Korean medical science, 2012, Volume: 27, Issue:7

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Humans; Kidney Failure, Chronic; Kidney Transplantation; Leukemia, Promyelocytic, Acute; Male; Oxides; Receptors, Retinoic Acid; Remission Induction; Retinoic Acid Receptor alpha; Ultrasonography

2012
Upfront maintenance therapy with arsenic trioxide in acute promyelocytic leukemia provides no benefit for non-t(15;17) subtype.
    Asia-Pacific journal of clinical oncology, 2012, Volume: 8, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Humans; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Mercaptopurine; Middle Aged; Oxides; Retrospective Studies; Tretinoin

2012
Oral administration of arsenic trioxide in the treatment of acute promyelocytic leukaemia and accelerated phase chronic myeloid leukaemia: an Australian single-centre study.
    Internal medicine journal, 2012, Volume: 42, Issue:8

    Topics: Administration, Oral; Adult; Aged; Arsenic Trioxide; Arsenicals; Australia; Female; Growth Inhibitors; Humans; Leukemia, Myeloid, Accelerated Phase; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Treatment Outcome

2012
ATRA plus arsenic gets another "A" in APL.
    Blood, 2012, Aug-23, Volume: 120, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin

2012
Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia.
    Cancer, 2013, Jan-01, Volume: 119, Issue:1

    Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prognosis; Recurrence

2013
Granulocyte colony-stimulating factor potentiates differentiation induction by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in the acute promyelocytic leukemia cell line HT93A.
    Oncology reports, 2012, Volume: 28, Issue:5

    Topics: Antigens, CD34; Apoptosis; Aquaporins; Arsenic Trioxide; Arsenicals; Biological Transport; Biomarkers, Tumor; CD11b Antigen; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Promyelocytic, Acute; Lewis X Antigen; Oxides; Tretinoin; Up-Regulation

2012
Cytotoxic effect of arsenic trioxide on acute promyelocytic leukemia cells through suppression of NFkβ-dependent induction of hTERT due to down-regulation of Pin1 transcription.
    Hematology (Amsterdam, Netherlands), 2012, Volume: 17, Issue:4

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA-Binding Proteins; Down-Regulation; Gene Expression Regulation, Leukemic; Genes, myc; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Promyelocytic, Acute; NF-kappa B; NIMA-Interacting Peptidylprolyl Isomerase; Nuclear Proteins; Oxides; Peptidylprolyl Isomerase; Phosphorylation; Survivin; Telomerase; Telomere Shortening; Transcription, Genetic; Tumor Protein p73; Tumor Suppressor Proteins

2012
[microRNAs expression profile in acute promyelocytic leukemia cell differentiation induced by all-trans retinoic acid and arsenic trioxide].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2012, Volume: 33, Issue:7

    Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; MicroRNAs; Oxides; RNA, Messenger; Tretinoin; Tumor Cells, Cultured

2012
High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia.
    Leukemia research, 2013, Volume: 37, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Retrospective Studies; Tretinoin

2013
Feasibility of oral arsenic trioxide treatment for acute promyelocytic leukemia during hemodialysis.
    Annals of hematology, 2013, Volume: 92, Issue:3

    Topics: Administration, Oral; Adult; Arsenic Trioxide; Arsenicals; Feasibility Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Renal Dialysis; Treatment Outcome

2013
Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.
    Annals of hematology, 2013, Volume: 92, Issue:1

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Follow-Up Studies; Germany; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Leukocyte Count; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Oxides; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Risk; Thioguanine; Treatment Outcome; Tretinoin

2013
Prognostic significance of CD44v6/v7 in acute promyelocytic leukemia.
    Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Female; Humans; Hyaluronan Receptors; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin; Tumor Cells, Cultured; Young Adult

2012
[Management of relapsed acute promyelocytic leukemia].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 2

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Brain; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Oxides; Recurrence; Tetrahydronaphthalenes

2012
Long term curative effects of sequential therapy with all-trans retinoic acid, arsenious oxide and chemotherapy on patients with acute promyelocytic leukemia.
    Hematology (Amsterdam, Netherlands), 2012, Volume: 17, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Treatment Outcome; Tretinoin; Young Adult

2012
The deubiquitinating enzyme USP37 regulates the oncogenic fusion protein PLZF/RARA stability.
    Oncogene, 2013, Oct-24, Volume: 32, Issue:43

    Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Transformation, Neoplastic; Endopeptidases; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Mice; Oncogene Proteins, Fusion; Oxides; Protein Stability; Translocation, Genetic

2013
[Effects of cucurmosin combined with common chemotherapeutics on proliferation and apoptosis of NB4 cells].
    Zhongguo shi yan xue ye xue za zhi, 2012, Volume: 20, Issue:6

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Plant Proteins; Tretinoin

2012
All-trans retinoic acid and arsenic trioxide resistance of acute promyelocytic leukemia with the variant STAT5B-RARA fusion gene.
    Leukemia, 2013, Volume: 27, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; STAT5 Transcription Factor; Tretinoin

2013
BIBR 1532 increases arsenic trioxide-mediated apoptosis in acute promyelocytic leukemia cells: therapeutic potential for APL.
    Anti-cancer agents in medicinal chemistry, 2013, Volume: 13, Issue:7

    Topics: Aminobenzoates; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Naphthalenes; Oxides; Telomerase

2013
Ultrastructural localization of F-actin using phalloidin and quantum dots in HL-60 promyelocytic leukemia cell line after cell death induction by arsenic trioxide.
    Acta histochemica, 2013, Volume: 115, Issue:5

    Topics: Actins; Apoptosis; Arsenic Trioxide; Arsenicals; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Microscopy, Electron, Transmission; Oxides; Phalloidine; Quantum Dots

2013
Arsenic speciation in saliva of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
    Analytical and bioanalytical chemistry, 2013, Volume: 405, Issue:6

    Topics: Adult; Antineoplastic Agents; Arsenates; Arsenic Trioxide; Arsenicals; Arsenites; Cacodylic Acid; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Methylation; Middle Aged; Oxides; Saliva; Spectrophotometry, Atomic

2013
Role of arsenic trioxide in acute promyelocytic leukemia.
    Current treatment options in oncology, 2013, Volume: 14, Issue:2

    Topics: Aminoglycosides; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase III as Topic; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Randomized Controlled Trials as Topic; Tretinoin

2013
Determination of arsenic metabolites in patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:9

    Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Chromatography, High Pressure Liquid; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Metabolomics; Middle Aged; Oxides; Young Adult

2013
Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia.
    Blood, 2002, Aug-01, Volume: 100, Issue:3

    Topics: Acetamides; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Butyrates; Cell Differentiation; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tretinoin; Tumor Cells, Cultured

2002
[Diamide and cyclosporin A enhanced arsenic trioxide-induced apoptosis in NB4 cells].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2002, Volume: 23, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cyclosporine; Diamide; Drug Synergism; Enzyme Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Membrane Potentials; Mitochondria; Oxides; Sulfhydryl Reagents; Tumor Cells, Cultured

2002
Arsenic trioxide, retinoic acid and Ara-c regulated the expression of annexin II on the surface of APL cells, a novel co-receptor for plasminogen/tissue plasminogen activator.
    Thrombosis research, 2002, Apr-01, Volume: 106, Issue:1

    Topics: Adolescent; Adult; Annexin A2; Antineoplastic Agents; AraC Transcription Factor; Arsenic Trioxide; Arsenicals; Bacterial Proteins; Female; Fibrinolysin; Gene Expression Regulation; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Plasminogen Activators; Repressor Proteins; RNA, Messenger; Tissue Plasminogen Activator; Transcription Factors; Transfection; Tretinoin; Tumor Cells, Cultured

2002
Atypical blasts and bone marrow necrosis associated with near-triploid relapse of acute promyelocytic leukemia after arsenic trioxide treatment.
    Human pathology, 2002, Volume: 33, Issue:8

    Topics: Adult; Arsenic Trioxide; Arsenicals; Biopsy; Bone Marrow; Chromosome Aberrations; Fatal Outcome; Female; Humans; Karyotyping; Leukemia, Promyelocytic, Acute; Necrosis; Oxides; Ploidies; Recurrence

2002
Real-time quantification of the multidrug resistance-1 gene expression in relapsed acute promyelocytic leukemia treated with arsenic trioxide.
    Haematologica, 2002, Volume: 87, Issue:10

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dose-Response Relationship, Drug; Female; Genes, MDR; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Reverse Transcriptase Polymerase Chain Reaction

2002
Arsenic trioxide promotes histone H3 phosphoacetylation at the chromatin of CASPASE-10 in acute promyelocytic leukemia cells.
    The Journal of biological chemistry, 2002, Dec-20, Volume: 277, Issue:51

    Topics: Acetylation; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Northern; Blotting, Western; Caspase 10; Caspases; Chromatin; DNA, Complementary; Dose-Response Relationship, Drug; Enzyme Activation; Histones; Humans; Leukemia, Promyelocytic, Acute; Oligonucleotide Array Sequence Analysis; Oligopeptides; Oxides; Phosphorylation; Polymerase Chain Reaction; Precipitin Tests; Protease Inhibitors; Protein Binding; Serine; Time Factors; Tumor Cells, Cultured

2002
In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia.
    The Journal of experimental medicine, 2002, Nov-18, Volume: 196, Issue:10

    Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Division; Cyclic AMP; Leukemia, Promyelocytic, Acute; Mice; Mice, Transgenic; Oxides; Signal Transduction; Theophylline; Tretinoin; Tumor Cells, Cultured

2002
[Experimental study of low dose arsenic trioxide in treatment of patients with acute promyelocytic leukemia].
    Ai zheng = Aizheng = Chinese journal of cancer, 2002, Volume: 21, Issue:4

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Isoquinolines; Leukemia, Promyelocytic, Acute; Oxides; Sulfonamides; Thionucleotides; Tumor Cells, Cultured

2002
Two cases of therapy-related acute promyelocytic leukemia (t-APL) after mantle cell lymphoma and gestational trophoblastic disease.
    Annals of hematology, 2002, Volume: 81, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Arsenic Trioxide; Arsenicals; Etoposide; Female; Gestational Trophoblastic Disease; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, Mantle-Cell; Male; Neoplasms, Second Primary; Oxides; Pregnancy; Tretinoin

2002
Molecular remission and reconstitution of a full chimera with arsenic trioxide in a patient with acute promyelocytic leukemia relapsed after allogeneic bone marrow transplantation.
    Leukemia, 2002, Volume: 16, Issue:12

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Molecular Diagnostic Techniques; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; RNA, Neoplasm; Salvage Therapy; Transplantation Chimera; Transplantation, Homologous

2002
[The comparison between the mechanisms of sodium selenite induced apoptosis and arsenic trioxide induced apoptosis in human acute promyelocytic leukemia cell line NB4 cells].
    Zhongguo shi yan xue ye xue za zhi, 2002, Volume: 10, Issue:3

    Topics: Acetylcysteine; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Division; DNA, Neoplasm; Flow Cytometry; Glutathione; Humans; Intracellular Membranes; Leukemia, Promyelocytic, Acute; Membrane Potentials; Mitochondria; Oxides; Reactive Oxygen Species; Sodium Selenite; Tumor Cells, Cultured

2002
P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) are induced by arsenic trioxide (As(2)O(3)), but are not the main mechanism of As(2)O(3)-resistance in acute promyelocytic leukemia cells.
    Leukemia, 2003, Volume: 17, Issue:3

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Resistance, Neoplasm; Gene Expression Regulation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tumor Cells, Cultured

2003
[Successful treatment after acute promyelocytic leukemia (APL) syndrome of relapsed API with arsenic trioxide].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:3

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Female; Humans; Informed Consent; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Recurrence; Remission Induction

2003
[In vitro study of the effects of arsenic trioxide combined with 8-CPT-cAMP on differentiation induction in retinoic acid resistant acute promyelocytic leukemia cells].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2003, Volume: 24, Issue:1

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cyclic AMP; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Thionucleotides; Tretinoin

2003
[Clinical observation of the short-term efficacy of the treatment with combination of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in newly diagnosed acute promyelocytic leukemia (APL)].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2003, Volume: 24, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Follow-Up Studies; Gene Expression; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Remission Induction; Time Factors; Treatment Outcome; Tretinoin

2003
[Preliminary observation of the combination of arsenic trioxide and all-trans retinoic acid for the treatment of acute promyelocytic leukemia].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2003, Volume: 24, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Treatment Outcome; Tretinoin

2003
Sustained molecular remission in advanced acute promyelocytic leukemia with combined pulsed retinoic acid and arsenic trioxide. Clinical evidence of synergistic effect and real-time quantification of minimal residual disease.
    Haematologica, 2003, Volume: 88, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm, Residual; Oxides; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin

2003
Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:5

    Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Child; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Retrospective Studies; Secondary Prevention; Survival Rate

2003
Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells.
    Cancer research, 2003, Apr-15, Volume: 63, Issue:8

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Differentiation; Coculture Techniques; Glutathione Peroxidase; Hematopoietic Stem Cells; Humans; Hydrogen Peroxide; K562 Cells; Leukemia, Promyelocytic, Acute; Liver Neoplasms; Lymphoma; Methylation; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tumor Cells, Cultured

2003
Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines.
    Leukemia, 2003, Volume: 17, Issue:5

    Topics: Annexin A5; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Division; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Glutathione; Humans; In Situ Nick-End Labeling; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Reactive Oxygen Species; Tumor Cells, Cultured

2003
Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells.
    Leukemia, 2003, Volume: 17, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caffeine; Dithiothreitol; Drug Interactions; Humans; Leukemia, Promyelocytic, Acute; Membrane Potentials; Mitochondria; Mitosis; Oxides; Tumor Cells, Cultured

2003
Gene expression profile changes in NB4 cells induced by arsenic trioxide.
    Acta pharmacologica Sinica, 2003, Volume: 24, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Oligonucleotide Array Sequence Analysis; Oncogenes; Oxides; Tumor Cells, Cultured

2003
Prolonged molecular remission after arsenic trioxide and all-trans retinoic acid for acute promyelocytic leukemia relapsed after allogeneic stem cell transplantation.
    Leukemia, 2003, Volume: 17, Issue:9

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Tretinoin

2003
Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Oct-01, Volume: 21, Issue:19

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Clinical Trials as Topic; Electrocardiography; Female; Humans; Leukemia, Promyelocytic, Acute; Long QT Syndrome; Male; Middle Aged; Neoplasms; Oxides; Retrospective Studies; Torsades de Pointes

2003
Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells.
    Molecular cancer therapeutics, 2003, Volume: 2, Issue:11

    Topics: Acetylcysteine; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase Inhibitors; Caspases; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Oxides; Plasma Cells; Superoxides; Tumor Cells, Cultured

2003
[Effects of As2O3 on tissue factor, plasminogen activator inhibitor-1 and -2 expression in NB4, HL-60 and THP-1 cells].
    Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2003, Volume: 34, Issue:4

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Oxides; Plasminogen Activator Inhibitor 1; Plasminogen Activator Inhibitor 2; Thromboplastin; Tumor Cells, Cultured

2003
[Study on cardiac toxicity in acute promyelocyte leukemia treatment of arsenic trioxide intravenous infusion in general dose].
    Zhonghua nei ke za zhi, 2003, Volume: 42, Issue:11

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Calcium Channels; Electrocardiography; Female; Heart; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides

2003
The revival of the ancient drug--arsenic.
    Chinese medical journal, 2003, Volume: 116, Issue:11

    Topics: Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Medicine, Chinese Traditional; Oxides

2003
Effect of arsenic trioxide on cytokine expression by acute promyelocytic leukemia cells.
    Chinese medical journal, 2003, Volume: 116, Issue:11

    Topics: Arsenic Trioxide; Arsenicals; Cells, Cultured; Cytokines; Granulocyte Colony-Stimulating Factor; Humans; Interleukin-1; Interleukin-6; Interleukin-8; Leukemia, Promyelocytic, Acute; Oxides; Tumor Necrosis Factor-alpha

2003
The effect of arsenic trioxide on QT interval prolongation during APL therapy.
    Chinese medical journal, 2003, Volume: 116, Issue:11

    Topics: Arsenic Trioxide; Arsenicals; Electrocardiography; Humans; Leukemia, Promyelocytic, Acute; Oxides

2003
Arsenic enhances the activation of Stat1 by interferon gamma leading to synergistic expression of IRF-1.
    Oncogene, 2003, Dec-11, Volume: 22, Issue:57

    Topics: Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Cell Differentiation; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Interferon Regulatory Factor-1; Interferon-gamma; Leukemia, Promyelocytic, Acute; Oxides; Phosphoproteins; Promoter Regions, Genetic; Signal Transduction; STAT1 Transcription Factor; Superoxides; Trans-Activators; Tretinoin; Tumor Cells, Cultured

2003
Impairment of heart rate variability control during arsenic trioxide treatment for acute promyelocytic leukemia.
    Leukemia, 2004, Volume: 18, Issue:3

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Heart Rate; Humans; Leukemia, Promyelocytic, Acute; Oxides

2004
JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells.
    Blood, 2004, May-01, Volume: 103, Issue:9

    Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cells, Cultured; Clone Cells; Drug Resistance, Neoplasm; Enzyme Activation; Glutathione; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Promyelocytic, Acute; Mice; Mice, Knockout; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinases; Oxides; Receptor, EphA4

2004
[Clinical and experimental study of cardiac effects of conventional dosage arsenic trioxide in APL patients].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2004, Volume: 25, Issue:1

    Topics: Adult; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Calcium; Calcium Channels, L-Type; Cricetinae; Electrocardiography; Female; Heart; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides

2004
[Successful bone marrow transplantation with a matched unrelated donor in an acute promyelocytic leukemia patient after reinduction therapy with arsenic trioxide].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2004, Volume: 45, Issue:1

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Combined Modality Therapy; Histocompatibility Testing; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Oxides; Remission Induction; Tissue Donors; Transplantation, Homologous; Treatment Outcome

2004
Herpes zoster during treatment with arsenic trioxide.
    Annals of hematology, 2004, Volume: 83, Issue:6

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Herpes Zoster; Humans; Leukemia, Promyelocytic, Acute; Oxides

2004
Herpes zoster during treatment with arsenic trioxide.
    Annals of hematology, 2004, Volume: 83, Issue:3

    Topics: 2-Aminopurine; Antineoplastic Agents; Antiviral Agents; Arsenic Trioxide; Arsenicals; Famciclovir; Female; Herpes Zoster; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Treatment Outcome

2004
Biography of Zhu Chen.
    Proceedings of the National Academy of Sciences of the United States of America, 2004, Apr-13, Volume: 101, Issue:15

    Topics: Arsenic Trioxide; Arsenicals; China; Hematology; History, 20th Century; History, 21st Century; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin

2004
[Effects of combination therapy with all-trans retinoic acid and arsenic trioxide on acute promyelocytic leukemia].
    Ai zheng = Aizheng = Chinese journal of cancer, 2004, Volume: 23, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin

2004
Bone marrow necrosis in a patient with acute promyelocytic leukemia during re-induction therapy with arsenic trioxide.
    European journal of haematology, 2004, Volume: 72, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Bone Marrow Diseases; Fever; Humans; Hydroxyurea; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Middle Aged; Necrosis; Oxides; Pancytopenia; Remission Induction

2004
Death by arsenic: implications of PML sumoylation.
    Cancer cell, 2004, Volume: 5, Issue:4

    Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; Neoplasm Proteins; Nuclear Proteins; Oxides; Phosphorylation; Promyelocytic Leukemia Protein; Transcription Factors; Tumor Suppressor Proteins

2004
Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis.
    Cancer cell, 2004, Volume: 5, Issue:4

    Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cells, Cultured; CHO Cells; Cricetinae; Growth Inhibitors; HeLa Cells; Humans; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Phosphorylation; Promyelocytic Leukemia Protein; Signal Transduction; Small Ubiquitin-Related Modifier Proteins; Transcription Factors; Tumor Suppressor Proteins

2004
Acute promyelocytic leukemia cell line AP-1060 established as a cytokine-dependent culture from a patient clinically resistant to all-trans retinoic acid and arsenic trioxide.
    Leukemia, 2004, Volume: 18, Issue:7

    Topics: Arsenic Trioxide; Arsenicals; Cell Culture Techniques; Cell Line, Tumor; Cytokines; Drug Resistance, Neoplasm; Humans; Karyotyping; Leukemia, Promyelocytic, Acute; Mutation, Missense; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Telomerase; Telomere; Tretinoin

2004
Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia.
    Haematologica, 2004, Volume: 89, Issue:5

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Child, Preschool; Combined Modality Therapy; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Remission Induction

2004
Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies.
    Leukemia research, 2004, Volume: 28, Issue:9

    Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Female; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Middle Aged; Oxides; Recurrence; Tretinoin

2004
Inhibition of apoptosis in acute promyelocytic leukemia cells leads to increases in levels of oxidized protein and LMP2 immunoproteasome.
    Proceedings of the National Academy of Sciences of the United States of America, 2004, Aug-10, Volume: 101, Issue:32

    Topics: Aging; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase Inhibitors; Cell Line, Tumor; Cysteine Endopeptidases; Enzyme Inhibitors; Humans; Hydrogen Peroxide; Iron; Leukemia, Promyelocytic, Acute; Oxidation-Reduction; Oxidative Stress; Oxides; Proteins

2004
Phenylarsine oxide (PAO) more intensely induces apoptosis in acute promyelocytic leukemia and As2O3-resistant APL cell lines than As2O3 by activating the mitochondrial pathway.
    Leukemia & lymphoma, 2004, Volume: 45, Issue:5

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Membrane Potentials; Mitochondria; Oxides; Proto-Oncogene Proteins c-bcl-2

2004
Treatment of acute promyelocytic leukemia in children: arsenic or ATRA.
    Leukemia, 2004, Volume: 18, Issue:10

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Survival Rate; Treatment Outcome; Tretinoin

2004
Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience.
    Leukemia, 2004, Volume: 18, Issue:10

    Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Remission Induction; Survival Rate; Treatment Outcome

2004
Molecular remission with arsenic trioxide in patients with newly diagnosed acute promyelocytic leukemia.
    Haematologica, 2004, Volume: 89, Issue:10

    Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Child; Drug Evaluation; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Polymerase Chain Reaction; Proto-Oncogene Proteins c-bcr; Remission Induction; Retrospective Studies; Treatment Outcome

2004
Nursing considerations for nontraditional treatment approaches to hematologic malignancies.
    ONS news, 2004, Volume: 19, Issue:9 Suppl

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Nurse's Role; Oncology Nursing; Oxides; Treatment Outcome

2004
Sodium selenite induces apoptosis in acute promyelocytic leukemia-derived NB4 cells by a caspase-3-dependent mechanism and a redox pathway different from that of arsenic trioxide.
    Annals of hematology, 2004, Volume: 83, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Leukemia, Promyelocytic, Acute; Mitochondria; Oxidation-Reduction; Oxides; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction; Sodium Selenite; Sulfhydryl Compounds; Tretinoin

2004
Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells.
    Leukemia, 2005, Volume: 19, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Flavonoids; Growth Inhibitors; Humans; Kinetics; Leukemia, Promyelocytic, Acute; MAP Kinase Kinase 1; Membrane Potentials; Mitochondria; Oxides; RNA, Small Interfering; Transfection

2005
Hematological and molecular remission with combination chemotherapy in a patient with PLZF-RARalpha acute promyelocytic leukemia (APML).
    Annals of hematology, 2005, Volume: 84, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Translocation, Genetic

2005
[In vitro study on arsenic trioxide-inducing apoptosis in primary acute promyelocytic leukemie cells].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 1997, Volume: 18, Issue:12

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Proliferation; Cells, Cultured; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides

1997
[Effect of arsenic trioxide on drug transporting molecules in acute promyelocytic leukemia cell line].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2004, Volume: 26, Issue:10

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Oxides; Tretinoin; Vault Ribonucleoprotein Particles

2004
[Effects of protein tyrosine kinase, protein tyrosine phosphatase and protein kinase C on the apoptosis of arsenic trioxide treated NB4 cells and human cortex neurons].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2004, Volume: 25, Issue:10

    Topics: Adult; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium; Cell Line, Tumor; Cells, Cultured; Cerebral Cortex; Cytoplasm; Dose-Response Relationship, Drug; Humans; Leukemia, Promyelocytic, Acute; Male; Neurons; Oxides; Protein Kinase C; Protein Tyrosine Phosphatases; Protein-Tyrosine Kinases

2004
PRAM-1 potentiates arsenic trioxide-induced JNK activation.
    The Journal of biological chemistry, 2005, Mar-11, Volume: 280, Issue:10

    Topics: Adaptor Proteins, Signal Transducing; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Enzyme Activation; Humans; JNK Mitogen-Activated Protein Kinases; Kinetics; Leukemia, Promyelocytic, Acute; Microfilament Proteins; Oligopeptides; Oxides; Proteins; src Homology Domains; Tretinoin

2005
Repeated arsenic trioxide intravenous infusion causes focal bone marrow necrosis in two acute promyelocytic leukemia patients.
    Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih, 2004, Volume: 19, Issue:4

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Bone Marrow Diseases; Child; Female; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Necrosis; Oxides

2004
Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway.
    Oncogene, 2005, Mar-10, Volume: 24, Issue:11

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Caspase 2; Caspase 9; Caspases; Cell Death; Cell Line, Tumor; Fibroblasts; Humans; Kinetics; Leukemia, Promyelocytic, Acute; Mitochondria; Necrosis; Oxides; Proto-Oncogene Proteins c-bcl-2

2005
Significance of intracellular arsenic trioxide for therapeutic response in acute promyelocytic leukemia.
    American journal of hematology, 2005, Volume: 78, Issue:2

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Biological Transport; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis

2005
Simultaneous and ultrarapid determination of reactive oxygen species and reduced glutathione in apoptotic leukemia cells by microchip electrophoresis.
    Electrophoresis, 2005, Volume: 26, Issue:6

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Electrophoresis, Microchip; Fluorescent Dyes; Glutathione; Humans; Lasers; Leukemia, Promyelocytic, Acute; Miniaturization; Oxides; Reactive Oxygen Species; Reproducibility of Results; Rhodamines; Signal Transduction; Spectrometry, Fluorescence; Tumor Cells, Cultured

2005
Triterpenoid CDDO-Im downregulates PML/RARalpha expression in acute promyelocytic leukemia cells.
    Cell death and differentiation, 2005, Volume: 12, Issue:5

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Leukemic; Humans; Imidazoles; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Nuclear Proteins; Oleanolic Acid; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Recombinant Fusion Proteins; Retinoic Acid Receptor alpha; Transcription Factors; Tretinoin; Tumor Cells, Cultured; Tumor Suppressor Proteins

2005
Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia.
    British journal of haematology, 2005, Volume: 128, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bryostatins; Cell Cycle; Cell Line, Tumor; Cell Transformation, Neoplastic; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Macrolides; Myelopoiesis; Oxides; Tretinoin

2005
[Arsenic treatment for leukemia: new model of human cancer target treatment].
    Zhonghua yi xue za zhi, 2005, Feb-23, Volume: 85, Issue:7

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Pyrimidines; Tretinoin

2005
Successful treatment of relapsed acute promyelocytic leukemia in a patient receiving continuous ambulatory peritoneal dialysis with oral arsenic trioxide.
    Archives of internal medicine, 2005, May-09, Volume: 165, Issue:9

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Peritoneal Dialysis, Continuous Ambulatory; Recurrence; Treatment Outcome

2005
Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia.
    Proceedings of the National Academy of Sciences of the United States of America, 2005, May-24, Volume: 102, Issue:21

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Computational Biology; Drug Synergism; Electrophoresis, Gel, Two-Dimensional; Gene Expression Regulation, Neoplastic; Granulocytes; Humans; Leukemia, Promyelocytic, Acute; Mass Spectrometry; Oligonucleotide Array Sequence Analysis; Oxides; Proteomics; Reverse Transcriptase Polymerase Chain Reaction; Systems Biology; Tretinoin

2005
Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells.
    Leukemia, 2005, Volume: 19, Issue:8

    Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin; Tumor Cells, Cultured

2005
Fluid retention during arsenic trioxide treatment in acute promyelocytic leukemia.
    American journal of hematology, 2005, Volume: 79, Issue:3

    Topics: Aged; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Edema; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Oxides

2005
[Therapeutic effects of combination of arsenic trioxide with low-dose all-trans retinoic acid on induction of remission acute promyeloeytic leukemia].
    Zhonghua yi xue za zhi, 2005, Apr-27, Volume: 85, Issue:16

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Treatment Outcome; Tretinoin

2005
As2O3 enhances the anion transport activity of band 3 and the action is related with the C-terminal 16 residues of the protein.
    Journal of drug targeting, 2005, Volume: 13, Issue:4

    Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Adult; Anion Exchange Protein 1, Erythrocyte; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Erythrocytes; Female; Gene Deletion; HeLa Cells; Humans; In Vitro Techniques; Leukemia, Promyelocytic, Acute; Male; Oxides; Transfection; Yeasts

2005
Clinical effects of arsenic trioxide by slowing-intravenous infusion on acute promyelocyte leukemia.
    Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih, 2005, Volume: 20, Issue:2

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cerebral Hemorrhage; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides

2005
[Clinical observation and follow-up study on acute promyelocytic leukemia in childhood treated mainly with arsenic trioxide].
    Zhonghua er ke za zhi = Chinese journal of pediatrics, 2005, Volume: 43, Issue:7

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Remission Induction; Survival Rate; Treatment Outcome

2005
Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death.
    Leukemia, 2005, Volume: 19, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; DNA-Binding Proteins; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Remission Induction; Telomerase; Telomere; Tretinoin; Tumor Cells, Cultured

2005
Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias.
    British journal of haematology, 2005, Volume: 130, Issue:5

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Flow Cytometry; Humans; In Situ Nick-End Labeling; Jurkat Cells; Leukemia; Leukemia, Promyelocytic, Acute; Leukemia, T-Cell; Oxides; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; RNA, Small Interfering; Signal Transduction; Transfection; Tumor Cells, Cultured

2005
Arsenic trioxide in the treatment of relapsed and refractory acute promyelocytic leukemia.
    Internal medicine (Tokyo, Japan), 2005, Volume: 44, Issue:8

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Japan; Leukemia, Promyelocytic, Acute; Oxides; Recurrence

2005
Delayed recovery of normal hematopoiesis in arsenic trioxide treatment of acute promyelocytic leukemia: a comparison to all-trans retinoic acid treatment.
    Internal medicine (Tokyo, Japan), 2005, Volume: 44, Issue:8

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation; Erythrocyte Count; Hematopoiesis; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Leukocytes; Oxides; Platelet Count; Time Factors; Tretinoin

2005
Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia.
    Leukemia research, 2006, Volume: 30, Issue:3

    Topics: Adult; Antineoplastic Agents; Arrhythmias, Cardiac; Arsenic Trioxide; Arsenicals; Black or African American; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Retrospective Studies

2006
Arsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXRalpha phosphorylation.
    The Journal of clinical investigation, 2005, Volume: 115, Issue:10

    Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinogens, Environmental; Chlorocebus aethiops; COS Cells; Environmental Exposure; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Promyelocytic, Acute; MAP Kinase Kinase 4; Oxides; Phosphorylation; Receptors, Estrogen; Receptors, Glucocorticoid; Retinoid X Receptor alpha; Serine; Signal Transduction; Transcription, Genetic; Transcriptional Activation

2005
[The impact of arsenic trioxide or all-trans retinoic acid treatment on coagulopathy in acute promyelocytic leukemia].
    Zhonghua nei ke za zhi, 2001, Volume: 40, Issue:12

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation Disorders; Down-Regulation; Female; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; RNA, Messenger; Thrombomodulin; Thromboplastin; Tretinoin

2001
Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Prognosis; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Survival Rate; Treatment Outcome

2006
Current management and new approaches in the treatment of APL.
    Clinical advances in hematology & oncology : H&O, 2003, Volume: 1, Issue:10

    Topics: Aminoglycosides; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Drug Monitoring; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Stem Cell Transplantation; Tretinoin

2003
Hypoxia-simulating agents selectively stimulate arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
    Haematologica, 2005, Volume: 90, Issue:12

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Division; Cell Hypoxia; Cobalt; Deferoxamine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tretinoin; U937 Cells

2005
Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
    Haematologica, 2005, Volume: 90, Issue:12

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Cell Differentiation; Cell Division; Cell Hypoxia; Cell Line, Tumor; Cobalt; Deferoxamine; Drug Synergism; Gene Expression Regulation, Leukemic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Oxygen; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin; U937 Cells

2005
Serial studies of methylation of CDKN2B and CDKN2A in relapsed acute promyelocytic leukaemia treated with arsenic trioxide.
    British journal of haematology, 2005, Volume: 131, Issue:5

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Case-Control Studies; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Humans; Leukemia, Promyelocytic, Acute; Methylation; Neoplasm, Residual; Oxides; Reverse Transcriptase Polymerase Chain Reaction

2005
[Oral administration of arsenic trioxide induced molecular remission in relapsed acute promyelocytic leukemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2005, Volume: 46, Issue:11

    Topics: Administration, Oral; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Neoplasm Recurrence, Local; Oxides; Remission Induction

2005
[Acute pancreatitis during the treatment of relapsed acute promyelocytic leukemia with As2O3].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2006, Volume: 47, Issue:1

    Topics: Acute Disease; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Pancreatitis; Recurrence

2006
Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia.
    Blood, 2006, Apr-01, Volume: 107, Issue:7

    Topics: Administration, Oral; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Meningeal Neoplasms; Middle Aged; Oxides; Recurrence

2006
Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine.
    Biological & pharmaceutical bulletin, 2006, Volume: 29, Issue:5

    Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chromatography, High Pressure Liquid; Drug Resistance, Neoplasm; Humans; Injections, Intravenous; Leukemia, Promyelocytic, Acute; Male; Methylation; Oxides; Seafood; Tretinoin

2006
Solid tumors subsequent to arsenic trioxide treatment for acute promyelocytic leukemia.
    Leukemia research, 2007, Volume: 31, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Arsenic Trioxide; Arsenicals; Colonic Neoplasms; Female; Growth Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Male; Nasopharyngeal Neoplasms; Neoplasms; Oxides

2007
Role of GSTP1-1 in mediating the effect of As2O3 in the Acute Promyelocytic Leukemia cell line NB4.
    Annals of hematology, 2006, Volume: 85, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activation; Glutathione S-Transferase pi; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oxidation-Reduction; Oxidative Stress; Oxides; Time Factors

2006
Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia.
    Haematologica, 2006, Volume: 91, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Evaluation; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin

2006
Two cases of acute promyelocytic leukemia complicated by torsade de pointes during arsenic trioxide therapy.
    International journal of hematology, 2006, Volume: 83, Issue:4

    Topics: Adult; Anthracyclines; Antifungal Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cardiomyopathies; Female; Fluconazole; Humans; Hypokalemia; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Time Factors; Torsades de Pointes

2006
Recurrent extramedullary relapse of acute promyelocytic leukemia after allogeneic stem cell transplantation: successful treatment by arsenic trioxide in combination with local radiotherapy.
    International journal of hematology, 2006, Volume: 83, Issue:4

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Combined Modality Therapy; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Radiography; Recurrence; Remission Induction; Sarcoma, Myeloid; Stem Cell Transplantation; Translocation, Genetic; Transplantation, Homologous; Tretinoin

2006
[Adverse effects of intravenous arsenic trioxide and their prevention].
    Zhonghua nei ke za zhi, 2006, Volume: 45, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides

2006
[Long-term survival analysis in 170 cases of acute promyelocytic leukemia].
    Zhongguo shi yan xue ye xue za zhi, 2006, Volume: 14, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Prognosis; Proportional Hazards Models; Remission Induction; Retrospective Studies; Survival Analysis; Survival Rate; Tretinoin

2006
Use of Novoseven for arsenic trioxide-induced bleeding in PML.
    American journal of hematology, 2006, Volume: 81, Issue:9

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Factor VII; Factor VIIa; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Lung Diseases; Oxides; Recombinant Proteins

2006
Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses.
    Cancer research, 2006, Jul-01, Volume: 66, Issue:13

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; Mice; Mice, Knockout; Oxides; p38 Mitogen-Activated Protein Kinases; Phosphorylation

2006
Real-time PCR analysis of PML-RAR alpha in newly diagnosed acute promyelocytic leukaemia patients treated with arsenic trioxide as a front-line therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:10

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Child; Early Diagnosis; Female; Follow-Up Studies; Gene Expression; Glucosephosphate Dehydrogenase; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Oncogene Proteins, Fusion; Oxides; Protein Isoforms; Recombinant Fusion Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction

2006
Arsenic-induced APL differentiation in cerebrospinal fluid.
    Leukemia research, 2007, Volume: 31, Issue:5

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cell Differentiation; Cerebrospinal Fluid; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocytes; Oxides; Remission Induction; Treatment Outcome

2007
Arsenic trioxide-responsive leukemia cutis in a patient with acute promyelocytic leukemia after ATRA treatment.
    Leukemia & lymphoma, 2006, Volume: 47, Issue:7

    Topics: Adolescent; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Female; Humans; Leukemia; Leukemia, Promyelocytic, Acute; Oxides; Risk; Skin; Tretinoin

2006
Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide.
    Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Arsenic; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prospective Studies

2007
Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells.
    Blood, 2007, Jan-15, Volume: 109, Issue:2

    Topics: Acute Disease; Aquaporins; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Gene Expression Profiling; Humans; K562 Cells; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Oxides; Point Mutation; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Tretinoin; Up-Regulation

2007
Pharmacologic inhibitors of extracellular signal-regulated kinase (ERKs) and c-Jun NH(2)-terminal kinase (JNK) decrease glutathione content and sensitize human promonocytic leukemia cells to arsenic trioxide-induced apoptosis.
    Journal of cellular physiology, 2006, Volume: 209, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Glutathione; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia; Leukemia, Promyelocytic, Acute; Oxides; Peroxides; Reactive Oxygen Species

2006
A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center.
    Leukemia research, 2007, Volume: 31, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Disease-Free Survival; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Survival Rate; Tretinoin

2007
Anion exchanger 2 mediates the action of arsenic trioxide.
    British journal of haematology, 2006, Volume: 134, Issue:5

    Topics: Anion Transport Proteins; Annexin A5; Antiporters; Apoptosis; Arsenic Trioxide; Arsenicals; Biomarkers; Blotting, Western; CD11b Antigen; CD11c Antigen; Cell Line, Tumor; Cell Survival; Flow Cytometry; Humans; Hydrogen-Ion Concentration; Leukemia, Promyelocytic, Acute; Oxides; Reverse Transcriptase Polymerase Chain Reaction; SLC4A Proteins

2006
Arsenic trioxide induced acute flare-up of rheumatoid arthritis in a patient with APL.
    Annals of hematology, 2007, Volume: 86, Issue:2

    Topics: Aged; Arsenic Trioxide; Arsenicals; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides

2007
Increased oxidative DNA products in patients with acute promyelocytic leukemia during arsenic therapy.
    Haematologica, 2006, Volume: 91, Issue:11

    Topics: 8-Hydroxy-2'-Deoxyguanosine; Arsenic Trioxide; Arsenicals; Deoxyguanosine; DNA; Humans; Leukemia, Promyelocytic, Acute; Oxidation-Reduction; Oxides; Reactive Oxygen Species

2006
Leukocytosis and retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.
    Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih, 2006, Volume: 21, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Dyspnea; Female; Fever; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Leukocytosis; Male; Middle Aged; Oxides; Remission Induction; Syndrome

2006
Prolonged molecular remission in a newly diagnosed acute promyelocytic leukaemia with a severe cardiomyopathy using low-dose gemtuzumab ozogamicin and all-trans retinoic acid.
    Annals of hematology, 2007, Volume: 86, Issue:4

    Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cardiomyopathies; Drug Therapy, Combination; Echocardiography; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Tretinoin

2007
Arsenic trioxide induces apoptosis via the mitochondrial pathway by upregulating the expression of Bax and Bim in human B cells.
    International journal of oncology, 2007, Volume: 30, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; B-Lymphocytes; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Cytochromes c; Cytoplasm; Humans; Leukemia, Promyelocytic, Acute; Male; Membrane Potentials; Membrane Proteins; Mitochondria; Oxidative Stress; Oxides; Proto-Oncogene Proteins; Up-Regulation

2007
Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
    Cancer, 2007, Apr-01, Volume: 109, Issue:7

    Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasm Recurrence, Local; Oxides; Remission Induction; Treatment Outcome; Tretinoin

2007
Arsenic trioxide induces p53-dependent apoptotic signals in myeloma cells with SiRNA-silenced p53: MAP kinase pathway is preferentially activated in cells expressing inactivated p53.
    International journal of oncology, 2007, Volume: 30, Issue:4

    Topics: Antineoplastic Agents; APOBEC Deaminases; Apoptosis; Arsenic Trioxide; Arsenicals; Cyclin-Dependent Kinase Inhibitor p21; Cytidine Deaminase; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Mitochondrial Membranes; Mitogen-Activated Protein Kinase Kinases; Muscle Proteins; Mutation; Oxides; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Protein p53

2007
Current treatment of acute promyelocytic leukemia.
    Haematologica, 2007, Volume: 92, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Clinical Trials as Topic; Computer Systems; Disease Management; Drug Monitoring; Hematopoietic Stem Cells; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Mice; Multicenter Studies as Topic; Oncogene Proteins, Fusion; Oxides; Polymerase Chain Reaction; Predictive Value of Tests; Recurrence; Sensitivity and Specificity; Transfection; Tretinoin

2007
Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
    Haematologica, 2007, Volume: 92, Issue:3

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Ataxin-1; Ataxins; Biomarkers, Tumor; Cell Division; Cell Line, Tumor; Female; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred C57BL; Neoplastic Stem Cells; Nerve Tissue Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Recombinant Fusion Proteins; Transfection; Tretinoin; Tumor Stem Cell Assay

2007
Arsenic trioxide represses NF-kappaB activation and increases apoptosis in ATRA-treated APL cells.
    Annals of the New York Academy of Sciences, 2006, Volume: 1090

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Base Sequence; DNA Probes; Humans; Leukemia, Promyelocytic, Acute; NF-kappa B; Oxides; Tretinoin

2006
Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
    Leukemia research, 2007, Volume: 31, Issue:11

    Topics: Adult; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides

2007
Chinese folk treatment reveals power of arsenic to treat cancer, new studies under way.
    Journal of the National Cancer Institute, 2007, May-02, Volume: 99, Issue:9

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; China; Clinical Trials, Phase III as Topic; Humans; Leukemia, Promyelocytic, Acute; National Institutes of Health (U.S.); Oxides; United States

2007
[Effects of arsenic trioxide or retinoic acid on mRNA and protein expression of tissue factor and thrombomodulin and procoagulant activity in NB4 cells].
    Zhongguo shi yan xue ye xue za zhi, 2007, Volume: 15, Issue:2

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; RNA, Messenger; Thrombomodulin; Thromboplastin; Tretinoin; Tumor Cells, Cultured

2007
Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity.
    Haematologica, 2007, Volume: 92, Issue:6

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Ceramides; Glucosyltransferases; Humans; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Promyelocytic, Acute; Metabolic Networks and Pathways; Oxides

2007
Eosinophils derived from acute promyelocytic leukemia cells after arsenic trioxide treatment.
    International journal of hematology, 2007, Volume: 85, Issue:5

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Lineage; Eosinophils; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides

2007
Oral arsenic trioxide therapy for acute promyelocytic leukemia before and after liver transplantation for hepatitis B virus-related liver failure.
    Annals of hematology, 2007, Volume: 86, Issue:10

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Hepatitis B; Hepatitis B virus; Humans; Leukemia, Promyelocytic, Acute; Liver Failure; Liver Transplantation; Male; Oxides; RNA, Viral; Time Factors; Transplantation, Homologous; Virus Activation

2007
Glycolytic metabolism confers resistance to combined all-trans retinoic acid and arsenic trioxide-induced apoptosis in HL60rho0 cells.
    Leukemia research, 2008, Volume: 32, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Resistance, Neoplasm; Genes, Mitochondrial; Glycolysis; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin

2008
Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen.
    Haematologica, 2007, Volume: 92, Issue:7

    Topics: Arsenic Trioxide; Arsenicals; Cytogenetics; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Promyelocytic, Acute; Mutation; Oxides; Prognosis; Retrospective Studies; Treatment Outcome

2007
Advances in management of acute promyelocytic leukemia with arsenic trioxide.
    Chinese journal of integrative medicine, 2007, Volume: 13, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin

2007
Acute intestinal pseudo-obstruction after induction treatment of relapsed acute promyelocytic leukemia with arsenic trioxide.
    Pediatric blood & cancer, 2008, Volume: 50, Issue:4

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Digestive System Surgical Procedures; Female; Humans; Intestinal Pseudo-Obstruction; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides

2008
Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment.
    Leukemia research, 2008, Volume: 32, Issue:2

    Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Central Nervous System; Humans; Leukemia, Promyelocytic, Acute; Oxides

2008
The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia.
    Blood, 2007, Dec-01, Volume: 110, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Australia; Base Sequence; Bone Marrow; Chromosome Aberrations; Clinical Trials as Topic; Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; DNA Mutational Analysis; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Mutant Chimeric Proteins; Neoplasm Proteins; Oxides; Receptors, Retinoic Acid; Registries; Remission Induction; Retinoic Acid Receptor alpha; RNA, Messenger; Sequence Deletion; Tretinoin

2007
Arsenic trioxide entered cerebrospinal fluid with the help of mannitol overwhelm the meningeal relapse of acute promyelocytic leukemia.
    Haematologica, 2007, Volume: 92, Issue:9

    Topics: Adult; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Female; Humans; Injections, Intravenous; Leukemia, Promyelocytic, Acute; Magnetic Resonance Imaging; Mannitol; Meningeal Neoplasms; Neoplasm Recurrence, Local; Oxides; Remission Induction

2007
NADPH oxidase-derived reactive oxygen species are responsible for the high susceptibility to arsenic cytotoxicity in acute promyelocytic leukemia cells.
    Leukemia research, 2008, Volume: 32, Issue:3

    Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Humans; Leukemia, Promyelocytic, Acute; NADPH Oxidases; Oxides; Reactive Oxygen Species

2008
Prolonged oral arsenic trioxide therapy and nephrolithiasis [corrected].
    Leukemia & lymphoma, 2007, Volume: 48, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Case-Control Studies; Drug Administration Schedule; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Nephrolithiasis; Oxides; Time Factors

2007
Reply to 'Arsenic patent keeps drug for rare cancer out of reach for many'.
    Nature medicine, 2007, Volume: 13, Issue:11

    Topics: Adult; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; China; Humans; Leukemia, Promyelocytic, Acute; Oxides; Patents as Topic; United States; United States Food and Drug Administration

2007
Adhesion molecules and Differentiation Syndrome: phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia.
    Haematologica, 2007, Volume: 92, Issue:12

    Topics: Animals; Antigens, CD; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Adhesion; Cell Adhesion Molecules; Cell Differentiation; Gene Expression Regulation, Leukemic; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred BALB C; Mice, Knockout; Neoplasm Proteins; Oxides; Phenylbutyrates; Syndrome; Tretinoin; Tumor Cells, Cultured

2007
QT prolongation: a case of arsenical pericardial and pleural effusion.
    Cardiovascular toxicology, 2008, Volume: 8, Issue:1

    Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Long QT Syndrome; Male; Oxides; Pericardial Effusion; Pleural Effusion; Recovery of Function; Withholding Treatment

2008
[Effect of arsenic trioxide on the expression of apoptosis-related genes in NB4 cells].
    Zhongguo shi yan xue ye xue za zhi, 2007, Volume: 15, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; CDC2 Protein Kinase; Cell Line, Tumor; Cyclin B; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Promyelocytic, Acute; Microtubule-Associated Proteins; Oxides; Survivin

2007
Analytical artefacts in the speciation of arsenic in clinical samples.
    Analytica chimica acta, 2008, Jan-21, Volume: 607, Issue:1

    Topics: Arsenic Trioxide; Arsenicals; Artifacts; Chromatography, High Pressure Liquid; Humans; Leukemia, Promyelocytic, Acute; Mass Spectrometry; Multiple Myeloma; Oxides; Spectrometry, Fluorescence

2008
Insight into the selectivity of arsenic trioxide for acute promyelocytic leukemia cells by characterizing Saccharomyces cerevisiae deletion strains that are sensitive or resistant to the metalloid.
    The international journal of biochemistry & cell biology, 2008, Volume: 40, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Biological Transport; Cell Line, Tumor; Cytoskeletal Proteins; DNA Repair; Gene Deletion; Glutathione; Humans; Leukemia, Promyelocytic, Acute; Membrane Proteins; Mitogen-Activated Protein Kinases; Osmotic Pressure; Oxidative Stress; Oxides; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Vacuoles

2008
Optical neuropathy possibly related to arsenic during acute promyelocytic leukemia treatment.
    Leukemia & lymphoma, 2008, Volume: 49, Issue:1

    Topics: Adult; Arsenic; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Optic Neuropathy, Ischemic; Oxides

2008
[Successful cyclosporine treatment for thrombocytopenia after salvage therapy with arsenic trioxide therapy followed by autologous hematopoietic stem cell transplantation in acute promyelocytic leukemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2007, Volume: 48, Issue:12

    Topics: Arsenic Trioxide; Arsenicals; Autoimmune Diseases; Cyclosporine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Salvage Therapy; Thrombocytopenia; Transplantation, Autologous

2007
Simultaneous appearance of central nervous system relapse and subarachnoid hemorrhage during the treatment for acute promyelocytic leukemia.
    Annals of hematology, 2008, Volume: 87, Issue:7

    Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Combined Modality Therapy; Endothelium, Vascular; Gemtuzumab; Humans; Injections, Spinal; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Magnetic Resonance Imaging; Male; Meninges; Middle Aged; Oxides; Postoperative Complications; Recurrence; Subarachnoid Hemorrhage; Tomography, X-Ray Computed

2008
Effect of the combination of ATRA, ATO and DNR on CD11b expression in NB4 cells.
    Leukemia research, 2008, Volume: 32, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; CD11b Antigen; Cell Line, Tumor; Daunorubicin; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin

2008
All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
    Pediatric blood & cancer, 2008, Volume: 51, Issue:1

    Topics: Adolescent; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Dysplastic Nevus Syndrome; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin

2008
Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2.
    The Journal of biological chemistry, 2008, May-02, Volume: 283, Issue:18

    Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Blast Crisis; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Enzyme Activation; Enzyme Inhibitors; Eukaryotic Initiation Factor-4E; Fibroblasts; Gene Targeting; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Promyelocytic, Acute; Mice; Mitogen-Activated Protein Kinases; Oxides; Phosphorylation; Protein Serine-Threonine Kinases; Tumor Stem Cell Assay

2008
Hyperleukocytosis from arsenic trioxide.
    Pediatric blood & cancer, 2008, Volume: 50, Issue:6

    Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Oxides; Recurrence

2008
Arsenic trioxide inhibits ATRA-induced prostaglandin E2 and cyclooxygenase-1 in NB4 cells, a model of acute promyelocytic leukemia.
    Leukemia, 2008, Volume: 22, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; CD11c Antigen; Cell Differentiation; Cyclooxygenase 1; Dinoprostone; Drug Therapy, Combination; Humans; Indomethacin; Leukemia, Promyelocytic, Acute; Models, Biological; Oxides; Tretinoin; Tumor Cells, Cultured

2008
Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide.
    European journal of haematology, 2008, Volume: 81, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Remission Induction; Salvage Therapy; Tretinoin

2008
Retrospective analysis of 65 Chinese children with acute promyelocytic leukemia: a single center experience.
    Pediatric blood & cancer, 2008, Volume: 51, Issue:2

    Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Humans; Infant; Leukemia, Promyelocytic, Acute; Male; Oxides; Prognosis; Recurrence; Retrospective Studies; Treatment Outcome; Tretinoin

2008
Acute renal failure, gastrointestinal bleeding, and cardiac arrhythmia after administration of arsenic trioxide for acute promyelocytic leukemia.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, May-15, Volume: 65, Issue:10

    Topics: Acute Kidney Injury; Aged, 80 and over; Antineoplastic Agents; Arrhythmias, Cardiac; Arsenic Trioxide; Arsenicals; Fatal Outcome; Female; Gastrointestinal Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Oxides

2008
Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase.
    The Journal of biological chemistry, 2008, Jul-04, Volume: 283, Issue:27

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Cycle Proteins; Checkpoint Kinase 1; Checkpoint Kinase 2; DNA Damage; DNA-Binding Proteins; Dose-Response Relationship, Drug; Enzyme Activation; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; Oxides; p38 Mitogen-Activated Protein Kinases; Phosphoprotein Phosphatases; Phosphorylation; Protein Kinases; Protein Phosphatase 2C; Protein Serine-Threonine Kinases; RNA, Small Interfering; Tumor Suppressor Protein p53; Tumor Suppressor Proteins

2008
Death-associated protein 5 (DAP5/p97/NAT1) contributes to retinoic acid-induced granulocytic differentiation and arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
    Apoptosis : an international journal on programmed cell death, 2008, Volume: 13, Issue:7

    Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Base Sequence; Cell Differentiation; Cell Line, Tumor; Eukaryotic Initiation Factor-2; Eukaryotic Initiation Factor-4G; Granulocytes; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Models, Biological; Oxides; Phosphatidylinositol 3-Kinases; Protein Kinases; Proto-Oncogene Proteins c-akt; RNA-Binding Proteins; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Tretinoin; Up-Regulation

2008
Ancient remedy performs new tricks.
    Science (New York, N.Y.), 1996, Aug-02, Volume: 273, Issue:5275

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Medicine, Chinese Traditional; Oxides; Remission Induction

1996
In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins.
    Blood, 1996, Aug-01, Volume: 88, Issue:3

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, Large B-Cell, Diffuse; Medicine, Chinese Traditional; Monocytes; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured

1996
The PML and PML/RARalpha domains: from autoimmunity to molecular oncology and from retinoic acid to arsenic.
    Experimental cell research, 1996, Dec-15, Volume: 229, Issue:2

    Topics: Animals; Antibodies, Antinuclear; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autoantigens; Autoimmune Diseases; Cell Differentiation; CHO Cells; Cricetinae; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Transcription Factors; Transfection; Tretinoin; Tumor Suppressor Proteins

1996
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.
    Blood, 1997, May-01, Volume: 89, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Cell Adhesion; Cell Division; Cell Survival; DNA, Neoplasm; Drug Resistance, Neoplasm; Humans; Immunophenotyping; Kinetics; Leukemia, Promyelocytic, Acute; Oxides; Phagocytosis; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Subcellular Fractions; Time Factors; Tretinoin; Tumor Cells, Cultured

1997
Arsenic and apoptosis in the treatment of acute promyelocytic leukemia.
    Journal of the National Cancer Institute, 1998, Jan-21, Volume: 90, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Tretinoin

1998
Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.
    Journal of the National Cancer Institute, 1998, Jan-21, Volume: 90, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Northern; Blotting, Western; Down-Regulation; Electrophoresis, Polyacrylamide Gel; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transglutaminases; Tretinoin; Tumor Cells, Cultured

1998
Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells.
    Blood, 1998, Jun-01, Volume: 91, Issue:11

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Microscopy, Confocal; Oxides; Tretinoin; Tumor Cells, Cultured

1998
Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner.
    Blood, 1998, Sep-01, Volume: 92, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Cell Division; Embryo, Mammalian; Fibroblasts; Gene Expression Regulation; Humans; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Melarsoprol; Mice; Neoplasm Proteins; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Proto-Oncogene Proteins c-bcl-2; Receptors, Retinoic Acid; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins

1998
[Double effects of arsenic trioxide (As2O3) on acute promyelocytic leukemic cell line].
    Zhonghua yi xue za zhi, 1997, Volume: 77, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Transformation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Tumor Cells, Cultured

1997
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.
    The New England journal of medicine, 1998, Nov-05, Volume: 339, Issue:19

    Topics: Adolescent; Adult; Aged; Antigens, CD; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Caspases; Cell Differentiation; Child; Humans; Immunophenotyping; Leukemia, Promyelocytic, Acute; Leukocytes, Mononuclear; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction

1998
Arsenic--new life for an old potion.
    The New England journal of medicine, 1998, Nov-05, Volume: 339, Issue:19

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Remission Induction

1998
Acute promyelocytic leukemia: a curable disease.
    Leukemia, 1998, Volume: 12, Issue:12

    Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Drug Resistance; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Karyotyping; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplasm, Residual; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Recurrence; Research; Rome; Transcription Factors; Tretinoin; Tumor Suppressor Proteins

1998
Scientists explore use of arsenic in therapy.
    Journal of the National Cancer Institute, 1998, Dec-16, Volume: 90, Issue:24

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Neoplasms; Oxides

1998
Application of heavy metal and cytokine for differentiation-inducing therapy in acute promyelocytic leukemia.
    Journal of the National Cancer Institute, 1998, Dec-16, Volume: 90, Issue:24

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Transformation, Neoplastic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin; Tumor Cells, Cultured

1998
Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia.
    British journal of haematology, 1998, Volume: 103, Issue:4

    Topics: Acute Disease; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chronic Disease; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence

1998
Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
    Oncogene, 1999, Jan-28, Volume: 18, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Differentiation; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; DNA-Binding Proteins; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Humans; Kruppel-Like Transcription Factors; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Zinc Finger Protein; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transcription Factors; Translocation, Genetic; Tretinoin; Tumor Cells, Cultured

1999
Treatment of acute promyelocytic leukemia with arsenic trioxide.
    The New England journal of medicine, 1999, Apr-01, Volume: 340, Issue:13

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow; Caspases; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction

1999
Treatment of acute promyelocytic leukemia with arsenic trioxide.
    The New England journal of medicine, 1999, Apr-01, Volume: 340, Issue:13

    Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; History, 16th Century; History, 18th Century; History, 19th Century; History, 20th Century; Humans; Leukemia; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction

1999
PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
    Molecular and cellular biology, 1999, Volume: 19, Issue:7

    Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspase Inhibitors; Caspases; Cell Nucleus; DNA; Humans; Leukemia, Promyelocytic, Acute; Molecular Weight; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Rabbits; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Staining and Labeling; SUMO-1 Protein; U937 Cells; Ubiquitins

1999
In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 induces contemporaneously apoptosis, a caspase-3-mediated degradation of PML/RARalpha protein and the PML retargeting on PML-nuclear bodies.
    Leukemia, 1999, Volume: 13, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Cell Line; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Retinoids; Transcription Factors; Tumor Suppressor Proteins

1999
Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemic patient.
    Pacing and clinical electrophysiology : PACE, 1999, Volume: 22, Issue:6 Pt 1

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Electrocardiography; Female; Heart Block; Humans; Leukemia, Promyelocytic, Acute; Oxides

1999
Arsenic: a new place?
    Pathology, 1999, Volume: 31, Issue:2

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin

1999
Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia.
    Bone marrow transplantation, 1999, Volume: 24, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Humans; Leukemia, Promyelocytic, Acute; Male; Neoplasms, Second Primary; Oxides; Recurrence; Transplantation, Autologous; Tretinoin

1999
Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia.
    Annals of hematology, 1999, Volume: 78, Issue:7

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Chromosome Banding; Colony-Forming Units Assay; Drug Resistance, Neoplasm; Feeding and Eating Disorders; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Metaphase; Middle Aged; Musculoskeletal Diseases; Oxides; Pain; Polymerase Chain Reaction; Recurrence; Tretinoin

1999
Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway.
    Blood, 1999, Sep-15, Volume: 94, Issue:6

    Topics: Amitrole; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Catalase; Cytochrome c Group; Cytosol; Flow Cytometry; Glutathione Peroxidase; HL-60 Cells; Humans; Hydrogen Peroxide; Intracellular Membranes; K562 Cells; Kinetics; Leukemia, Promyelocytic, Acute; Membrane Potentials; Mitochondria; Oxides; Thiomalates; Tumor Cells, Cultured; U937 Cells

1999
Re: Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations.
    Journal of the National Cancer Institute, 1999, Oct-06, Volume: 91, Issue:19

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Growth Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Lymphocytes; Neoplasms, Second Primary; Oxides

1999
Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
    Haematologica, 1999, Volume: 84, Issue:11

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Binding Sites; Bone Marrow; Carrier Proteins; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Ligands; Male; Middle Aged; Mutation, Missense; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Point Mutation; Protein Structure, Tertiary; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tretinoin

1999
Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia.
    Leukemia, 2000, Volume: 14, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Cell Differentiation; DNA, Neoplasm; Electrophoresis, Agar Gel; Enzyme Precursors; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Membrane Potentials; Microscopy, Electron; Mitochondria; Mutation; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tretinoin; Tumor Cells, Cultured

2000
Pseudotumor cerebri after treatment of relapsed acute promyelocytic leukemia with arsenic trioxide.
    Leukemia, 2000, Volume: 14, Issue:2

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Neoplasms; Diplopia; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Papilledema; Pseudotumor Cerebri

2000
In vitro exposure of acute promyelocytic leukemia cells to arsenic trioxide (As2O3) induces the solitary expression of CD66c (NCA-50/90), a member of the CEA family.
    Tissue antigens, 1999, Volume: 54, Issue:6

    Topics: Antigens, CD; Antigens, Differentiation; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Adhesion Molecules; Cell Membrane; Epitopes; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tumor Cells, Cultured

1999
Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice.
    Leukemia, 2000, Volume: 14, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; bcl-Associated Death Protein; bcl-X Protein; Carrier Proteins; Cell Cycle; Cell Differentiation; Cell Division; Drug Resistance, Neoplasm; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, SCID; Mice, Transgenic; Neoplasm Proteins; Neoplasm Transplantation; Oxides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Recombinant Fusion Proteins; Transplantation, Heterologous; Tretinoin; Tumor Cells, Cultured

2000
Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid.
    British journal of haematology, 2000, Volume: 108, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Drug Therapy, Combination; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Promyelocytic, Acute; Male; Oxides; Translocation, Genetic; Tretinoin; Tumor Cells, Cultured

2000
Arsenic trioxide (As2O3) gradually downregulates tissue factor expression without affecting thrombomodulin expression in acute promyelocytic leukemia cells.
    Leukemia, 2000, Volume: 14, Issue:5

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Reverse Transcriptase Polymerase Chain Reaction; Thrombomodulin; Thromboplastin; Transcription, Genetic; Tretinoin; Tumor Cells, Cultured

2000
Successful treatment of all-trans retinoic acid resistant and chemotherapy naïve acute promyelocytic patients with arsenic trioxide--two case reports.
    Leukemia & lymphoma, 2000, Volume: 38, Issue:1-2

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Pregnancy; Tretinoin

2000
Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia.
    Leukemia & lymphoma, 2000, Volume: 38, Issue:1-2

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin

2000
[Successful treatment of relapsed and refractory acute promyelocytic leukemia with arsenic trioxide (As2O3)].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2000, Volume: 41, Issue:4

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Neoplasm Recurrence, Local; Oxides; Pleural Effusion; Remission Induction; Treatment Outcome; Tretinoin

2000
Arsenic trioxide treatment of relapsed acute promyelocytic leukaemia: initial Australian experience.
    Australian and New Zealand journal of medicine, 1999, Volume: 29, Issue:3

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Australia; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides

1999
Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:13

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Dyspnea; Fever; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides; Pleural Effusion; Syndrome; Tretinoin

2000
Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
    Proceedings of the National Academy of Sciences of the United States of America, 2000, Aug-29, Volume: 97, Issue:18

    Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, Nude; Mice, Transgenic; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Translocation, Genetic; Transplantation, Heterologous; Tretinoin

2000
Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3).
    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2000, Volume: 13, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cytogenetics; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin

2000
Unusual manifestations of acute leukemia. Case 1. CNS extramedullary relapse of acute promyelocytic leukemia after arsenic trioxide-induced remission.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Oct-01, Volume: 18, Issue:19

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Central Nervous System; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Male; Oxides; Remission Induction

2000
Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis.
    Leukemia, 2000, Volume: 14, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 8; Caspase 9; Caspases; Enzyme Activation; fas Receptor; Glutathione; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tumor Cells, Cultured

2000
From the Food and Drug Administration.
    JAMA, 2000, Nov-01, Volume: 284, Issue:17

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Buprenorphine; Child; Drug and Narcotic Control; Drug Combinations; Drugs, Investigational; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Leukemia, Promyelocytic, Acute; Lopinavir; Opioid-Related Disorders; Oxides; Pyrimidinones; Receptors, Opioid; Ritonavir; United States; United States Food and Drug Administration

2000
Arsenic compound approved as cancer chemotherapy agent.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2000, Nov-01, Volume: 57, Issue:21

    Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome

2000
Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
    Annals of internal medicine, 2000, Dec-05, Volume: 133, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Electrocardiography, Ambulatory; Female; Humans; Leukemia, Promyelocytic, Acute; Long QT Syndrome; Male; Middle Aged; Oxides; Prospective Studies; Recurrence; Remission Induction; Tachycardia, Ventricular

2000
Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo.
    Blood, 2001, Jan-01, Volume: 97, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Northern; Blotting, Western; Cell Culture Techniques; Cell Differentiation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance; Female; Humans; Leukemia, Experimental; Leukemia, Promyelocytic, Acute; Mice; Mice, SCID; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Survival Rate; Tretinoin

2001
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.
    The oncologist, 2001, Volume: 6, Issue:1

    Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Arsenic Trioxide; Arsenicals; Bexarotene; Breast Neoplasms; Drug Approval; Female; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, T-Cell, Cutaneous; Nitriles; Oxides; Paclitaxel; Tamoxifen; Tetrahydronaphthalenes; Triazoles; United States; United States Food and Drug Administration

2001
Molecular remission without blood product support using all-trans retinoic acid (ATRA) induction and combined arsenic trioxide/ATRA consolidation in a Jehovah's Witness with de novo acute promyelocytic leukaemia.
    British journal of haematology, 2000, Volume: 111, Issue:4

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Christianity; Cytogenetic Analysis; Drug Therapy, Combination; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Middle Aged; Oxides; Platelet Count; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin

2000
Hyperleukocytosis during induction therapy with arsenic trioxide for relapsed acute promyelocytic leukemia associated with central nervous system infarction.
    Blood, 2000, Dec-01, Volume: 96, Issue:12

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Infarction; Fatal Outcome; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides; Recurrence; Remission Induction

2000
[Studies on red orpiment induction of NB4 and HL-60 cell apoptosis].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 1998, Volume: 19, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Materia Medica; Oxides; Tumor Cells, Cultured

1998
[Tissue factor expression during all-trans retinoic acid or arsenic trioxide treatment in acute promyelocytic leukemia].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 1998, Volume: 19, Issue:9

    Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Hemostatics; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; RNA, Messenger; Thromboplastin; Tretinoin

1998
[In vitro study on arsenic trioxide-induced apoptosis of retinoic acid resistant acute promyelocytic leukemia cell line(MR-2)].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 1998, Volume: 19, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin; Tumor Cells, Cultured

1998
Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide.
    Blood, 2001, Mar-01, Volume: 97, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Monitoring; Electrocardiography; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Torsades de Pointes

2001
Co-biomodulation with arsenic trioxide in multiple myeloma.
    Leukemia research, 2001, Volume: 25, Issue:3

    Topics: Adjuvants, Immunologic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Humans; Killer Cells, Lymphokine-Activated; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Oxides

2001
Regulation of Pax3 transcriptional activity by SUMO-1-modified PML.
    Oncogene, 2001, Jan-04, Volume: 20, Issue:1

    Topics: 3T3 Cells; Animals; Arsenic Trioxide; Arsenicals; Carrier Proteins; Cell Nucleus; Cells, Cultured; Co-Repressor Proteins; DNA-Binding Proteins; Embryo, Mammalian; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Leukemia, Promyelocytic, Acute; Mice; Molecular Chaperones; Neoplasm Proteins; Nuclear Proteins; Oxides; Paired Box Transcription Factors; PAX3 Transcription Factor; Promyelocytic Leukemia Protein; Repressor Proteins; SUMO-1 Protein; Transcription Factors; Transcription, Genetic; Tumor Suppressor Proteins; Ubiquitins

2001
Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia.
    Chinese medical journal, 1998, Volume: 111, Issue:12

    Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Female; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence

1998
Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
    American journal of hematology, 2001, Volume: 66, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Drug Evaluation; Drug Synergism; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Pilot Projects; Prospective Studies; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Salvage Therapy; Treatment Outcome

2001
Central nervous system relapse in a patient with acute promyelocytic leukaemia treated with arsenic tri-oxide.
    British journal of haematology, 2001, Volume: 113, Issue:1

    Topics: Adult; Animals; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Central Nervous System Diseases; Choroid Plexus; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence

2001
Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage.
    Leukemia, 2001, Volume: 15, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence

2001
Effects of all-trans-retinoic acid and arsenic trioxide on the hemostatic disturbance associated with acute promyelocytic leukemia.
    Thrombosis research, 2001, May-01, Volume: 102, Issue:3

    Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Case-Control Studies; Female; Hemorrhage; Hemostasis; Hemostatics; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Thromboplastin; Tretinoin

2001
Hot on the TRAIL of acute promyelocytic leukemia.
    Nature medicine, 2001, Volume: 7, Issue:6

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Caspases; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Ligands; Membrane Glycoproteins; Neoplasm Proteins; NF-kappa B; Oncogene Proteins, Fusion; Oxides; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Tretinoin; Tumor Necrosis Factor-alpha

2001
Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL.
    Nature medicine, 2001, Volume: 7, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Caspases; Cell Differentiation; Coculture Techniques; Humans; Immunoblotting; Inhibitor of Apoptosis Proteins; Leukemia, Promyelocytic, Acute; Membrane Glycoproteins; Neoplasm Proteins; NF-kappa B; Oncogene Proteins, Fusion; Oxides; Paracrine Communication; Proteins; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Signal Transduction; TNF Receptor-Associated Factor 1; TNF-Related Apoptosis-Inducing Ligand; Tretinoin; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha

2001
A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF.
    Leukemia, 2001, Volume: 15, Issue:8

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Drug Therapy, Combination; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, SCID; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tumor Cells, Cultured

2001
XAS applied to pharmaceuticals: drug administration and bioavailability.
    Journal of synchrotron radiation, 2001, Mar-01, Volume: 8, Issue:Pt 2

    Topics: Arsenic Trioxide; Arsenicals; Biological Availability; Chemistry, Pharmaceutical; Hair; Histidine; Humans; Leukemia, Promyelocytic, Acute; Menkes Kinky Hair Syndrome; Organometallic Compounds; Oxides; Parenteral Nutrition; Spectrometry, X-Ray Emission; Synchrotrons; Zinc

2001
Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells.
    Biochemical and biophysical research communications, 2001, Aug-31, Volume: 286, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Cell Division; Cycloheximide; Enzyme Activation; G2 Phase; Growth Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Mitosis; Monocytes; Myeloid Progenitor Cells; Oxides; Phosphorylation; Protein Synthesis Inhibitors; Proto-Oncogene Proteins c-bcl-2; U937 Cells

2001
Unusual sites of involvement by hematologic malignancies. Case 3. External auditory canal tumor: a rare chloroma in acute promyelocytic leukemia with a complete response to arsenic trioxide.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-01, Volume: 19, Issue:19

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Ear Canal; Ear Neoplasms; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin

2001
Arsenic trioxide is a potent inhibitor of the interaction of SMRT corepressor with Its transcription factor partners, including the PML-retinoic acid receptor alpha oncoprotein found in human acute promyelocytic leukemia.
    Molecular and cellular biology, 2001, Volume: 21, Issue:21

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Nucleus; DNA-Binding Proteins; Enzyme Activation; Humans; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; Microscopy, Confocal; Nuclear Receptor Co-Repressor 2; Oxides; Phosphorylation; Plasmids; Precipitin Tests; Protein Binding; Receptors, Retinoic Acid; Repressor Proteins; Retinoic Acid Receptor alpha; Signal Transduction; Time Factors; Transfection; Two-Hybrid System Techniques

2001
Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
    Annals of internal medicine, 2001, Nov-06, Volume: 135, Issue:9

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Electrocardiography; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tachycardia, Ventricular

2001
[The mechanisms of arsenic trioxide-induced apoptosis in hematopoietic malignant cells].
    Zhonghua yi xue za zhi, 1999, Volume: 79, Issue:6

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tumor Cells, Cultured; U937 Cells

1999
[Effects of all-trans retinoic acid, arsenic trioxide and daunorubicin on tissue factor expression in NB4 cells].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 1999, Volume: 20, Issue:9

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Daunorubicin; Factor VIII; Humans; Leukemia, Promyelocytic, Acute; Oxides; RNA, Messenger; Thromboplastin; Tretinoin; Tumor Cells, Cultured

1999
Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676).
    British journal of haematology, 2001, Volume: 115, Issue:1

    Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Arsenic Trioxide; Arsenicals; Central Nervous System; Combined Modality Therapy; Female; Gemtuzumab; Gene Rearrangement; Genes, MDR; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Oxides; Sialic Acid Binding Ig-like Lectin 3; Translocation, Genetic; Tretinoin

2001
Successful treatment of a case of relapsed acute promyelocytic leukemia with arsenic trioxide.
    Internal medicine (Tokyo, Japan), 2001, Volume: 40, Issue:11

    Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Treatment Outcome

2001
Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment.
    Chinese medical journal, 2000, Volume: 113, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation Factors; Female; Hemostasis; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Thromboplastin; Tretinoin

2000
Long-term survey of outcome in acute promyelocytic leukemia.
    Chinese medical journal, 2000, Volume: 113, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Prognosis; Remission Induction; Time Factors; Treatment Outcome; Tretinoin

2000
[Drug resistance of acute promyelocytic leukemia (APL) to all-trans retinoic acid (ATRA) and its reversion].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2000, Volume: 22, Issue:2

    Topics: Alprostadil; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Arsenic Trioxide; Arsenicals; Cell Survival; Drug Interactions; Drug Resistance; Harringtonines; HL-60 Cells; Homoharringtonine; Humans; Interferon alpha-2; Interferon-alpha; Leukemia, Promyelocytic, Acute; Oxides; Recombinant Proteins; Tretinoin

2000
Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells.
    Chinese medical journal, 2001, Volume: 114, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; RNA, Messenger; Thromboplastin; Tretinoin; Tumor Cells, Cultured

2001
[Ailing No. I in treating 62 cases of acute promyelocytic leukemia].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 1999, Volume: 19, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Drugs, Chinese Herbal; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides

1999
[Cell differentiation and apoptosis of tumor cells].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 1999, Volume: 19, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Transformation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Oxides

1999
[A study of tissue factor expression and hemostatic molecular markers in patients with acute promyelocytic leukemia].
    Zhonghua nei ke za zhi, 2001, Volume: 40, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Hemostasis; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; RNA, Messenger; Thromboplastin; Tretinoin

2001
[Effects of arsenic trioxide on K562 cells stably expressing two promyelocytic leukemia-specific fusion proteins].
    Zhonghua yi xue za zhi, 2000, Volume: 80, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Differentiation; Cell Division; Gene Expression; Growth Inhibitors; Humans; K562 Cells; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tretinoin

2000
[Effects of all-trans retinoic acid and arsenic trioxide on tissue factor expression of acute promyelocytic leukemia cells].
    Zhonghua yi xue za zhi, 2000, Volume: 80, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation; Cells, Cultured; Female; Gene Expression; Humans; Leukemia, Promyelocytic, Acute; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; RNA, Messenger; Thromboplastin; Transcription, Genetic; Tretinoin; Tumor Cells, Cultured; U937 Cells

2000
Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk.
    Blood, 2002, Feb-01, Volume: 99, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Division; Cyclic AMP; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Receptor Cross-Talk; Signal Transduction; Thionucleotides; Tumor Cells, Cultured

2002
Arsenic trioxide newly joins treatment strategies for acute promyelocytic leukemia.
    Internal medicine (Tokyo, Japan), 2001, Volume: 40, Issue:12

    Topics: Antineoplastic Agents; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Treatment Outcome

2001
Successful unrelated bone marrow transplantation after arsenic trioxide treatment in a patient with relapsed acute promyelocytic leukemia.
    International journal of hematology, 2002, Volume: 75, Issue:1

    Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Bone Marrow Transplantation; Combined Modality Therapy; Drug Resistance; Female; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Tretinoin

2002
[Seven years' summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide--an analysis of 242 cases].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2000, Volume: 21, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Survival Rate

2000
[Mechanism of tissue factor expression on NB4 cells down-regulated by all-trans retinoic acid and arsenic trioxide].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2000, Volume: 21, Issue:5

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cycloheximide; Dactinomycin; Down-Regulation; Gene Expression Regulation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Thromboplastin; Tretinoin; Tumor Cells, Cultured

2000
Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide.
    British journal of haematology, 2002, Volume: 117, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence; Remission Induction; Tretinoin

2002
Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring.
    Leukemia, 2002, Volume: 16, Issue:4

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Monitoring; Electrocardiography; Female; Heart; Heart Diseases; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prospective Studies; Remission Induction; Tretinoin

2002
Clinical usefulness of arsenic trioxide in the treatment of acute promyelocytic leukemia.
    Haematologica, 2002, Volume: 87, Issue:5

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Salvage Therapy

2002
The MRP1-mediated effluxes of arsenic and antimony do not require arsenic-glutathione and antimony-glutathione complex formation.
    Journal of bioenergetics and biomembranes, 2002, Volume: 34, Issue:2

    Topics: Antimony; Antimony Potassium Tartrate; Arsenic; Arsenic Trioxide; Arsenicals; Biological Transport, Active; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Glutathione; Humans; K562 Cells; Kinetics; Leukemia, Promyelocytic, Acute; Multidrug Resistance-Associated Proteins; Oxides; Spectrophotometry, Atomic; Tumor Cells, Cultured

2002
Differentiation induction as a treatment for hematologic malignancies.
    Oncogene, 2002, May-13, Volume: 21, Issue:21

    Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Hematologic Neoplasms; Leukemia, Promyelocytic, Acute; Models, Biological; Oncogene Proteins, Fusion; Oxides; Signal Transduction; Transcription, Genetic

2002
Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia.
    Proceedings of the National Academy of Sciences of the United States of America, 2002, Jul-09, Volume: 99, Issue:14

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Immunocompetence; Leukemia, Promyelocytic, Acute; Liposomes; Mice; Mice, Inbred C3H; Mice, SCID; Mice, Transgenic; Neoplasm Proteins; Neoplasm Transplantation; Oncogene Proteins, Fusion; Oxides; Tretinoin

2002